<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S0223523420305249</prism:url><dc:identifier>doi:10.1016/j.ejmech.2020.112552</dc:identifier><eid>1-s2.0-S0223523420305249</eid><prism:doi>10.1016/j.ejmech.2020.112552</prism:doi><pii>S0223-5234(20)30524-9</pii><dc:title>Design, synthesis, and Structure–Activity Relationships (SAR) of 3-vinylindazole derivatives as new selective tropomyosin receptor kinases (Trk) inhibitors </dc:title><prism:publicationName>European Journal of Medicinal Chemistry</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>fla</pubtype><prism:issn>02235234</prism:issn><prism:volume>203</prism:volume><prism:startingPage>112552</prism:startingpage><prism:pageRange>112552</prism:pagerange><articleNumber>112552</articlenumber><dc:format>text/xml</dc:format><prism:coverDate>2020-10-01</prism:coverdate><prism:coverDisplayDate>1 October 2020</prism:coverdisplaydate><prism:copyright>© 2020 Elsevier Masson SAS. All rights reserved.</prism:copyright><prism:publisher>Elsevier Masson SAS.</prism:publisher><dc:creator>Duan, Yunxin</dc:creator><dc:creator>Wang, Jie</dc:creator><dc:creator>Zhu, Sihua</dc:creator><dc:creator>Tu, Zheng-Chao</dc:creator><dc:creator>Zhang, Zhang</dc:creator><dc:creator>Chan, Shingpan</dc:creator><dc:creator>Ding, Ke</dc:creator><dc:description>
                  Neurotrophic receptor tyrosine kinase (NTRK) fusions are oncogenic drivers for a variety of adult and pediatric tumors, validated by the US FDA approval of small molecular Trk inhibitors Larotrectinib (1, LOXO-101) and Entrectinib (2). However, gene mutation mediated resistance becomes a major challenge for Trk inhibitor therapies. Herein, we report the design, synthesis and Structure–Activity Relationship investigation of a series of 3-vinylindazole derivatives as new Trk inhibitors with low nanomolar potencies. A representative compound, 7
                     mb, binds to TrkA/B/C with K
                     d values of 1.6, 3.1 and 4.9 nM, and suppresses their kinase functions with IC50 values of 1.6, 2.9 and 2.0 nM, respectively, but is obviously less potent for the majority of a panel of 403 wild-type kinases in a KINOMEscan selectivity investigation. The compound also potently suppresses proliferation of a panel of BaF3 cells stably transformed with NTRK fusions with IC50 values in low nM ranges. Additionally, the compound exhibits strong inhibition against the Larotrectinib-resistant cells with NTRK1-G667C or NTRK3-G696A mutations with IC50 values of 0.031 and 0.018 μM, respectively. Although the relatively poor oral bioavailability of 7
                     mb will limit its further development, this compound may be utilized a lead molecule for further structural optimization.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><dcterms:subject>Tropomyosin receptor kinase (Trk)</dcterms:subject><dcterms:subject>Neurotrophic receptor tyrosine kinase gene (NTRK)</dcterms:subject><dcterms:subject>Fusion</dcterms:subject><dcterms:subject>Inhibitor</dcterms:subject><dcterms:subject>Resistance</dcterms:subject><dcterms:subject>Mutation</dcterms:subject><link href="https://api.elsevier.com/content/article/pii/S0223523420305249" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S0223523420305249" rel="scidir"/></link></coredata><objects><object ref="fx50" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="54" height="44" size="1168">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx50.jpg?httpAccept=%2A%2F%2A</object><object ref="fx19" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="41" height="32" size="876">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx19.jpg?httpAccept=%2A%2F%2A</object><object ref="sc1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="689" height="347" size="43357">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-sc1.jpg?httpAccept=%2A%2F%2A</object><object ref="fx5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="47" height="45" size="1098">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx5.jpg?httpAccept=%2A%2F%2A</object><object ref="fx23" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="52" height="25" size="891">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx23.jpg?httpAccept=%2A%2F%2A</object><object ref="fx40" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="51" height="36" size="1032">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx40.jpg?httpAccept=%2A%2F%2A</object><object ref="fx56" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="51" height="49" size="1158">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx56.jpg?httpAccept=%2A%2F%2A</object><object ref="fx48" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="51" height="41" size="1086">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx48.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="166" height="96" size="3834">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx2.jpg?httpAccept=%2A%2F%2A</object><object ref="fx51" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="48" height="28" size="904">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx51.jpg?httpAccept=%2A%2F%2A</object><object ref="fx36" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="38" height="42" size="893">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx36.jpg?httpAccept=%2A%2F%2A</object><object ref="fx54" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="51" height="49" size="1157">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx54.jpg?httpAccept=%2A%2F%2A</object><object ref="fx57" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="48" height="34" size="1149">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx57.jpg?httpAccept=%2A%2F%2A</object><object ref="fx9" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="31" height="16" size="633">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx9.jpg?httpAccept=%2A%2F%2A</object><object ref="fx35" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="51" height="29" size="955">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx35.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="624" height="226" size="53256">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="fx39" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="51" height="29" size="953">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx39.jpg?httpAccept=%2A%2F%2A</object><object ref="fx3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="43" height="40" size="979">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="622" height="353" size="32654">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="fx20" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="53" height="51" size="1213">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx20.jpg?httpAccept=%2A%2F%2A</object><object ref="fx26" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="53" height="51" size="1214">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx26.jpg?httpAccept=%2A%2F%2A</object><object ref="fx34" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="42" height="35" size="940">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx34.jpg?httpAccept=%2A%2F%2A</object><object ref="fx41" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="48" height="27" size="916">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx41.jpg?httpAccept=%2A%2F%2A</object><object ref="fx46" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="43" height="43" size="993">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx46.jpg?httpAccept=%2A%2F%2A</object><object ref="sc2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="667" height="367" size="42255">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-sc2.jpg?httpAccept=%2A%2F%2A</object><object ref="fx29" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="46" height="25" size="894">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx29.jpg?httpAccept=%2A%2F%2A</object><object ref="fx8" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="47" height="45" size="1098">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx8.jpg?httpAccept=%2A%2F%2A</object><object ref="fx14" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="45" height="44" size="1037">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx14.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="345" height="200" size="26356">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="557" height="295" size="49142">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="fx25" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="54" height="26" size="949">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx25.jpg?httpAccept=%2A%2F%2A</object><object ref="fx18" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="53" height="51" size="1217">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx18.jpg?httpAccept=%2A%2F%2A</object><object ref="fx4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="28" height="13" size="556">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx4.jpg?httpAccept=%2A%2F%2A</object><object ref="fx13" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="34" height="29" size="838">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx13.jpg?httpAccept=%2A%2F%2A</object><object ref="fx32" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="53" height="51" size="1214">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx32.jpg?httpAccept=%2A%2F%2A</object><object ref="fx15" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="47" height="23" size="764">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx15.jpg?httpAccept=%2A%2F%2A</object><object ref="fx47" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="48" height="28" size="904">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx47.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="781" height="312" size="58514">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="fx24" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="53" height="51" size="1214">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx24.jpg?httpAccept=%2A%2F%2A</object><object ref="fx17" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="40" height="32" size="716">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx17.jpg?httpAccept=%2A%2F%2A</object><object ref="fx37" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="51" height="29" size="954">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx37.jpg?httpAccept=%2A%2F%2A</object><object ref="fx43" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="48" height="28" size="903">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx43.jpg?httpAccept=%2A%2F%2A</object><object ref="fx38" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="47" height="33" size="952">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx38.jpg?httpAccept=%2A%2F%2A</object><object ref="fx31" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="47" height="29" size="885">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx31.jpg?httpAccept=%2A%2F%2A</object><object ref="fx49" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="48" height="28" size="904">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx49.jpg?httpAccept=%2A%2F%2A</object><object ref="fx53" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="48" height="28" size="902">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx53.jpg?httpAccept=%2A%2F%2A</object><object ref="fx52" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="49" height="41" size="1060">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx52.jpg?httpAccept=%2A%2F%2A</object><object ref="fx45" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="48" height="27" size="918">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx45.jpg?httpAccept=%2A%2F%2A</object><object ref="fx16" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="53" height="51" size="1214">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx16.jpg?httpAccept=%2A%2F%2A</object><object ref="fx30" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="53" height="51" size="1214">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx30.jpg?httpAccept=%2A%2F%2A</object><object ref="fx27" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="51" height="29" size="953">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx27.jpg?httpAccept=%2A%2F%2A</object><object ref="fx21" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="40" height="31" size="895">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx21.jpg?httpAccept=%2A%2F%2A</object><object ref="fx12" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="48" height="46" size="1088">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx12.jpg?httpAccept=%2A%2F%2A</object><object ref="fx10" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="47" height="45" size="1099">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx10.jpg?httpAccept=%2A%2F%2A</object><object ref="fx28" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="52" height="50" size="1200">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx28.jpg?httpAccept=%2A%2F%2A</object><object ref="fx6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="47" height="45" size="1098">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx6.jpg?httpAccept=%2A%2F%2A</object><object ref="sc4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="578" height="383" size="36365">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-sc4.jpg?httpAccept=%2A%2F%2A</object><object ref="fx11" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="32" height="24" size="702">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx11.jpg?httpAccept=%2A%2F%2A</object><object ref="fx42" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="49" height="43" size="1115">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx42.jpg?httpAccept=%2A%2F%2A</object><object ref="fx22" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="53" height="51" size="1213">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx22.jpg?httpAccept=%2A%2F%2A</object><object ref="sc3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="667" height="470" size="49781">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-sc3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="735" height="393" size="72297">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="fx7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="34" height="18" size="744">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx7.jpg?httpAccept=%2A%2F%2A</object><object ref="fx44" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="45" height="39" size="1071">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx44.jpg?httpAccept=%2A%2F%2A</object><object ref="fx55" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="47" height="33" size="1165">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx55.jpg?httpAccept=%2A%2F%2A</object><object ref="fx33" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="45" height="28" size="895">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx33.jpg?httpAccept=%2A%2F%2A</object><object ref="fx50" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="203" height="164" size="4307">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx50.sml?httpAccept=%2A%2F%2A</object><object ref="fx19" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="182" height="142" size="2976">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx19.sml?httpAccept=%2A%2F%2A</object><object ref="sc1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="110" size="4962">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-sc1.sml?httpAccept=%2A%2F%2A</object><object ref="fx5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="209" height="201" size="3297">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx5.sml?httpAccept=%2A%2F%2A</object><object ref="fx23" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="106" size="3902">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx23.sml?httpAccept=%2A%2F%2A</object><object ref="fx40" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="154" size="4503">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx40.sml?httpAccept=%2A%2F%2A</object><object ref="fx56" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="171" height="164" size="3694">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx56.sml?httpAccept=%2A%2F%2A</object><object ref="fx48" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="202" height="164" size="4106">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx48.sml?httpAccept=%2A%2F%2A</object><object ref="fx2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="126" size="3724">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx2.sml?httpAccept=%2A%2F%2A</object><object ref="fx51" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="216" height="124" size="2779">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx51.sml?httpAccept=%2A%2F%2A</object><object ref="fx36" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="172" height="188" size="3076">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx36.sml?httpAccept=%2A%2F%2A</object><object ref="fx54" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="171" height="164" size="3588">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx54.sml?httpAccept=%2A%2F%2A</object><object ref="fx57" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="213" height="151" size="4203">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx57.sml?httpAccept=%2A%2F%2A</object><object ref="fx9" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="139" height="73" size="1967">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx9.sml?httpAccept=%2A%2F%2A</object><object ref="fx35" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="125" size="4371">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx35.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="79" size="8533">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="fx39" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="125" size="4245">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx39.sml?httpAccept=%2A%2F%2A</object><object ref="fx3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="193" height="179" size="3055">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx3.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="124" size="4278">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="fx20" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="171" height="164" size="3630">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx20.sml?httpAccept=%2A%2F%2A</object><object ref="fx26" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="171" height="164" size="3627">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx26.sml?httpAccept=%2A%2F%2A</object><object ref="fx34" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="188" height="158" size="2959">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx34.sml?httpAccept=%2A%2F%2A</object><object ref="fx41" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="216" height="123" size="2870">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx41.sml?httpAccept=%2A%2F%2A</object><object ref="fx46" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="193" height="193" size="2995">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx46.sml?httpAccept=%2A%2F%2A</object><object ref="sc2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="121" size="4989">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-sc2.sml?httpAccept=%2A%2F%2A</object><object ref="fx29" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="207" height="114" size="2802">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx29.sml?httpAccept=%2A%2F%2A</object><object ref="fx8" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="209" height="201" size="3226">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx8.sml?httpAccept=%2A%2F%2A</object><object ref="fx14" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="202" height="198" size="3121">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx14.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="127" size="9323">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx1.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="116" size="9708">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="fx25" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="105" size="3822">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx25.sml?httpAccept=%2A%2F%2A</object><object ref="fx18" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="171" height="164" size="3628">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx18.sml?httpAccept=%2A%2F%2A</object><object ref="fx4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="126" height="57" size="1554">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx4.sml?httpAccept=%2A%2F%2A</object><object ref="fx13" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="152" height="130" size="2380">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx13.sml?httpAccept=%2A%2F%2A</object><object ref="fx32" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="171" height="164" size="3642">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx32.sml?httpAccept=%2A%2F%2A</object><object ref="fx15" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="209" height="101" size="2303">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx15.sml?httpAccept=%2A%2F%2A</object><object ref="fx47" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="216" height="124" size="2805">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx47.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="88" size="10163">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="fx24" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="171" height="164" size="3548">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx24.sml?httpAccept=%2A%2F%2A</object><object ref="fx17" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="179" height="141" size="2300">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx17.sml?httpAccept=%2A%2F%2A</object><object ref="fx37" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="125" size="4259">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx37.sml?httpAccept=%2A%2F%2A</object><object ref="fx43" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="216" height="124" size="2875">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx43.sml?httpAccept=%2A%2F%2A</object><object ref="fx38" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="209" height="146" size="2965">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx38.sml?httpAccept=%2A%2F%2A</object><object ref="fx31" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="212" height="131" size="2722">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx31.sml?httpAccept=%2A%2F%2A</object><object ref="fx49" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="216" height="124" size="2764">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx49.sml?httpAccept=%2A%2F%2A</object><object ref="fx53" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="216" height="124" size="2795">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx53.sml?httpAccept=%2A%2F%2A</object><object ref="fx52" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="194" height="164" size="4241">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx52.sml?httpAccept=%2A%2F%2A</object><object ref="fx45" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="216" height="123" size="2841">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx45.sml?httpAccept=%2A%2F%2A</object><object ref="fx16" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="171" height="164" size="3651">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx16.sml?httpAccept=%2A%2F%2A</object><object ref="fx30" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="171" height="164" size="3579">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx30.sml?httpAccept=%2A%2F%2A</object><object ref="fx27" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="125" size="4316">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx27.sml?httpAccept=%2A%2F%2A</object><object ref="fx21" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="180" height="140" size="2771">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx21.sml?httpAccept=%2A%2F%2A</object><object ref="fx12" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="214" height="204" size="3199">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx12.sml?httpAccept=%2A%2F%2A</object><object ref="fx10" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="209" height="201" size="3272">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx10.sml?httpAccept=%2A%2F%2A</object><object ref="fx28" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="171" height="164" size="3649">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx28.sml?httpAccept=%2A%2F%2A</object><object ref="fx6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="209" height="201" size="3278">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx6.sml?httpAccept=%2A%2F%2A</object><object ref="sc4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="145" size="5403">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-sc4.sml?httpAccept=%2A%2F%2A</object><object ref="fx11" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="145" height="110" size="2370">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx11.sml?httpAccept=%2A%2F%2A</object><object ref="fx42" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="218" height="190" size="3254">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx42.sml?httpAccept=%2A%2F%2A</object><object ref="fx22" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="171" height="164" size="3552">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx22.sml?httpAccept=%2A%2F%2A</object><object ref="sc3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="154" size="5735">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-sc3.sml?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="117" size="11092">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="fx7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="151" height="80" size="2239">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx7.sml?httpAccept=%2A%2F%2A</object><object ref="fx44" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="202" height="177" size="3133">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx44.sml?httpAccept=%2A%2F%2A</object><object ref="fx55" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="208" height="146" size="3585">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx55.sml?httpAccept=%2A%2F%2A</object><object ref="fx33" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="203" height="126" size="2504">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx33.sml?httpAccept=%2A%2F%2A</object><object ref="fx50" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="242" height="195" size="6407">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx50_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx19" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="182" height="142" size="4696">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx19_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3051" height="1537" size="326244">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-sc1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="209" height="201" size="5660">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx23" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="232" height="112" size="4884">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx23_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx40" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="227" height="160" size="5447">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx40_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx56" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="226" height="217" size="6317">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx56_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx48" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="226" height="183" size="5595">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx48_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="737" height="425" size="26849">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx51" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="216" height="124" size="4550">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx51_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx36" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="172" height="188" size="5329">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx36_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx54" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="226" height="217" size="6318">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx54_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx57" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="213" height="151" size="6478">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx57_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx9" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="139" height="73" size="3116">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx9_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx35" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="227" height="130" size="5032">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx35_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2764" height="999" size="425488">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx39" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="227" height="130" size="5036">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx39_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="193" height="179" size="4927">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2756" height="1563" size="251309">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx20" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="238" height="228" size="6601">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx20_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx26" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="238" height="228" size="6598">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx26_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx34" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="188" height="158" size="5363">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx34_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx41" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="216" height="123" size="4487">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx41_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx46" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="193" height="193" size="5188">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx46_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2953" height="1625" size="346387">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-sc2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx29" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="207" height="114" size="4359">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx29_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx8" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="209" height="201" size="5660">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx8_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx14" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="202" height="198" size="5416">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx14_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1528" height="886" size="178666">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2469" height="1308" size="371346">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx25" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="239" height="115" size="5010">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx25_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx18" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="238" height="228" size="6590">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx18_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="126" height="57" size="2514">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx13" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="152" height="130" size="3740">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx13_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx32" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="238" height="228" size="6607">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx32_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx15" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="209" height="101" size="3849">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx15_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx47" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="216" height="124" size="4554">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx47_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3459" height="1383" size="572636">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-gr4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx24" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="238" height="228" size="6594">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx24_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx17" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="179" height="141" size="4231">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx17_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx37" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="227" height="130" size="5031">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx37_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx43" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="216" height="124" size="4552">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx43_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx38" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="209" height="146" size="5518">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx38_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx31" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="212" height="131" size="4407">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx31_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx49" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="216" height="124" size="4550">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx49_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx53" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="216" height="124" size="4553">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx53_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx52" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="221" height="187" size="5874">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx52_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx45" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="216" height="123" size="4496">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx45_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx16" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="238" height="228" size="6598">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx16_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx30" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="238" height="228" size="6606">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx30_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx27" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="227" height="130" size="5022">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx27_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx21" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="180" height="140" size="4783">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx21_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx12" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="214" height="204" size="5870">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx12_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx10" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="209" height="201" size="5651">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx10_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx28" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="232" height="222" size="6358">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx28_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="209" height="201" size="5665">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2559" height="1695" size="280871">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-sc4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx11" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="145" height="110" size="3501">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx11_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx42" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="218" height="190" size="5644">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx42_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx22" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="238" height="228" size="6603">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx22_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2953" height="2081" size="394400">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-sc3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3256" height="1743" size="730885">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-gr5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="151" height="80" size="3378">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx7_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx44" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="202" height="177" size="5245">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx44_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx55" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="208" height="146" size="6347">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx55_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx33" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="203" height="126" size="4109">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-fx33_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="mmc1" category="standard" type="APPLICATION" multimediatype="Microsoft Word file" mimetype="application/word" size="11619840">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-mmc1.doc?httpAccept=%2A%2F%2A</object><object ref="am" category="standard" type="AAM-PDF" multimediatype="Acrobat PDF file" mimetype="application/pdf" size="976427">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523420305249-am.pdf?httpAccept=%2A%2F%2A</object></objects><scopus-id>85088042935</scopus-id><scopus-eid>2-s2.0-85088042935</scopus-eid><pubmed-id>32702585</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/85088042935" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271932</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291732</xocs:ssid>
         <xocs:ssid type="subj">291789</xocs:ssid>
         <xocs:ssid type="subj">291858</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>European Journal of Medicinal Chemistry</xocs:srctitle>
      <xocs:normalized-srctitle>EUROPEANJOURNALMEDICINALCHEMISTRY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20200713">2020-07-13</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20200713">2020-07-13</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20200720">2020-07-20</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20200720">2020-07-20</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2020-09-10T20:42:47</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S0223523420305249</xocs:eid>
      <xocs:pii-formatted>S0223-5234(20)30524-9</xocs:pii-formatted>
      <xocs:pii-unformatted>S0223523420305249</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.ejmech.2020.112552</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.1</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S0223523420X0016X</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20210204">2021-02-04T15:45:21.045066Z</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20201001</xocs:date-search-begin>
      <xocs:year-nav>2020</xocs:year-nav>
      <xocs:indexeddate epoch="1594652442">2020-07-13T15:00:42.107317Z</xocs:indexeddate>
      <xocs:articleinfo>absattachment articleinfo articlenumber articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issn issnnorm itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pii piinorm pubdatestart pubdatetxt pubyr sectiontitle sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings suppl tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table e-component body acknowledge affil appendices articletitle auth authfirstini authfull authkeywords authlast footnotes grantnumber grantsponsor grantsponsorid highlightsabst nomenclature primabst pubtype ref specialabst</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>0223-5234</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>02235234</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>203</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>203</xocs:volume>
      </xocs:volume-list>
      <xocs:suppl>C</xocs:suppl>
      <xocs:vol-iss-suppl-text>Volume 203</xocs:vol-iss-suppl-text>
      <xocs:sort-order>33</xocs:sort-order>
      <xocs:first-fp>112552</xocs:first-fp>
      <xocs:article-number>112552</xocs:article-number>
      <xocs:pages>
         <xocs:first-page>112552</xocs:first-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>20201001</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>1 October 2020</xocs:cover-date-text>
      <xocs:cover-date-start>2020-10-01</xocs:cover-date-start>
      <xocs:cover-date-year>2020</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>Full papers</xocs:hub-sec-title>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>fla</xocs:document-subtype>
      <xocs:copyright-line>© 2020 Elsevier Masson SAS. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>DESIGNSYNTHESISSTRUCTUREACTIVITYRELATIONSHIPSSAR3VINYLINDAZOLEDERIVATIVESNEWSELECTIVETROPOMYOSINRECEPTORKINASESTRKINHIBITORS</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>DUAN</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>Y</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:nomenclature">
            <xocs:item-toc-section-title>Abbreviations</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>1</xocs:item-toc-label>
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>2</xocs:item-toc-label>
            <xocs:item-toc-section-title>Molecular design</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>3</xocs:item-toc-label>
            <xocs:item-toc-section-title>Chemistry</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>4</xocs:item-toc-label>
            <xocs:item-toc-section-title>Results and discussion</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>5</xocs:item-toc-label>
            <xocs:item-toc-section-title>Conclusion</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>6</xocs:item-toc-label>
            <xocs:item-toc-section-title>Experiment section</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>6.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>General methods for chemistry</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>6.1.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedure A for 3-Iodoindazole derivatives</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>6.1.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedure B for THP protection</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>6.1.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedure C for Heck coupling reaction</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>6.1.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedure D for THP deprotection</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>6.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>
                  <ce:italic>In vitro</ce:italic> enzymatic activity assay</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>6.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>Construction of BaF3 model and cell culture</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>6.4</xocs:item-toc-label>
               <xocs:item-toc-section-title>Anti-proliferation activity <ce:italic>in vitro</ce:italic>
               </xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>6.5</xocs:item-toc-label>
               <xocs:item-toc-section-title>Western blot analysis</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>6.6</xocs:item-toc-label>
               <xocs:item-toc-section-title>Determination of pharmacokinetic parameters in rats</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>6.7</xocs:item-toc-label>
               <xocs:item-toc-section-title>Molecular modeling</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgements</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:appendices">
            <xocs:item-toc-label>Appendix A</xocs:item-toc-label>
            <xocs:item-toc-section-title>Supplementary data</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sref1">
            <xocs:ref-normalized-surname>HUANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>609</xocs:ref-first-fp>
            <xocs:ref-last-lp>642</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref2">
            <xocs:ref-normalized-surname>SKAPER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>12</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref3">
            <xocs:ref-normalized-surname>DEINHARDT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>103</xocs:ref-first-fp>
            <xocs:ref-last-lp>119</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref4">
            <xocs:ref-normalized-surname>MARTINZANCA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1989</xocs:ref-pub-year>
            <xocs:ref-first-fp>24</xocs:ref-first-fp>
            <xocs:ref-last-lp>33</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref5">
            <xocs:ref-normalized-surname>KLEIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1989</xocs:ref-pub-year>
            <xocs:ref-first-fp>3701</xocs:ref-first-fp>
            <xocs:ref-last-lp>3709</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref6">
            <xocs:ref-normalized-surname>LAMBALLE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1991</xocs:ref-pub-year>
            <xocs:ref-first-fp>967</xocs:ref-first-fp>
            <xocs:ref-last-lp>979</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref7">
            <xocs:ref-normalized-surname>COCCO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>731</xocs:ref-first-fp>
            <xocs:ref-last-lp>747</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref8">
            <xocs:ref-normalized-surname>VAISHNAVI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>25</xocs:ref-first-fp>
            <xocs:ref-last-lp>34</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref9">
            <xocs:ref-normalized-surname>PULCIANI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1982</xocs:ref-pub-year>
            <xocs:ref-first-fp>539</xocs:ref-first-fp>
            <xocs:ref-last-lp>542</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref10">
            <xocs:ref-normalized-surname>AMATU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-article-number>e000023</xocs:ref-article-number>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref11">
            <xocs:ref-normalized-surname>DRILON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>920</xocs:ref-first-fp>
            <xocs:ref-last-lp>926</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref12">
            <xocs:ref-normalized-surname>TOGNON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>367</xocs:ref-first-fp>
            <xocs:ref-last-lp>376</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref13">
            <xocs:ref-normalized-surname>KNEZEVICH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-first-fp>184</xocs:ref-first-fp>
            <xocs:ref-last-lp>187</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref14">
            <xocs:ref-normalized-surname>GRECO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>44</xocs:ref-first-fp>
            <xocs:ref-last-lp>49</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref15">
            <xocs:ref-normalized-surname>FRATTINI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>1141</xocs:ref-first-fp>
            <xocs:ref-last-lp>1149</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref16">
            <xocs:ref-normalized-surname>KIM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-article-number>e91940</xocs:ref-article-number>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref17">
            <xocs:ref-normalized-surname>VAISHNAVI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>1469</xocs:ref-first-fp>
            <xocs:ref-last-lp>1472</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref18">
            <xocs:ref-normalized-surname>BAILEY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>733</xocs:ref-first-fp>
            <xocs:ref-last-lp>751</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref19">
            <xocs:ref-normalized-surname>BAILEY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>831</xocs:ref-first-fp>
            <xocs:ref-last-lp>849</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref20">
            <xocs:ref-normalized-surname>BAILEY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>325</xocs:ref-first-fp>
            <xocs:ref-last-lp>339</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref21">
            <xocs:ref-normalized-surname>BERNARDGAUTHIER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>6897</xocs:ref-first-fp>
            <xocs:ref-last-lp>6910</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref22">
            <xocs:ref-normalized-surname>BERNARDGAUTHIER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1737</xocs:ref-first-fp>
            <xocs:ref-last-lp>1743</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref23">
            <xocs:ref-normalized-surname>BAILEY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>2697</xocs:ref-first-fp>
            <xocs:ref-last-lp>2702</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref24">
            <xocs:ref-normalized-surname>DOEBELE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>1049</xocs:ref-first-fp>
            <xocs:ref-last-lp>1057</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref25">
            <xocs:ref-normalized-surname>MENICHINCHERI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>3392</xocs:ref-first-fp>
            <xocs:ref-last-lp>3408</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref26">
            <xocs:ref-normalized-surname>RICHARD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>6523</xocs:ref-first-fp>
            <xocs:ref-last-lp>6540</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref27">
            <xocs:ref-normalized-surname>FUSE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>2130</xocs:ref-first-fp>
            <xocs:ref-last-lp>2143</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref28">
            <xocs:ref-normalized-surname>YAKES</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>2298</xocs:ref-first-fp>
            <xocs:ref-last-lp>2308</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref29">
            <xocs:ref-normalized-surname>SHAMROE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>1540</xocs:ref-first-fp>
            <xocs:ref-last-lp>1546</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref30">
            <xocs:ref-normalized-surname>DRILON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>43</xocs:ref-first-fp>
            <xocs:ref-last-lp>44</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref31">
            <xocs:ref-normalized-surname>DRILON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>731</xocs:ref-first-fp>
            <xocs:ref-last-lp>739</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref32">
            <xocs:ref-normalized-surname>HYMAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>162</xocs:ref-first-fp>
            <xocs:ref-last-lp>163</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref33">
            <xocs:ref-normalized-surname>RUSSO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>36</xocs:ref-first-fp>
            <xocs:ref-last-lp>44</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref34">
            <xocs:ref-normalized-surname>DRILON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>963</xocs:ref-first-fp>
            <xocs:ref-last-lp>972</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref35">
            <xocs:ref-normalized-surname>RICHARD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>1413</xocs:ref-first-fp>
            <xocs:ref-last-lp>1437</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib36a">
            <xocs:ref-normalized-surname>LITTKE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>4020</xocs:ref-first-fp>
            <xocs:ref-last-lp>4028</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib36b">
            <xocs:ref-normalized-surname>KOTHA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>9633</xocs:ref-first-fp>
            <xocs:ref-last-lp>9695</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref36">
            <xocs:ref-normalized-surname>CHINCHILLA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>874</xocs:ref-first-fp>
            <xocs:ref-last-lp>922</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref37">
            <xocs:ref-normalized-surname>HECK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1972</xocs:ref-pub-year>
            <xocs:ref-first-fp>2320</xocs:ref-first-fp>
            <xocs:ref-last-lp>2322</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref38">
            <xocs:ref-normalized-surname>MITSUNOBU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1967</xocs:ref-pub-year>
            <xocs:ref-first-fp>935</xocs:ref-first-fp>
            <xocs:ref-last-lp>939</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>O</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib40a">
            <xocs:ref-normalized-surname>ANIL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1994</xocs:ref-pub-year>
            <xocs:ref-first-fp>7901</xocs:ref-first-fp>
            <xocs:ref-last-lp>7902</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib40b">
            <xocs:ref-normalized-surname>PAUL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1994</xocs:ref-pub-year>
            <xocs:ref-first-fp>5969</xocs:ref-first-fp>
            <xocs:ref-last-lp>5970</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref39">
            <xocs:ref-normalized-surname>RODEMS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>9</xocs:ref-first-fp>
            <xocs:ref-last-lp>19</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref40">
            <xocs:ref-normalized-surname>SHIRAHASHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>2023</xocs:ref-first-fp>
            <xocs:ref-last-lp>2326</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref41">
            <xocs:ref-normalized-surname>ABIAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>329</xocs:ref-first-fp>
            <xocs:ref-last-lp>336</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref42">
            <xocs:ref-normalized-surname>REN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>879</xocs:ref-first-fp>
            <xocs:ref-last-lp>894</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>DUANX2020X112552</xocs:refkey3>
         <xocs:refkey4ai>DUANX2020X112552XY</xocs:refkey4ai>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:open-research>
         <xocs:or-embargo-opening-date>2022-07-20T00:00:00.000Z</xocs:or-embargo-opening-date>
      </xocs:open-research>
      <xocs:self-archiving>
         <xocs:sa-start-date>2022-07-20T00:00:00.000Z</xocs:sa-start-date>
         <xocs:sa-user-license>http://creativecommons.org/licenses/by-nc-nd/4.0/</xocs:sa-user-license>
      </xocs:self-archiving>
      <xocs:copyright-info>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">© 2020 Elsevier Masson SAS. All rights reserved.</xocs:cp-notice>
         </xocs:cp-notices>
      </xocs:copyright-info>
      <xocs:funding-list has-funding-info="1">
         <xocs:funding-addon-generated-timestamp>2020-06-15T00:56:58.270Z</xocs:funding-addon-generated-timestamp>
         <xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/eoas</xocs:funding-addon-type>
         <xocs:funding>
            <xocs:funding-agency-acronym>NSFC</xocs:funding-agency-acronym>
            <xocs:funding-agency>National Natural Science Foundation of China</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100001809</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/1814991</xocs:funding-agency-country>
         </xocs:funding>
      </xocs:funding-list>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S0223-5234(20)30524-9</xocs:pii-formatted>
         <xocs:pii-unformatted>S0223523420305249</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S0223523420305249</xocs:eid>
         <xocs:doi>10.1016/j.ejmech.2020.112552</xocs:doi>
         <xocs:cid>271932</xocs:cid>
         <xocs:timestamp>2021-02-04T15:45:21.045066Z</xocs:timestamp>
         <xocs:cover-date-start>2020-10-01</xocs:cover-date-start>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/MAIN/application/pdf/08d6637593bdcc538428c15338795610/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>2806777</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>22</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S0223523420305249-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/PREVIEW/image/png/f1ef04976204f94503a2ea0cd9b15761/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>57145</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx50.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx50/DOWNSAMPLED/image/jpeg/68c3d103b93d9aeaeb9be70e6eb03339/fx50.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx50</xocs:file-basename>
               <xocs:filename>fx50.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1168</xocs:filesize>
               <xocs:pixel-height>44</xocs:pixel-height>
               <xocs:pixel-width>54</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx19.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx19/DOWNSAMPLED/image/jpeg/b9eb7506e0ae935eb1325a9ea7f39048/fx19.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx19</xocs:file-basename>
               <xocs:filename>fx19.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>876</xocs:filesize>
               <xocs:pixel-height>32</xocs:pixel-height>
               <xocs:pixel-width>41</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-sc1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/sc1/DOWNSAMPLED/image/jpeg/c27c4b21c46bb906e0e8009354ecc5a5/sc1.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>43357</xocs:filesize>
               <xocs:pixel-height>347</xocs:pixel-height>
               <xocs:pixel-width>689</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx5/DOWNSAMPLED/image/jpeg/73e7b4cba802bef4d49c46be15eece44/fx5.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1098</xocs:filesize>
               <xocs:pixel-height>45</xocs:pixel-height>
               <xocs:pixel-width>47</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx23.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx23/DOWNSAMPLED/image/jpeg/26bb9501092f38637ed3b7cd0c85e371/fx23.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx23</xocs:file-basename>
               <xocs:filename>fx23.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>891</xocs:filesize>
               <xocs:pixel-height>25</xocs:pixel-height>
               <xocs:pixel-width>52</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx40.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx40/DOWNSAMPLED/image/jpeg/d4d184c3f969c4f3a6c7c749d9f3d24e/fx40.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx40</xocs:file-basename>
               <xocs:filename>fx40.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1032</xocs:filesize>
               <xocs:pixel-height>36</xocs:pixel-height>
               <xocs:pixel-width>51</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx56.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx56/DOWNSAMPLED/image/jpeg/3a1d82424f4dbe6d60e5216146a8c1dd/fx56.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx56</xocs:file-basename>
               <xocs:filename>fx56.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1158</xocs:filesize>
               <xocs:pixel-height>49</xocs:pixel-height>
               <xocs:pixel-width>51</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx48.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx48/DOWNSAMPLED/image/jpeg/387faa3c116722088312dd68edbcaa87/fx48.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx48</xocs:file-basename>
               <xocs:filename>fx48.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1086</xocs:filesize>
               <xocs:pixel-height>41</xocs:pixel-height>
               <xocs:pixel-width>51</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx2/DOWNSAMPLED/image/jpeg/1e59340f4370f35af1daccf3c8bf789f/fx2.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3834</xocs:filesize>
               <xocs:pixel-height>96</xocs:pixel-height>
               <xocs:pixel-width>166</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx51.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx51/DOWNSAMPLED/image/jpeg/c0db9a3505ee2483eeea97457d291d5a/fx51.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx51</xocs:file-basename>
               <xocs:filename>fx51.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>904</xocs:filesize>
               <xocs:pixel-height>28</xocs:pixel-height>
               <xocs:pixel-width>48</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx36.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx36/DOWNSAMPLED/image/jpeg/8634a3911dec69fffbbfe6f08af0126a/fx36.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx36</xocs:file-basename>
               <xocs:filename>fx36.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>893</xocs:filesize>
               <xocs:pixel-height>42</xocs:pixel-height>
               <xocs:pixel-width>38</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx54.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx54/DOWNSAMPLED/image/jpeg/2a4e25b12249e8a032d395d24a1a3aac/fx54.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx54</xocs:file-basename>
               <xocs:filename>fx54.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1157</xocs:filesize>
               <xocs:pixel-height>49</xocs:pixel-height>
               <xocs:pixel-width>51</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx57.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx57/DOWNSAMPLED/image/jpeg/46091d1692f094d1eff65959d6a158c5/fx57.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx57</xocs:file-basename>
               <xocs:filename>fx57.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1149</xocs:filesize>
               <xocs:pixel-height>34</xocs:pixel-height>
               <xocs:pixel-width>48</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx9.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx9/DOWNSAMPLED/image/jpeg/140e51902319b4eee2da4cd895a10d30/fx9.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>633</xocs:filesize>
               <xocs:pixel-height>16</xocs:pixel-height>
               <xocs:pixel-width>31</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx35.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx35/DOWNSAMPLED/image/jpeg/130a5817264ae35fce98dfea9636a111/fx35.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx35</xocs:file-basename>
               <xocs:filename>fx35.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>955</xocs:filesize>
               <xocs:pixel-height>29</xocs:pixel-height>
               <xocs:pixel-width>51</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/gr2/DOWNSAMPLED/image/jpeg/7715d14fb18665bf9ee23e184e165b14/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>53256</xocs:filesize>
               <xocs:pixel-height>226</xocs:pixel-height>
               <xocs:pixel-width>624</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx39.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx39/DOWNSAMPLED/image/jpeg/ca18f6ddf7166b85cd278e4677495887/fx39.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx39</xocs:file-basename>
               <xocs:filename>fx39.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>953</xocs:filesize>
               <xocs:pixel-height>29</xocs:pixel-height>
               <xocs:pixel-width>51</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx3/DOWNSAMPLED/image/jpeg/b4f244fea96b5f090d2738b80494ebe3/fx3.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>979</xocs:filesize>
               <xocs:pixel-height>40</xocs:pixel-height>
               <xocs:pixel-width>43</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/gr1/DOWNSAMPLED/image/jpeg/5b7d14243545baf7de224995425ad25b/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>32654</xocs:filesize>
               <xocs:pixel-height>353</xocs:pixel-height>
               <xocs:pixel-width>622</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx20.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx20/DOWNSAMPLED/image/jpeg/c71adac7f81a685ea9d733ccea7491e4/fx20.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx20</xocs:file-basename>
               <xocs:filename>fx20.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1213</xocs:filesize>
               <xocs:pixel-height>51</xocs:pixel-height>
               <xocs:pixel-width>53</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx26.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx26/DOWNSAMPLED/image/jpeg/b192c6c164ca8533ad74157b1b24c67b/fx26.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx26</xocs:file-basename>
               <xocs:filename>fx26.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1214</xocs:filesize>
               <xocs:pixel-height>51</xocs:pixel-height>
               <xocs:pixel-width>53</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx34.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx34/DOWNSAMPLED/image/jpeg/60a16102dde0311a09d9c666f7678764/fx34.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx34</xocs:file-basename>
               <xocs:filename>fx34.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>940</xocs:filesize>
               <xocs:pixel-height>35</xocs:pixel-height>
               <xocs:pixel-width>42</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx41.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx41/DOWNSAMPLED/image/jpeg/6aa419263fe52cf1dd2e743cc2df6e1f/fx41.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx41</xocs:file-basename>
               <xocs:filename>fx41.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>916</xocs:filesize>
               <xocs:pixel-height>27</xocs:pixel-height>
               <xocs:pixel-width>48</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx46.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx46/DOWNSAMPLED/image/jpeg/b2ada30bcfe23f59769235e64d3386c8/fx46.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx46</xocs:file-basename>
               <xocs:filename>fx46.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>993</xocs:filesize>
               <xocs:pixel-height>43</xocs:pixel-height>
               <xocs:pixel-width>43</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-sc2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/sc2/DOWNSAMPLED/image/jpeg/406956dadb7573fb3723e567b53ea14a/sc2.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc2</xocs:file-basename>
               <xocs:filename>sc2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>42255</xocs:filesize>
               <xocs:pixel-height>367</xocs:pixel-height>
               <xocs:pixel-width>667</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx29.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx29/DOWNSAMPLED/image/jpeg/f0ca69af4e8c604d9eef98624413ed63/fx29.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx29</xocs:file-basename>
               <xocs:filename>fx29.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>894</xocs:filesize>
               <xocs:pixel-height>25</xocs:pixel-height>
               <xocs:pixel-width>46</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx8.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx8/DOWNSAMPLED/image/jpeg/567b0c22a9b7ca6c44941c2463a1620d/fx8.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1098</xocs:filesize>
               <xocs:pixel-height>45</xocs:pixel-height>
               <xocs:pixel-width>47</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx14.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx14/DOWNSAMPLED/image/jpeg/050201396f7c53371e3c5a4ac998989e/fx14.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx14</xocs:file-basename>
               <xocs:filename>fx14.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1037</xocs:filesize>
               <xocs:pixel-height>44</xocs:pixel-height>
               <xocs:pixel-width>45</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx1/DOWNSAMPLED/image/jpeg/f77ae65b44379a2dcd6f62d39e91092b/fx1.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>26356</xocs:filesize>
               <xocs:pixel-height>200</xocs:pixel-height>
               <xocs:pixel-width>345</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-gr3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/gr3/DOWNSAMPLED/image/jpeg/ab84a8e7281b6a67deb48fa1a3cd89d0/gr3.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>49142</xocs:filesize>
               <xocs:pixel-height>295</xocs:pixel-height>
               <xocs:pixel-width>557</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx25.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx25/DOWNSAMPLED/image/jpeg/2e9823c9f79e69d7db8f2f9a44da5bc6/fx25.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx25</xocs:file-basename>
               <xocs:filename>fx25.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>949</xocs:filesize>
               <xocs:pixel-height>26</xocs:pixel-height>
               <xocs:pixel-width>54</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx18.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx18/DOWNSAMPLED/image/jpeg/9c1014bacb2f188c74f8019614426a6f/fx18.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx18</xocs:file-basename>
               <xocs:filename>fx18.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1217</xocs:filesize>
               <xocs:pixel-height>51</xocs:pixel-height>
               <xocs:pixel-width>53</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx4/DOWNSAMPLED/image/jpeg/c3abff1469377e4238cbaffe1f7e09b0/fx4.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>556</xocs:filesize>
               <xocs:pixel-height>13</xocs:pixel-height>
               <xocs:pixel-width>28</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx13.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx13/DOWNSAMPLED/image/jpeg/b9450b1aeb69211495bd5971f6a68bfe/fx13.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx13</xocs:file-basename>
               <xocs:filename>fx13.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>838</xocs:filesize>
               <xocs:pixel-height>29</xocs:pixel-height>
               <xocs:pixel-width>34</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx32.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx32/DOWNSAMPLED/image/jpeg/c393dc9113869d14a523e2e26e812969/fx32.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx32</xocs:file-basename>
               <xocs:filename>fx32.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1214</xocs:filesize>
               <xocs:pixel-height>51</xocs:pixel-height>
               <xocs:pixel-width>53</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx15.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx15/DOWNSAMPLED/image/jpeg/83b8de48ea51b96fe97b14db05d70a49/fx15.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx15</xocs:file-basename>
               <xocs:filename>fx15.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>764</xocs:filesize>
               <xocs:pixel-height>23</xocs:pixel-height>
               <xocs:pixel-width>47</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx47.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx47/DOWNSAMPLED/image/jpeg/375b3befee8f12bb2575190face20501/fx47.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx47</xocs:file-basename>
               <xocs:filename>fx47.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>904</xocs:filesize>
               <xocs:pixel-height>28</xocs:pixel-height>
               <xocs:pixel-width>48</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-gr4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/gr4/DOWNSAMPLED/image/jpeg/6452f884da3c09f2400ecb8d99e00d5f/gr4.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>58514</xocs:filesize>
               <xocs:pixel-height>312</xocs:pixel-height>
               <xocs:pixel-width>781</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx24.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx24/DOWNSAMPLED/image/jpeg/0badd8854252595e5e447bea06f7270c/fx24.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx24</xocs:file-basename>
               <xocs:filename>fx24.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1214</xocs:filesize>
               <xocs:pixel-height>51</xocs:pixel-height>
               <xocs:pixel-width>53</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx17.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx17/DOWNSAMPLED/image/jpeg/3b6919e3ceabfaea4ab875a9b2aa627e/fx17.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx17</xocs:file-basename>
               <xocs:filename>fx17.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>716</xocs:filesize>
               <xocs:pixel-height>32</xocs:pixel-height>
               <xocs:pixel-width>40</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx37.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx37/DOWNSAMPLED/image/jpeg/1b4267beaa98a312b11360946d312619/fx37.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx37</xocs:file-basename>
               <xocs:filename>fx37.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>954</xocs:filesize>
               <xocs:pixel-height>29</xocs:pixel-height>
               <xocs:pixel-width>51</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx43.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx43/DOWNSAMPLED/image/jpeg/41c0965db77ce5f77ac18a37040e5993/fx43.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx43</xocs:file-basename>
               <xocs:filename>fx43.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>903</xocs:filesize>
               <xocs:pixel-height>28</xocs:pixel-height>
               <xocs:pixel-width>48</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx38.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx38/DOWNSAMPLED/image/jpeg/66af1122ba840fd3c482a0a4d31d300b/fx38.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx38</xocs:file-basename>
               <xocs:filename>fx38.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>952</xocs:filesize>
               <xocs:pixel-height>33</xocs:pixel-height>
               <xocs:pixel-width>47</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx31.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx31/DOWNSAMPLED/image/jpeg/44189f77a0fb992ecd4627f373e8a5a7/fx31.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx31</xocs:file-basename>
               <xocs:filename>fx31.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>885</xocs:filesize>
               <xocs:pixel-height>29</xocs:pixel-height>
               <xocs:pixel-width>47</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx49.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx49/DOWNSAMPLED/image/jpeg/5affad5066ef6f74f196651ec130bfa5/fx49.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx49</xocs:file-basename>
               <xocs:filename>fx49.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>904</xocs:filesize>
               <xocs:pixel-height>28</xocs:pixel-height>
               <xocs:pixel-width>48</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx53.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx53/DOWNSAMPLED/image/jpeg/7a4220c15d46af8770f206f7a8224da0/fx53.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx53</xocs:file-basename>
               <xocs:filename>fx53.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>902</xocs:filesize>
               <xocs:pixel-height>28</xocs:pixel-height>
               <xocs:pixel-width>48</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx52.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx52/DOWNSAMPLED/image/jpeg/a347435e60e8c711d6ad2a4cd3cf052f/fx52.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx52</xocs:file-basename>
               <xocs:filename>fx52.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1060</xocs:filesize>
               <xocs:pixel-height>41</xocs:pixel-height>
               <xocs:pixel-width>49</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx45.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx45/DOWNSAMPLED/image/jpeg/8ed519c694f19cd8e89a7318c41651c3/fx45.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx45</xocs:file-basename>
               <xocs:filename>fx45.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>918</xocs:filesize>
               <xocs:pixel-height>27</xocs:pixel-height>
               <xocs:pixel-width>48</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx16.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx16/DOWNSAMPLED/image/jpeg/98f5c1614058bd5c2dad10f8f641bdac/fx16.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx16</xocs:file-basename>
               <xocs:filename>fx16.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1214</xocs:filesize>
               <xocs:pixel-height>51</xocs:pixel-height>
               <xocs:pixel-width>53</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx30.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx30/DOWNSAMPLED/image/jpeg/147952dcb5e8861e95eee9e4beeec23b/fx30.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx30</xocs:file-basename>
               <xocs:filename>fx30.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1214</xocs:filesize>
               <xocs:pixel-height>51</xocs:pixel-height>
               <xocs:pixel-width>53</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx27.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx27/DOWNSAMPLED/image/jpeg/eaa0ae28c44e5861b2daed2e8e97e25c/fx27.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx27</xocs:file-basename>
               <xocs:filename>fx27.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>953</xocs:filesize>
               <xocs:pixel-height>29</xocs:pixel-height>
               <xocs:pixel-width>51</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx21.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx21/DOWNSAMPLED/image/jpeg/1c766dc6ee060559491cccd994dd3fa1/fx21.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx21</xocs:file-basename>
               <xocs:filename>fx21.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>895</xocs:filesize>
               <xocs:pixel-height>31</xocs:pixel-height>
               <xocs:pixel-width>40</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx12.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx12/DOWNSAMPLED/image/jpeg/b85c624920d65b0a531a48e04451e002/fx12.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx12</xocs:file-basename>
               <xocs:filename>fx12.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1088</xocs:filesize>
               <xocs:pixel-height>46</xocs:pixel-height>
               <xocs:pixel-width>48</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx10.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx10/DOWNSAMPLED/image/jpeg/ec050cd25d401926328680b1be5d6612/fx10.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx10</xocs:file-basename>
               <xocs:filename>fx10.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1099</xocs:filesize>
               <xocs:pixel-height>45</xocs:pixel-height>
               <xocs:pixel-width>47</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx28.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx28/DOWNSAMPLED/image/jpeg/ea3d923f93a8eec697f715832c95c66a/fx28.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx28</xocs:file-basename>
               <xocs:filename>fx28.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1200</xocs:filesize>
               <xocs:pixel-height>50</xocs:pixel-height>
               <xocs:pixel-width>52</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx6/DOWNSAMPLED/image/jpeg/560c0673fdb0d052ec08dbc359bc8de0/fx6.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1098</xocs:filesize>
               <xocs:pixel-height>45</xocs:pixel-height>
               <xocs:pixel-width>47</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-sc4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/sc4/DOWNSAMPLED/image/jpeg/e56dfcc635a8e5f9cf4fe5448cced96f/sc4.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc4</xocs:file-basename>
               <xocs:filename>sc4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>36365</xocs:filesize>
               <xocs:pixel-height>383</xocs:pixel-height>
               <xocs:pixel-width>578</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx11.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx11/DOWNSAMPLED/image/jpeg/336ea5a841d43482b8a68216d224fcca/fx11.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx11</xocs:file-basename>
               <xocs:filename>fx11.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>702</xocs:filesize>
               <xocs:pixel-height>24</xocs:pixel-height>
               <xocs:pixel-width>32</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx42.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx42/DOWNSAMPLED/image/jpeg/f5e6a8800d9aed2cd20d4bdd28b3f4ee/fx42.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx42</xocs:file-basename>
               <xocs:filename>fx42.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1115</xocs:filesize>
               <xocs:pixel-height>43</xocs:pixel-height>
               <xocs:pixel-width>49</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx22.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx22/DOWNSAMPLED/image/jpeg/2b85c4646a48f845d5f222059216b52f/fx22.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx22</xocs:file-basename>
               <xocs:filename>fx22.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1213</xocs:filesize>
               <xocs:pixel-height>51</xocs:pixel-height>
               <xocs:pixel-width>53</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-sc3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/sc3/DOWNSAMPLED/image/jpeg/65bdbac7cfdb603cd262443fb3f89d91/sc3.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc3</xocs:file-basename>
               <xocs:filename>sc3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>49781</xocs:filesize>
               <xocs:pixel-height>470</xocs:pixel-height>
               <xocs:pixel-width>667</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-gr5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/gr5/DOWNSAMPLED/image/jpeg/a3fad0eec6290aa8d00ebf9d657db14c/gr5.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>72297</xocs:filesize>
               <xocs:pixel-height>393</xocs:pixel-height>
               <xocs:pixel-width>735</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx7/DOWNSAMPLED/image/jpeg/37ac215a7ad22aeae96084839de18b6f/fx7.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>744</xocs:filesize>
               <xocs:pixel-height>18</xocs:pixel-height>
               <xocs:pixel-width>34</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx44.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx44/DOWNSAMPLED/image/jpeg/1c4fc3daa6c5c344fc6a9c1c333b4d69/fx44.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx44</xocs:file-basename>
               <xocs:filename>fx44.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1071</xocs:filesize>
               <xocs:pixel-height>39</xocs:pixel-height>
               <xocs:pixel-width>45</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx55.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx55/DOWNSAMPLED/image/jpeg/73d718b51519e9eba9e9fbe81c18ca79/fx55.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx55</xocs:file-basename>
               <xocs:filename>fx55.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>1165</xocs:filesize>
               <xocs:pixel-height>33</xocs:pixel-height>
               <xocs:pixel-width>47</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx33.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx33/DOWNSAMPLED/image/jpeg/a602a3a1579877737bd78adbc53b1cd8/fx33.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx33</xocs:file-basename>
               <xocs:filename>fx33.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>895</xocs:filesize>
               <xocs:pixel-height>28</xocs:pixel-height>
               <xocs:pixel-width>45</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx50.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx50/THUMBNAIL/image/gif/ae28b9b05067068cc34bd30bfb18f8fc/fx50.sml</xocs:ucs-locator>
               <xocs:file-basename>fx50</xocs:file-basename>
               <xocs:filename>fx50.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4307</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>203</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx19.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx19/THUMBNAIL/image/gif/3d158ef5cc011d6593b8f556b973e7b9/fx19.sml</xocs:ucs-locator>
               <xocs:file-basename>fx19</xocs:file-basename>
               <xocs:filename>fx19.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2976</xocs:filesize>
               <xocs:pixel-height>142</xocs:pixel-height>
               <xocs:pixel-width>182</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-sc1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/sc1/THUMBNAIL/image/gif/13c38ab31e148f8e0031dd1d9a2a10d8/sc1.sml</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4962</xocs:filesize>
               <xocs:pixel-height>110</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx5/THUMBNAIL/image/gif/fa445f05a33889d50d2fe74670795a75/fx5.sml</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3297</xocs:filesize>
               <xocs:pixel-height>201</xocs:pixel-height>
               <xocs:pixel-width>209</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx23.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx23/THUMBNAIL/image/gif/7f496edb404ef0d96f4976d3c22aca07/fx23.sml</xocs:ucs-locator>
               <xocs:file-basename>fx23</xocs:file-basename>
               <xocs:filename>fx23.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3902</xocs:filesize>
               <xocs:pixel-height>106</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx40.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx40/THUMBNAIL/image/gif/68dc48c3564698aa0bfb9b6542d7b166/fx40.sml</xocs:ucs-locator>
               <xocs:file-basename>fx40</xocs:file-basename>
               <xocs:filename>fx40.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4503</xocs:filesize>
               <xocs:pixel-height>154</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx56.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx56/THUMBNAIL/image/gif/ca3934ef72b10fc475cc224ae883704d/fx56.sml</xocs:ucs-locator>
               <xocs:file-basename>fx56</xocs:file-basename>
               <xocs:filename>fx56.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3694</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>171</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx48.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx48/THUMBNAIL/image/gif/c912bdcfe74fc835e46bcc0ac6143c1d/fx48.sml</xocs:ucs-locator>
               <xocs:file-basename>fx48</xocs:file-basename>
               <xocs:filename>fx48.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4106</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>202</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx2/THUMBNAIL/image/gif/b94a68879a31ec9258d9e3418e1b1dd3/fx2.sml</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3724</xocs:filesize>
               <xocs:pixel-height>126</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx51.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx51/THUMBNAIL/image/gif/f12fc8a0186286c755bba4f6dde144a9/fx51.sml</xocs:ucs-locator>
               <xocs:file-basename>fx51</xocs:file-basename>
               <xocs:filename>fx51.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2779</xocs:filesize>
               <xocs:pixel-height>124</xocs:pixel-height>
               <xocs:pixel-width>216</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx36.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx36/THUMBNAIL/image/gif/f04acb52f4c9b7f7715ec457f20b51e0/fx36.sml</xocs:ucs-locator>
               <xocs:file-basename>fx36</xocs:file-basename>
               <xocs:filename>fx36.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3076</xocs:filesize>
               <xocs:pixel-height>188</xocs:pixel-height>
               <xocs:pixel-width>172</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx54.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx54/THUMBNAIL/image/gif/9319b9098eb41b072e7988fc8dc83836/fx54.sml</xocs:ucs-locator>
               <xocs:file-basename>fx54</xocs:file-basename>
               <xocs:filename>fx54.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3588</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>171</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx57.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx57/THUMBNAIL/image/gif/d0b8e8860cb622abeb0a7d8d52e2890c/fx57.sml</xocs:ucs-locator>
               <xocs:file-basename>fx57</xocs:file-basename>
               <xocs:filename>fx57.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4203</xocs:filesize>
               <xocs:pixel-height>151</xocs:pixel-height>
               <xocs:pixel-width>213</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx9.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx9/THUMBNAIL/image/gif/b8b3c8b9094d55503f1e16e9bf8133bb/fx9.sml</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1967</xocs:filesize>
               <xocs:pixel-height>73</xocs:pixel-height>
               <xocs:pixel-width>139</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx35.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx35/THUMBNAIL/image/gif/40e5a5db4e2d7fe7ea844068d8cdc9ae/fx35.sml</xocs:ucs-locator>
               <xocs:file-basename>fx35</xocs:file-basename>
               <xocs:filename>fx35.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4371</xocs:filesize>
               <xocs:pixel-height>125</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/gr2/THUMBNAIL/image/gif/dd073617a4b4551f537214a6f912f99b/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>8533</xocs:filesize>
               <xocs:pixel-height>79</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx39.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx39/THUMBNAIL/image/gif/f4a6a00b2ebe9c7e516b5cef3fb08052/fx39.sml</xocs:ucs-locator>
               <xocs:file-basename>fx39</xocs:file-basename>
               <xocs:filename>fx39.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4245</xocs:filesize>
               <xocs:pixel-height>125</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx3/THUMBNAIL/image/gif/d32e024d67be809de152885b00280a23/fx3.sml</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3055</xocs:filesize>
               <xocs:pixel-height>179</xocs:pixel-height>
               <xocs:pixel-width>193</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/gr1/THUMBNAIL/image/gif/f3d4e14c1a5526b727bc961a09f8e689/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4278</xocs:filesize>
               <xocs:pixel-height>124</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx20.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx20/THUMBNAIL/image/gif/7bb7b822d4b4d35edda6aec016302e62/fx20.sml</xocs:ucs-locator>
               <xocs:file-basename>fx20</xocs:file-basename>
               <xocs:filename>fx20.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3630</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>171</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx26.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx26/THUMBNAIL/image/gif/39558884eb004ab86750e45e7f5e1a01/fx26.sml</xocs:ucs-locator>
               <xocs:file-basename>fx26</xocs:file-basename>
               <xocs:filename>fx26.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3627</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>171</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx34.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx34/THUMBNAIL/image/gif/7aa3ddd6b770285a6cda2cca50283306/fx34.sml</xocs:ucs-locator>
               <xocs:file-basename>fx34</xocs:file-basename>
               <xocs:filename>fx34.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2959</xocs:filesize>
               <xocs:pixel-height>158</xocs:pixel-height>
               <xocs:pixel-width>188</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx41.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx41/THUMBNAIL/image/gif/792acd34ac00ef4e47ef918b4db469fb/fx41.sml</xocs:ucs-locator>
               <xocs:file-basename>fx41</xocs:file-basename>
               <xocs:filename>fx41.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2870</xocs:filesize>
               <xocs:pixel-height>123</xocs:pixel-height>
               <xocs:pixel-width>216</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx46.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx46/THUMBNAIL/image/gif/09ae1b02fd901237ce87b207bdf7af51/fx46.sml</xocs:ucs-locator>
               <xocs:file-basename>fx46</xocs:file-basename>
               <xocs:filename>fx46.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2995</xocs:filesize>
               <xocs:pixel-height>193</xocs:pixel-height>
               <xocs:pixel-width>193</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-sc2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/sc2/THUMBNAIL/image/gif/6906033081f81da74a6df48d1900986f/sc2.sml</xocs:ucs-locator>
               <xocs:file-basename>sc2</xocs:file-basename>
               <xocs:filename>sc2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4989</xocs:filesize>
               <xocs:pixel-height>121</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx29.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx29/THUMBNAIL/image/gif/8d24c68636a047e3d9f8a371c2a76b1a/fx29.sml</xocs:ucs-locator>
               <xocs:file-basename>fx29</xocs:file-basename>
               <xocs:filename>fx29.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2802</xocs:filesize>
               <xocs:pixel-height>114</xocs:pixel-height>
               <xocs:pixel-width>207</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx8.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx8/THUMBNAIL/image/gif/65336acb0c5d7b1e158295633000b81e/fx8.sml</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3226</xocs:filesize>
               <xocs:pixel-height>201</xocs:pixel-height>
               <xocs:pixel-width>209</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx14.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx14/THUMBNAIL/image/gif/4420c418e56f71a059bfc55757c41c34/fx14.sml</xocs:ucs-locator>
               <xocs:file-basename>fx14</xocs:file-basename>
               <xocs:filename>fx14.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3121</xocs:filesize>
               <xocs:pixel-height>198</xocs:pixel-height>
               <xocs:pixel-width>202</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx1/THUMBNAIL/image/gif/3c5de95e6663b072a55c29b0ebea57be/fx1.sml</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9323</xocs:filesize>
               <xocs:pixel-height>127</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-gr3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/gr3/THUMBNAIL/image/gif/f3984a4dd404e8ebeca3c5c326dbabf4/gr3.sml</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9708</xocs:filesize>
               <xocs:pixel-height>116</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx25.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx25/THUMBNAIL/image/gif/05311f2b065b1bf8f0f252848dd90906/fx25.sml</xocs:ucs-locator>
               <xocs:file-basename>fx25</xocs:file-basename>
               <xocs:filename>fx25.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3822</xocs:filesize>
               <xocs:pixel-height>105</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx18.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx18/THUMBNAIL/image/gif/1d446766a2df6b79b8cca4c93c930859/fx18.sml</xocs:ucs-locator>
               <xocs:file-basename>fx18</xocs:file-basename>
               <xocs:filename>fx18.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3628</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>171</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx4/THUMBNAIL/image/gif/34309ca6115554ba3ea67249516a1cde/fx4.sml</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>1554</xocs:filesize>
               <xocs:pixel-height>57</xocs:pixel-height>
               <xocs:pixel-width>126</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx13.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx13/THUMBNAIL/image/gif/a993352e965c8adf7819efceeb27b2f4/fx13.sml</xocs:ucs-locator>
               <xocs:file-basename>fx13</xocs:file-basename>
               <xocs:filename>fx13.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2380</xocs:filesize>
               <xocs:pixel-height>130</xocs:pixel-height>
               <xocs:pixel-width>152</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx32.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx32/THUMBNAIL/image/gif/e9e61e5bdccfeaab4e554029b3d97f15/fx32.sml</xocs:ucs-locator>
               <xocs:file-basename>fx32</xocs:file-basename>
               <xocs:filename>fx32.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3642</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>171</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx15.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx15/THUMBNAIL/image/gif/ac9b02e1d914307d7364c2b139391527/fx15.sml</xocs:ucs-locator>
               <xocs:file-basename>fx15</xocs:file-basename>
               <xocs:filename>fx15.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2303</xocs:filesize>
               <xocs:pixel-height>101</xocs:pixel-height>
               <xocs:pixel-width>209</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx47.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx47/THUMBNAIL/image/gif/b1b1c22ac1bf7d6b63d7544d2cf49e00/fx47.sml</xocs:ucs-locator>
               <xocs:file-basename>fx47</xocs:file-basename>
               <xocs:filename>fx47.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2805</xocs:filesize>
               <xocs:pixel-height>124</xocs:pixel-height>
               <xocs:pixel-width>216</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-gr4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/gr4/THUMBNAIL/image/gif/16666acf71c525bd01be9e978292cb74/gr4.sml</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10163</xocs:filesize>
               <xocs:pixel-height>88</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx24.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx24/THUMBNAIL/image/gif/7432bccd12fb7e8e734f38ffb9897d9b/fx24.sml</xocs:ucs-locator>
               <xocs:file-basename>fx24</xocs:file-basename>
               <xocs:filename>fx24.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3548</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>171</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx17.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx17/THUMBNAIL/image/gif/b67d8ad9f4a2a6761ffe4e5ee318fa33/fx17.sml</xocs:ucs-locator>
               <xocs:file-basename>fx17</xocs:file-basename>
               <xocs:filename>fx17.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2300</xocs:filesize>
               <xocs:pixel-height>141</xocs:pixel-height>
               <xocs:pixel-width>179</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx37.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx37/THUMBNAIL/image/gif/ead980b966bbef129cccef322f16e70c/fx37.sml</xocs:ucs-locator>
               <xocs:file-basename>fx37</xocs:file-basename>
               <xocs:filename>fx37.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4259</xocs:filesize>
               <xocs:pixel-height>125</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx43.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx43/THUMBNAIL/image/gif/4476660587fd0ff7fbe1ffb3662bbfa1/fx43.sml</xocs:ucs-locator>
               <xocs:file-basename>fx43</xocs:file-basename>
               <xocs:filename>fx43.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2875</xocs:filesize>
               <xocs:pixel-height>124</xocs:pixel-height>
               <xocs:pixel-width>216</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx38.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx38/THUMBNAIL/image/gif/231ff4f8827e6b98078a63cceff37841/fx38.sml</xocs:ucs-locator>
               <xocs:file-basename>fx38</xocs:file-basename>
               <xocs:filename>fx38.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2965</xocs:filesize>
               <xocs:pixel-height>146</xocs:pixel-height>
               <xocs:pixel-width>209</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx31.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx31/THUMBNAIL/image/gif/606600e8e3e246c0450e71df3bf4d0cb/fx31.sml</xocs:ucs-locator>
               <xocs:file-basename>fx31</xocs:file-basename>
               <xocs:filename>fx31.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2722</xocs:filesize>
               <xocs:pixel-height>131</xocs:pixel-height>
               <xocs:pixel-width>212</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx49.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx49/THUMBNAIL/image/gif/359584ef7e7531145e979c6ea54959ec/fx49.sml</xocs:ucs-locator>
               <xocs:file-basename>fx49</xocs:file-basename>
               <xocs:filename>fx49.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2764</xocs:filesize>
               <xocs:pixel-height>124</xocs:pixel-height>
               <xocs:pixel-width>216</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx53.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx53/THUMBNAIL/image/gif/214ea9d088b05bf46ffcb926692ff777/fx53.sml</xocs:ucs-locator>
               <xocs:file-basename>fx53</xocs:file-basename>
               <xocs:filename>fx53.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2795</xocs:filesize>
               <xocs:pixel-height>124</xocs:pixel-height>
               <xocs:pixel-width>216</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx52.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx52/THUMBNAIL/image/gif/edab1a31bf560b1487c8250a37d4f9a9/fx52.sml</xocs:ucs-locator>
               <xocs:file-basename>fx52</xocs:file-basename>
               <xocs:filename>fx52.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4241</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>194</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx45.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx45/THUMBNAIL/image/gif/c27e80bd8542660ae3d516e3900114fd/fx45.sml</xocs:ucs-locator>
               <xocs:file-basename>fx45</xocs:file-basename>
               <xocs:filename>fx45.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2841</xocs:filesize>
               <xocs:pixel-height>123</xocs:pixel-height>
               <xocs:pixel-width>216</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx16.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx16/THUMBNAIL/image/gif/ce2ebd9ad84750c24f07de79b3faf84c/fx16.sml</xocs:ucs-locator>
               <xocs:file-basename>fx16</xocs:file-basename>
               <xocs:filename>fx16.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3651</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>171</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx30.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx30/THUMBNAIL/image/gif/8ad4a7f7bc6031c7a3486e4b1b15a724/fx30.sml</xocs:ucs-locator>
               <xocs:file-basename>fx30</xocs:file-basename>
               <xocs:filename>fx30.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3579</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>171</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx27.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx27/THUMBNAIL/image/gif/d9dae0c897d0bcabaf31b3961ebb6fcf/fx27.sml</xocs:ucs-locator>
               <xocs:file-basename>fx27</xocs:file-basename>
               <xocs:filename>fx27.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>4316</xocs:filesize>
               <xocs:pixel-height>125</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx21.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx21/THUMBNAIL/image/gif/2ec08d464ecdc2b217cf26c99643a709/fx21.sml</xocs:ucs-locator>
               <xocs:file-basename>fx21</xocs:file-basename>
               <xocs:filename>fx21.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2771</xocs:filesize>
               <xocs:pixel-height>140</xocs:pixel-height>
               <xocs:pixel-width>180</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx12.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx12/THUMBNAIL/image/gif/c10144d57fcab52cf679f36615239a5b/fx12.sml</xocs:ucs-locator>
               <xocs:file-basename>fx12</xocs:file-basename>
               <xocs:filename>fx12.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3199</xocs:filesize>
               <xocs:pixel-height>204</xocs:pixel-height>
               <xocs:pixel-width>214</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx10.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx10/THUMBNAIL/image/gif/67f1557e822fe8e3415f1d5ebc3aeeb2/fx10.sml</xocs:ucs-locator>
               <xocs:file-basename>fx10</xocs:file-basename>
               <xocs:filename>fx10.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3272</xocs:filesize>
               <xocs:pixel-height>201</xocs:pixel-height>
               <xocs:pixel-width>209</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx28.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx28/THUMBNAIL/image/gif/48971a97c701727afcf7a1cebf16545a/fx28.sml</xocs:ucs-locator>
               <xocs:file-basename>fx28</xocs:file-basename>
               <xocs:filename>fx28.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3649</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>171</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx6/THUMBNAIL/image/gif/eccd9c42191da16878d538c8aee2cb22/fx6.sml</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3278</xocs:filesize>
               <xocs:pixel-height>201</xocs:pixel-height>
               <xocs:pixel-width>209</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-sc4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/sc4/THUMBNAIL/image/gif/7ff0d94c17f5a82f7a2cfa7edc12e965/sc4.sml</xocs:ucs-locator>
               <xocs:file-basename>sc4</xocs:file-basename>
               <xocs:filename>sc4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5403</xocs:filesize>
               <xocs:pixel-height>145</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx11.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx11/THUMBNAIL/image/gif/4605972868d1c76d91471f6c976285fd/fx11.sml</xocs:ucs-locator>
               <xocs:file-basename>fx11</xocs:file-basename>
               <xocs:filename>fx11.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2370</xocs:filesize>
               <xocs:pixel-height>110</xocs:pixel-height>
               <xocs:pixel-width>145</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx42.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx42/THUMBNAIL/image/gif/69c7196692fd91d97e3dba2abf8be243/fx42.sml</xocs:ucs-locator>
               <xocs:file-basename>fx42</xocs:file-basename>
               <xocs:filename>fx42.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3254</xocs:filesize>
               <xocs:pixel-height>190</xocs:pixel-height>
               <xocs:pixel-width>218</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx22.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx22/THUMBNAIL/image/gif/8b6d05f15fd67f6c363bbaa231234d2f/fx22.sml</xocs:ucs-locator>
               <xocs:file-basename>fx22</xocs:file-basename>
               <xocs:filename>fx22.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3552</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>171</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-sc3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/sc3/THUMBNAIL/image/gif/82f94f087241b3aa0c58f583ce65827c/sc3.sml</xocs:ucs-locator>
               <xocs:file-basename>sc3</xocs:file-basename>
               <xocs:filename>sc3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5735</xocs:filesize>
               <xocs:pixel-height>154</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-gr5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/gr5/THUMBNAIL/image/gif/309f9a5771fd70f8c042f132395171dd/gr5.sml</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>11092</xocs:filesize>
               <xocs:pixel-height>117</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx7/THUMBNAIL/image/gif/5ab81609d01d6f4d7e7aec7674ce5c43/fx7.sml</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2239</xocs:filesize>
               <xocs:pixel-height>80</xocs:pixel-height>
               <xocs:pixel-width>151</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx44.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx44/THUMBNAIL/image/gif/14cbb8a533cd795c9afb877ce633c8aa/fx44.sml</xocs:ucs-locator>
               <xocs:file-basename>fx44</xocs:file-basename>
               <xocs:filename>fx44.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3133</xocs:filesize>
               <xocs:pixel-height>177</xocs:pixel-height>
               <xocs:pixel-width>202</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx55.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx55/THUMBNAIL/image/gif/be0825fd4112e9f402976bed706ba11e/fx55.sml</xocs:ucs-locator>
               <xocs:file-basename>fx55</xocs:file-basename>
               <xocs:filename>fx55.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>3585</xocs:filesize>
               <xocs:pixel-height>146</xocs:pixel-height>
               <xocs:pixel-width>208</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx33.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx33/THUMBNAIL/image/gif/e4ab6a131452c87adfdc0f0a365d9299/fx33.sml</xocs:ucs-locator>
               <xocs:file-basename>fx33</xocs:file-basename>
               <xocs:filename>fx33.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>2504</xocs:filesize>
               <xocs:pixel-height>126</xocs:pixel-height>
               <xocs:pixel-width>203</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx50_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx50/HIGHRES/image/jpeg/72b3ff2397810057cf892791c10a20ac/fx50_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx50</xocs:file-basename>
               <xocs:filename>fx50_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6407</xocs:filesize>
               <xocs:pixel-height>195</xocs:pixel-height>
               <xocs:pixel-width>242</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx19_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx19/HIGHRES/image/jpeg/bf944e8326402de4417f59e475046308/fx19_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx19</xocs:file-basename>
               <xocs:filename>fx19_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4696</xocs:filesize>
               <xocs:pixel-height>142</xocs:pixel-height>
               <xocs:pixel-width>182</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-sc1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/sc1/HIGHRES/image/jpeg/b8c32d5a721381607e2ddb0ca89a914b/sc1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>326244</xocs:filesize>
               <xocs:pixel-height>1537</xocs:pixel-height>
               <xocs:pixel-width>3051</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx5/HIGHRES/image/jpeg/dcd8a91d6a81f999dcdf3f0238dca2ba/fx5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5660</xocs:filesize>
               <xocs:pixel-height>201</xocs:pixel-height>
               <xocs:pixel-width>209</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx23_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx23/HIGHRES/image/jpeg/63885ea763d8820fc2792306d510b147/fx23_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx23</xocs:file-basename>
               <xocs:filename>fx23_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4884</xocs:filesize>
               <xocs:pixel-height>112</xocs:pixel-height>
               <xocs:pixel-width>232</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx40_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx40/HIGHRES/image/jpeg/3fbb6d12b6f82945bb2f01d73bd3711f/fx40_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx40</xocs:file-basename>
               <xocs:filename>fx40_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5447</xocs:filesize>
               <xocs:pixel-height>160</xocs:pixel-height>
               <xocs:pixel-width>227</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx56_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx56/HIGHRES/image/jpeg/734ac15e439f1fc26eee73f2ac05c3ec/fx56_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx56</xocs:file-basename>
               <xocs:filename>fx56_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6317</xocs:filesize>
               <xocs:pixel-height>217</xocs:pixel-height>
               <xocs:pixel-width>226</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx48_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx48/HIGHRES/image/jpeg/36bcb60bd4d10ad45635139194bfc189/fx48_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx48</xocs:file-basename>
               <xocs:filename>fx48_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5595</xocs:filesize>
               <xocs:pixel-height>183</xocs:pixel-height>
               <xocs:pixel-width>226</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx2/HIGHRES/image/jpeg/fdddcb71caf038ab3ac8c1263142989d/fx2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>26849</xocs:filesize>
               <xocs:pixel-height>425</xocs:pixel-height>
               <xocs:pixel-width>737</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx51_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx51/HIGHRES/image/jpeg/73a136f8e1c154f52261e094b5583b2f/fx51_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx51</xocs:file-basename>
               <xocs:filename>fx51_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4550</xocs:filesize>
               <xocs:pixel-height>124</xocs:pixel-height>
               <xocs:pixel-width>216</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx36_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx36/HIGHRES/image/jpeg/8f6483f379718cf7472decce6b46937b/fx36_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx36</xocs:file-basename>
               <xocs:filename>fx36_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5329</xocs:filesize>
               <xocs:pixel-height>188</xocs:pixel-height>
               <xocs:pixel-width>172</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx54_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx54/HIGHRES/image/jpeg/8fdba8160e9fd380b0cc86ad2ae4abf6/fx54_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx54</xocs:file-basename>
               <xocs:filename>fx54_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6318</xocs:filesize>
               <xocs:pixel-height>217</xocs:pixel-height>
               <xocs:pixel-width>226</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx57_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx57/HIGHRES/image/jpeg/f7c882e3cd4eca38adbe3f045164c33c/fx57_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx57</xocs:file-basename>
               <xocs:filename>fx57_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6478</xocs:filesize>
               <xocs:pixel-height>151</xocs:pixel-height>
               <xocs:pixel-width>213</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx9_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx9/HIGHRES/image/jpeg/bea119ba19610ee1aa311a2607cb2b37/fx9_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3116</xocs:filesize>
               <xocs:pixel-height>73</xocs:pixel-height>
               <xocs:pixel-width>139</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx35_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx35/HIGHRES/image/jpeg/aa8a15447882a4ed002e114d671bc48d/fx35_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx35</xocs:file-basename>
               <xocs:filename>fx35_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5032</xocs:filesize>
               <xocs:pixel-height>130</xocs:pixel-height>
               <xocs:pixel-width>227</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/gr2/HIGHRES/image/jpeg/a8fa8e48ab8d486c128e4a40d9005a67/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>425488</xocs:filesize>
               <xocs:pixel-height>999</xocs:pixel-height>
               <xocs:pixel-width>2764</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx39_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx39/HIGHRES/image/jpeg/35443305398d3a48872fbcb226dc5174/fx39_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx39</xocs:file-basename>
               <xocs:filename>fx39_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5036</xocs:filesize>
               <xocs:pixel-height>130</xocs:pixel-height>
               <xocs:pixel-width>227</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx3/HIGHRES/image/jpeg/eaf1a9d71cd47879431836de7b753bea/fx3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4927</xocs:filesize>
               <xocs:pixel-height>179</xocs:pixel-height>
               <xocs:pixel-width>193</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/gr1/HIGHRES/image/jpeg/1ca457bf328636ced5b9e82b3438ee26/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>251309</xocs:filesize>
               <xocs:pixel-height>1563</xocs:pixel-height>
               <xocs:pixel-width>2756</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx20_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx20/HIGHRES/image/jpeg/d4b16fccf8ec33dd1b3bcc37f5fd4e1b/fx20_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx20</xocs:file-basename>
               <xocs:filename>fx20_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6601</xocs:filesize>
               <xocs:pixel-height>228</xocs:pixel-height>
               <xocs:pixel-width>238</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx26_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx26/HIGHRES/image/jpeg/77af964c871b0e8b47b868934ecd857d/fx26_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx26</xocs:file-basename>
               <xocs:filename>fx26_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6598</xocs:filesize>
               <xocs:pixel-height>228</xocs:pixel-height>
               <xocs:pixel-width>238</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx34_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx34/HIGHRES/image/jpeg/436eee9870e5f75de4be985ab5cf2fe5/fx34_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx34</xocs:file-basename>
               <xocs:filename>fx34_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5363</xocs:filesize>
               <xocs:pixel-height>158</xocs:pixel-height>
               <xocs:pixel-width>188</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx41_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx41/HIGHRES/image/jpeg/c034a34711adf9500ad0d87d223bf414/fx41_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx41</xocs:file-basename>
               <xocs:filename>fx41_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4487</xocs:filesize>
               <xocs:pixel-height>123</xocs:pixel-height>
               <xocs:pixel-width>216</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx46_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx46/HIGHRES/image/jpeg/a6b9cf373394fc7ba257a328e1115826/fx46_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx46</xocs:file-basename>
               <xocs:filename>fx46_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5188</xocs:filesize>
               <xocs:pixel-height>193</xocs:pixel-height>
               <xocs:pixel-width>193</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-sc2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/sc2/HIGHRES/image/jpeg/b4c25bf4b59db8de4edc09a880e10796/sc2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc2</xocs:file-basename>
               <xocs:filename>sc2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>346387</xocs:filesize>
               <xocs:pixel-height>1625</xocs:pixel-height>
               <xocs:pixel-width>2953</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx29_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx29/HIGHRES/image/jpeg/0ab54e42670e10b9cba2bdf55475ba9d/fx29_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx29</xocs:file-basename>
               <xocs:filename>fx29_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4359</xocs:filesize>
               <xocs:pixel-height>114</xocs:pixel-height>
               <xocs:pixel-width>207</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx8_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx8/HIGHRES/image/jpeg/c6386277bca8182ce07918aa0373ec79/fx8_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5660</xocs:filesize>
               <xocs:pixel-height>201</xocs:pixel-height>
               <xocs:pixel-width>209</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx14_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx14/HIGHRES/image/jpeg/0d37a88d7575669f833e74f2b5d32c3e/fx14_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx14</xocs:file-basename>
               <xocs:filename>fx14_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5416</xocs:filesize>
               <xocs:pixel-height>198</xocs:pixel-height>
               <xocs:pixel-width>202</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx1/HIGHRES/image/jpeg/0c3bc7e6eee8baa4ea08a2088972b7fd/fx1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>178666</xocs:filesize>
               <xocs:pixel-height>886</xocs:pixel-height>
               <xocs:pixel-width>1528</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-gr3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/gr3/HIGHRES/image/jpeg/a545c3d72d92bd8ff93aefb212d7332a/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>371346</xocs:filesize>
               <xocs:pixel-height>1308</xocs:pixel-height>
               <xocs:pixel-width>2469</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx25_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx25/HIGHRES/image/jpeg/037c6f16bf711db4d2ff4fc30cd7a399/fx25_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx25</xocs:file-basename>
               <xocs:filename>fx25_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5010</xocs:filesize>
               <xocs:pixel-height>115</xocs:pixel-height>
               <xocs:pixel-width>239</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx18_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx18/HIGHRES/image/jpeg/f920c64b3b5a1396a0c46cfd9b1b42dd/fx18_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx18</xocs:file-basename>
               <xocs:filename>fx18_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6590</xocs:filesize>
               <xocs:pixel-height>228</xocs:pixel-height>
               <xocs:pixel-width>238</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx4/HIGHRES/image/jpeg/e503c2dfb885209f37f28b706042c05e/fx4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>2514</xocs:filesize>
               <xocs:pixel-height>57</xocs:pixel-height>
               <xocs:pixel-width>126</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx13_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx13/HIGHRES/image/jpeg/e9816cbb9ed66dbdd4380906ee8f7d6c/fx13_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx13</xocs:file-basename>
               <xocs:filename>fx13_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3740</xocs:filesize>
               <xocs:pixel-height>130</xocs:pixel-height>
               <xocs:pixel-width>152</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx32_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx32/HIGHRES/image/jpeg/db4568e996adea5c57aee58f29766391/fx32_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx32</xocs:file-basename>
               <xocs:filename>fx32_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6607</xocs:filesize>
               <xocs:pixel-height>228</xocs:pixel-height>
               <xocs:pixel-width>238</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx15_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx15/HIGHRES/image/jpeg/fb09ec73a8218e84ea50618b02d34710/fx15_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx15</xocs:file-basename>
               <xocs:filename>fx15_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3849</xocs:filesize>
               <xocs:pixel-height>101</xocs:pixel-height>
               <xocs:pixel-width>209</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx47_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx47/HIGHRES/image/jpeg/bc973b30ca4bcaedf066ad2fd4a9c03c/fx47_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx47</xocs:file-basename>
               <xocs:filename>fx47_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4554</xocs:filesize>
               <xocs:pixel-height>124</xocs:pixel-height>
               <xocs:pixel-width>216</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-gr4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/gr4/HIGHRES/image/jpeg/7d66268e9c1401170381a816e50c9333/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>572636</xocs:filesize>
               <xocs:pixel-height>1383</xocs:pixel-height>
               <xocs:pixel-width>3459</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx24_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx24/HIGHRES/image/jpeg/db148b60ced96e27179f7072529423e8/fx24_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx24</xocs:file-basename>
               <xocs:filename>fx24_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6594</xocs:filesize>
               <xocs:pixel-height>228</xocs:pixel-height>
               <xocs:pixel-width>238</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx17_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx17/HIGHRES/image/jpeg/a5a3e194a87bbcbe81b7674ba2a25feb/fx17_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx17</xocs:file-basename>
               <xocs:filename>fx17_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4231</xocs:filesize>
               <xocs:pixel-height>141</xocs:pixel-height>
               <xocs:pixel-width>179</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx37_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx37/HIGHRES/image/jpeg/50a69db5417c205babf90ba7d60a5eea/fx37_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx37</xocs:file-basename>
               <xocs:filename>fx37_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5031</xocs:filesize>
               <xocs:pixel-height>130</xocs:pixel-height>
               <xocs:pixel-width>227</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx43_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx43/HIGHRES/image/jpeg/856d0de66a1cf6bccdf3b5a8e3810418/fx43_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx43</xocs:file-basename>
               <xocs:filename>fx43_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4552</xocs:filesize>
               <xocs:pixel-height>124</xocs:pixel-height>
               <xocs:pixel-width>216</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx38_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx38/HIGHRES/image/jpeg/91431b704fca250dc506a27627d81330/fx38_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx38</xocs:file-basename>
               <xocs:filename>fx38_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5518</xocs:filesize>
               <xocs:pixel-height>146</xocs:pixel-height>
               <xocs:pixel-width>209</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx31_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx31/HIGHRES/image/jpeg/5a9f85de65f4f75708d7de52e19a1a08/fx31_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx31</xocs:file-basename>
               <xocs:filename>fx31_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4407</xocs:filesize>
               <xocs:pixel-height>131</xocs:pixel-height>
               <xocs:pixel-width>212</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx49_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx49/HIGHRES/image/jpeg/2005377c40fcdf5cd0d43fd795c7c650/fx49_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx49</xocs:file-basename>
               <xocs:filename>fx49_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4550</xocs:filesize>
               <xocs:pixel-height>124</xocs:pixel-height>
               <xocs:pixel-width>216</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx53_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx53/HIGHRES/image/jpeg/7239fc10e808807e86347771cea90afc/fx53_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx53</xocs:file-basename>
               <xocs:filename>fx53_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4553</xocs:filesize>
               <xocs:pixel-height>124</xocs:pixel-height>
               <xocs:pixel-width>216</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx52_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx52/HIGHRES/image/jpeg/1499e39f7188bc47c883476fa17c82de/fx52_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx52</xocs:file-basename>
               <xocs:filename>fx52_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5874</xocs:filesize>
               <xocs:pixel-height>187</xocs:pixel-height>
               <xocs:pixel-width>221</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx45_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx45/HIGHRES/image/jpeg/cc3f1667bdc28edef1a4d62175e8e849/fx45_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx45</xocs:file-basename>
               <xocs:filename>fx45_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4496</xocs:filesize>
               <xocs:pixel-height>123</xocs:pixel-height>
               <xocs:pixel-width>216</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx16_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx16/HIGHRES/image/jpeg/54dcc965cb40ba26443cc0e46c72c892/fx16_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx16</xocs:file-basename>
               <xocs:filename>fx16_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6598</xocs:filesize>
               <xocs:pixel-height>228</xocs:pixel-height>
               <xocs:pixel-width>238</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx30_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx30/HIGHRES/image/jpeg/270fc7009efd050b8b276341d1ed8e4c/fx30_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx30</xocs:file-basename>
               <xocs:filename>fx30_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6606</xocs:filesize>
               <xocs:pixel-height>228</xocs:pixel-height>
               <xocs:pixel-width>238</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx27_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx27/HIGHRES/image/jpeg/a215427967767a1d77f913561ba6ed3a/fx27_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx27</xocs:file-basename>
               <xocs:filename>fx27_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5022</xocs:filesize>
               <xocs:pixel-height>130</xocs:pixel-height>
               <xocs:pixel-width>227</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx21_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx21/HIGHRES/image/jpeg/d19473c475ed527a7bcbc8f18c96e37a/fx21_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx21</xocs:file-basename>
               <xocs:filename>fx21_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4783</xocs:filesize>
               <xocs:pixel-height>140</xocs:pixel-height>
               <xocs:pixel-width>180</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx12_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx12/HIGHRES/image/jpeg/230d7ceee080520fa7afd4b73bb7d09e/fx12_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx12</xocs:file-basename>
               <xocs:filename>fx12_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5870</xocs:filesize>
               <xocs:pixel-height>204</xocs:pixel-height>
               <xocs:pixel-width>214</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx10_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx10/HIGHRES/image/jpeg/1934549dca75468b39bcab712fe34126/fx10_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx10</xocs:file-basename>
               <xocs:filename>fx10_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5651</xocs:filesize>
               <xocs:pixel-height>201</xocs:pixel-height>
               <xocs:pixel-width>209</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx28_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx28/HIGHRES/image/jpeg/c930bf0fda1d8195cd1274a2f0b7e2f7/fx28_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx28</xocs:file-basename>
               <xocs:filename>fx28_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6358</xocs:filesize>
               <xocs:pixel-height>222</xocs:pixel-height>
               <xocs:pixel-width>232</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx6/HIGHRES/image/jpeg/ed16dca32d8c50a781485d12a55ffd9c/fx6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5665</xocs:filesize>
               <xocs:pixel-height>201</xocs:pixel-height>
               <xocs:pixel-width>209</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-sc4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/sc4/HIGHRES/image/jpeg/1805fe11448fbee2d5cae137654ea9b2/sc4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc4</xocs:file-basename>
               <xocs:filename>sc4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>280871</xocs:filesize>
               <xocs:pixel-height>1695</xocs:pixel-height>
               <xocs:pixel-width>2559</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx11_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx11/HIGHRES/image/jpeg/9267c9afaa61c7f9737a8b1a59a27fe7/fx11_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx11</xocs:file-basename>
               <xocs:filename>fx11_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3501</xocs:filesize>
               <xocs:pixel-height>110</xocs:pixel-height>
               <xocs:pixel-width>145</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx42_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx42/HIGHRES/image/jpeg/933467466c4112498a3fb9e6f305386b/fx42_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx42</xocs:file-basename>
               <xocs:filename>fx42_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5644</xocs:filesize>
               <xocs:pixel-height>190</xocs:pixel-height>
               <xocs:pixel-width>218</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx22_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx22/HIGHRES/image/jpeg/19ba1af342ef05c49fdeac6489bab14a/fx22_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx22</xocs:file-basename>
               <xocs:filename>fx22_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6603</xocs:filesize>
               <xocs:pixel-height>228</xocs:pixel-height>
               <xocs:pixel-width>238</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-sc3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/sc3/HIGHRES/image/jpeg/1a166c680d2344e445f9930c244043c4/sc3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc3</xocs:file-basename>
               <xocs:filename>sc3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>394400</xocs:filesize>
               <xocs:pixel-height>2081</xocs:pixel-height>
               <xocs:pixel-width>2953</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-gr5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/gr5/HIGHRES/image/jpeg/91f55c7aba03df64646367fa6edea5e3/gr5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>730885</xocs:filesize>
               <xocs:pixel-height>1743</xocs:pixel-height>
               <xocs:pixel-width>3256</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx7_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx7/HIGHRES/image/jpeg/189ae03082ec4c7a563f287bffc11fe4/fx7_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>3378</xocs:filesize>
               <xocs:pixel-height>80</xocs:pixel-height>
               <xocs:pixel-width>151</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx44_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx44/HIGHRES/image/jpeg/22fd05062e7a99ecd1dffb459207d282/fx44_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx44</xocs:file-basename>
               <xocs:filename>fx44_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5245</xocs:filesize>
               <xocs:pixel-height>177</xocs:pixel-height>
               <xocs:pixel-width>202</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx55_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx55/HIGHRES/image/jpeg/0abaf8ecff813a5d2210cbabf6d024a8/fx55_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx55</xocs:file-basename>
               <xocs:filename>fx55_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6347</xocs:filesize>
               <xocs:pixel-height>146</xocs:pixel-height>
               <xocs:pixel-width>208</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-fx33_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/fx33/HIGHRES/image/jpeg/108dee43b33cb08eb264f1476ad12e4e/fx33_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx33</xocs:file-basename>
               <xocs:filename>fx33_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>4109</xocs:filesize>
               <xocs:pixel-height>126</xocs:pixel-height>
               <xocs:pixel-width>203</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-mmc1.doc</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523420305249/mmc1/MAIN/application/msword/dbd7bf9c0699b4c36af6544392c68b64/mmc1.doc</xocs:ucs-locator>
               <xocs:file-basename>mmc1</xocs:file-basename>
               <xocs:filename>mmc1.doc</xocs:filename>
               <xocs:extension>doc</xocs:extension>
               <xocs:filesize>11619840</xocs:filesize>
               <xocs:attachment-type>APPLICATION</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523420305249-am.pdf</xocs:attachment-eid>
               <xocs:file-basename>am</xocs:file-basename>
               <xocs:filename>am.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:filesize>976427</xocs:filesize>
               <xocs:attachment-type>AAM-PDF</xocs:attachment-type>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/egi:108K1QMFSDP/MAIN/application/pdf/2ad551690c4fd253debebe286954be8d/am.pdf</xocs:ucs-locator>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" docsubtype="fla" version="5.6" xml:lang="en">
         <item-info>
            <jid>EJMECH</jid>
            <aid>112552</aid>
            <ce:article-number>112552</ce:article-number>
            <ce:pii>S0223-5234(20)30524-9</ce:pii>
            <ce:doi>10.1016/j.ejmech.2020.112552</ce:doi>
            <ce:copyright type="full-transfer" year="2020">Elsevier Masson SAS</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig1">
               <ce:label>Fig. 1</ce:label>
               <ce:caption id="cap0010">
                  <ce:simple-para id="fspara0010" view="all">Chemical structures of the representative TRK inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0020" role="short">Fig. 1</ce:alt-text>
               <ce:link locator="gr1" xlink:href="pii:S0223523420305249/gr1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig2">
               <ce:label>Fig. 2</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="fspara0015" view="all">Structure-based design of new selective Trk inhibitors: (A) Co-crystal structure of drug <ce:bold>2</ce:bold> with TrkA (PDB code <ce:inter-ref id="PC_linkbbdoBrcAOt" xlink:href="pdb:5KVT" xlink:type="simple">5KVT</ce:inter-ref>); (B) predicted binding mode of compound <ce:bold>7a</ce:bold> with TrkA; (C) superimposition of <ce:bold>7a</ce:bold> with compound <ce:bold>2</ce:bold> in TrkA.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0025" role="short">Fig. 2</ce:alt-text>
               <ce:link locator="gr2" xlink:href="pii:S0223523420305249/gr2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig3">
               <ce:label>Fig. 3</ce:label>
               <ce:caption id="cap0020">
                  <ce:simple-para id="fspara0020" view="all">Design of compound <ce:bold>7</ce:bold>
                     <ce:bold>mb</ce:bold>. (A) Predicted binding mode of <ce:bold>7m</ce:bold> with TrkA (PDB: <ce:inter-ref id="PC_linkYyba14vB54" xlink:href="pdb:5KVT" xlink:type="simple">5KVT</ce:inter-ref>); (B) Predicted binding mode of <ce:bold>7</ce:bold>
                     <ce:bold>mb</ce:bold> with TrkA (PDB: <ce:inter-ref id="PC_linkVVGucrF9z6" xlink:href="pdb:5KVT" xlink:type="simple">5KVT</ce:inter-ref>).</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0030" role="short">Fig. 3</ce:alt-text>
               <ce:link locator="gr3" xlink:href="pii:S0223523420305249/gr3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig4">
               <ce:label>Fig. 4</ce:label>
               <ce:caption id="cap0025">
                  <ce:simple-para id="fspara0025" view="all">Compound <ce:bold>7</ce:bold>
                     <ce:bold>mb</ce:bold> suppresses the activation of Trks in BaF3 model cells. (A) <ce:bold>7</ce:bold>
                     <ce:bold>mb</ce:bold> inhibits phosphorylation of Trk and its downstream proteins in BaF3-CD74-NTRK1 cells. (B) <ce:bold>7</ce:bold>
                     <ce:bold>mb</ce:bold> inhibits activation of Trk and its downstream proteins in BaF3-ETV6-NTRK2 cells. (C) <ce:bold>7</ce:bold>
                     <ce:bold>mb</ce:bold> inhibits phosphorylation of Trk and its downstream proteins in BaF3-ETV6-NTRK3 cells. Cells were harvested using SDS lysis buffer after treatment with <ce:bold>7</ce:bold>
                     <ce:bold>mb</ce:bold> in different concentrations of 0, 0.32, 1.6, 8, 40 and 200 nM for 6 h, and then proteins were analyzed using WB method.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0035" role="short">Fig. 4</ce:alt-text>
               <ce:link locator="gr4" xlink:href="pii:S0223523420305249/gr4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="fig5">
               <ce:label>Fig. 5</ce:label>
               <ce:caption id="cap0030">
                  <ce:simple-para id="fspara0030" view="all">KINOMEscan profiling of compound <ce:bold>7mb</ce:bold> at a concentration of 1.0 μM against 468 kinases. The interaction map was obtained by using the TREEspot kinase interaction mapping software provided by DiscoverX Corporation.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0040" role="short">Fig. 5</ce:alt-text>
               <ce:link locator="gr5" xlink:href="pii:S0223523420305249/gr5" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="sch1">
               <ce:label>Scheme 1</ce:label>
               <ce:caption id="cap0035">
                  <ce:simple-para id="fspara0035" view="all">Synthesis of Compounds 7a-7d, and 7g-7h <ce:sup loc="post">
                        <ce:italic>a</ce:italic>
                     </ce:sup>. <ce:sup loc="post">
                        <ce:italic>a</ce:italic>
                     </ce:sup> Reagents and conditions: (a) 1-iodo-3,5-difluorobenzene, Pd(PPh<ce:inf loc="post">3</ce:inf>)<ce:inf loc="post">4</ce:inf>, Na<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf>, 1,4-dioxane/H<ce:inf loc="post">2</ce:inf>O, 80 °C, overnight; or 3,5-difluorobenzyl bromide, Pd(PPh<ce:inf loc="post">3</ce:inf>)<ce:inf loc="post">4</ce:inf>, Na<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf>, THF/H<ce:inf loc="post">2</ce:inf>O, 70 °C, overnight; (b) TFA, DCM, rt, 6 h; (c) 1-ethynyl-3,5-difluorobenzene, Pd(PPh<ce:inf loc="post">3</ce:inf>)<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf>, CuI, DIPEA, DMF, 40 °C, overnight; (d) 3,5-difluorobenzenethiol, Pd<ce:inf loc="post">2</ce:inf>(dba)<ce:inf loc="post">3</ce:inf>, Xantphos, CsOH·H<ce:inf loc="post">2</ce:inf>O, DMF, 80 °C, 16 h; (e) 3,5-difluorophenol, K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf>, DMF, 80 °C, 4 h; (f) Fe powder, NH<ce:inf loc="post">4</ce:inf>Cl, EtOH/H<ce:inf loc="post">2</ce:inf>O, 75 °C, 3 h; (g) i. HBF<ce:inf loc="post">4</ce:inf>, NaNO<ce:inf loc="post">2</ce:inf>, H<ce:inf loc="post">2</ce:inf>O, 0 °C, 2 h; ii. CH<ce:inf loc="post">3</ce:inf>COOK, 18-crown-6, CHCl<ce:inf loc="post">3</ce:inf>, rt, overnight; (h) Pd/C, H<ce:inf loc="post">2</ce:inf>, DMF/EtOH, 60 °C, overnight; (i) I<ce:inf loc="post">2</ce:inf>, K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf>, DMF, rt, overnight; (j) DHP, p-TSA, DCM, 0 °C, 6 h; (k) 2-vinylpyridine, Pd(OAc)<ce:inf loc="post">2</ce:inf>, P(o-tol)<ce:inf loc="post">3</ce:inf>, DIPEA, DMF, 90 °C, overnight; (l) TFA, DCM, rt, overnight.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0045" role="short">Scheme 1</ce:alt-text>
               <ce:link locator="sc1" xlink:href="pii:S0223523420305249/sc1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="sch2">
               <ce:label>Scheme 2</ce:label>
               <ce:caption id="cap0040">
                  <ce:simple-para id="fspara0040" view="all">Synthesis of Compounds 7j, 7m, 7o, 7q-7z <ce:sup loc="post">
                        <ce:italic>a</ce:italic>
                     </ce:sup>.</ce:simple-para>
                  <ce:simple-para id="fspara0045" view="all">
                     <ce:sup loc="post">
                        <ce:italic>a</ce:italic>
                     </ce:sup>Reagents and conditions: (a) I<ce:inf loc="post">2</ce:inf>, K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf>, DMF, rt, overnight; (b) DHP, p-TSA, DCM, 0 °C, 6 h; (c) 2-vinylpyridine, Pd(OAc)<ce:inf loc="post">2</ce:inf>, P(o-tol)<ce:inf loc="post">3</ce:inf>, DIPEA, DMF, 90 °C, overnight; (d) Fe powder, NH<ce:inf loc="post">4</ce:inf>Cl, EtOH/H<ce:inf loc="post">2</ce:inf>O, 75 °C; (e) i. aromatic aldehydes, CH<ce:inf loc="post">3</ce:inf>COOH, MeOH, rt, 1 h, 80–90%; ii. NaBH<ce:inf loc="post">4</ce:inf>, DCM/MeOH, 0 °C to rt, 6 h; (f) TFA, DCM, rt, overnight; (g) LiHMDS, CH<ce:inf loc="post">3</ce:inf>I, anhydrous THF, 0 °C, 3 h; (h) 3,5-difluorobenzoyl chloride, TEA, anhydrous DCM, 0 °C, 2 h.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0050" role="short">Scheme 2</ce:alt-text>
               <ce:link locator="sc2" xlink:href="pii:S0223523420305249/sc2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="sch3">
               <ce:label>Scheme 3</ce:label>
               <ce:caption id="cap0045">
                  <ce:simple-para id="fspara0050" view="all">Synthesis of Compounds 7i, 7k, 7l, 7n, and 7p <ce:sup loc="post">
                        <ce:italic>a</ce:italic>
                     </ce:sup>.</ce:simple-para>
                  <ce:simple-para id="fspara0055" view="all">
                     <ce:sup loc="post">
                        <ce:italic>a</ce:italic>
                     </ce:sup>Reagents and conditions: (a) TBSCl, imidazole, DMF, rt, overnight; (b) I<ce:inf loc="post">2</ce:inf>, K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf>, DMF, rt, overnight; (c) DHP, p-TSA, DCM, 0 °C, 6 h; (d) TBAF, THF, rt, overnight, 6 h; (e) 3,5-difluorobenzyl bromide, K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf>, DMF, 45 °C, overnight; (f) 2-vinylpyridine, Pd(OAc)<ce:inf loc="post">2</ce:inf>, P(o-tol)<ce:inf loc="post">3</ce:inf>, DIPEA, DMF, 90 °C, overnight; (g) TFA, DCM, rt, overnight; (h) 3,5-difluorophenol, DIAD, PPh<ce:inf loc="post">3</ce:inf>, anhydrous THF, rt, 3 h; (i) Dess-Martin periodinane, DCM, rt, 2 h; (j) 3,5-difluoroaniline, sodium triacetoxyborohydride, CH<ce:inf loc="post">3</ce:inf>COOH, THF, 60 °C, 2 h; (k) LiHMDS, CH<ce:inf loc="post">3</ce:inf>I, anhydrous THF, 0 °C, 3 h; (l) NaOH, EtOH/H<ce:inf loc="post">2</ce:inf>O, 60 °C, 4 h; (m) 3,5-difluoroaniline, HATU, DIPEA, DCM, rt, overnight.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0055" role="short">Scheme 3</ce:alt-text>
               <ce:link locator="sc3" xlink:href="pii:S0223523420305249/sc3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="sch4">
               <ce:label>Scheme 4</ce:label>
               <ce:caption id="cap0050">
                  <ce:simple-para id="fspara0060" view="all">Synthesis of Compounds 7e, 7f, 7ma, and 7mb <ce:sup loc="post">
                        <ce:italic>a</ce:italic>
                     </ce:sup>.</ce:simple-para>
                  <ce:simple-para id="fspara0065" view="all">
                     <ce:sup loc="post">
                        <ce:italic>a</ce:italic>
                     </ce:sup>Reagents and conditions: (a) I<ce:inf loc="post">2</ce:inf>, K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf>, DMF, rt, overnight; (b) DHP, p-TSA, DCM, 0 °C, 6 h; or SEMCl, TBAB, 50% KOH/DCM, 0 °C, overnight; (c) 2-vinylpyridine, Pd(OAc)<ce:inf loc="post">2</ce:inf>, P(o-tol)<ce:inf loc="post">3</ce:inf>, DIPEA, DMF, 90 °C, overnight; (d) 3,5-difluoroaniline, Pd<ce:inf loc="post">2</ce:inf>(dba)<ce:inf loc="post">3</ce:inf>, Xantphos, Cs<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf>, 1,4-dioxane, reflux, overnight; (e) TBAF, ethylenediamine, THF, 60 °C, 3 h; (f) LiHMDS, CH<ce:inf loc="post">3</ce:inf>I, anhydrous THF, 0 °C, 3 h; (g) 1-(3,5-difluorophenyl)ethanamine hydrochloride, Pd<ce:inf loc="post">2</ce:inf>(dba)<ce:inf loc="post">3</ce:inf>, BINAP, sodium tert-butoxide, toluene, reflux, overnight; (h) TFA, DCM, rt, overnight.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0060" role="short">Scheme 4</ce:alt-text>
               <ce:link locator="sc4" xlink:href="pii:S0223523420305249/sc4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl1" rowsep="0">
               <ce:label>Table 1</ce:label>
               <ce:caption id="cap0055">
                  <ce:simple-para id="tspara0010" view="all">
                     <ce:italic>In Vitro</ce:italic> Trk kinase inhibitory activities of the designed compounds. <ce:cross-ref id="crosref0375" refid="tbl1fna">
                        <ce:sup loc="post">a</ce:sup>
                     </ce:cross-ref>.<ce:inline-figure baseline="0.0">
                        <ce:link locator="fx2" xlink:href="pii:S0223523420305249/fx2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
                        <ce:alt-text id="alttext0065" role="short">Image 2</ce:alt-text>
                     </ce:inline-figure>
                  </ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0070" role="short">Table 1</ce:alt-text>
               <tgroup cols="6">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <colspec colname="col6" colnum="6"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">Compounds</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">R<inf loc="post">1</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">Linker</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" nameend="col6" namest="col4" role="colgroup">Kinase inhibition (IC<inf loc="post">50</inf>, nM)</entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">TrkA</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">TrkB</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">TrkC</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>7a</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx3" xlink:href="pii:S0223523420305249/fx3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0075" role="short">Image 3</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx4" xlink:href="pii:S0223523420305249/fx4" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0080" role="short">Image 4</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">7.6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.9</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>7b</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx5" xlink:href="pii:S0223523420305249/fx5" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0085" role="short">Image 5</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">253.6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">728.8</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">533.9</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>7c</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx6" xlink:href="pii:S0223523420305249/fx6" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0090" role="short">Image 6</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx7" xlink:href="pii:S0223523420305249/fx7" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0095" role="short">Image 7</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">23.9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.8</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.4</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>7d</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx8" xlink:href="pii:S0223523420305249/fx8" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0100" role="short">Image 8</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx9" xlink:href="pii:S0223523420305249/fx9" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0105" role="short">Image 9</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">23.3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">7.8</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>7e</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx10" xlink:href="pii:S0223523420305249/fx10" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0110" role="short">Image 10</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx11" xlink:href="pii:S0223523420305249/fx11" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0115" role="short">Image 11</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">110.6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">30.7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">112.7</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>7f</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx12" xlink:href="pii:S0223523420305249/fx12" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0120" role="short">Image 12</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx13" xlink:href="pii:S0223523420305249/fx13" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0125" role="short">Image 13</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">40.6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">23.6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">25.0</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>7g</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx14" xlink:href="pii:S0223523420305249/fx14" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0130" role="short">Image 14</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx15" xlink:href="pii:S0223523420305249/fx15" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0135" role="short">Image 15</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">8.5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">12.4</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>7h</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx16" xlink:href="pii:S0223523420305249/fx16" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0140" role="short">Image 16</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx17" xlink:href="pii:S0223523420305249/fx17" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0145" role="short">Image 17</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>1000</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>1000</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">455.4</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>7i</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx18" xlink:href="pii:S0223523420305249/fx18" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0150" role="short">Image 18</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx19" xlink:href="pii:S0223523420305249/fx19" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0155" role="short">Image 19</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>1000</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>1000</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">597.3</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>7j</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx20" xlink:href="pii:S0223523420305249/fx20" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0160" role="short">Image 20</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx21" xlink:href="pii:S0223523420305249/fx21" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0165" role="short">Image 21</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">188.6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">243.7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">118.6</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>7k</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx22" xlink:href="pii:S0223523420305249/fx22" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0170" role="short">Image 22</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx23" xlink:href="pii:S0223523420305249/fx23" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0175" role="short">Image 23</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">13.2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.7</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>7l</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx24" xlink:href="pii:S0223523420305249/fx24" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0180" role="short">Image 24</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx25" xlink:href="pii:S0223523420305249/fx25" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0185" role="short">Image 25</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">20.9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">7.2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.6</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>7m</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx26" xlink:href="pii:S0223523420305249/fx26" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0190" role="short">Image 26</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx27" xlink:href="pii:S0223523420305249/fx27" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0195" role="short">Image 27</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">8.3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.7</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>7n</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx28" xlink:href="pii:S0223523420305249/fx28" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0200" role="short">Image 28</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx29" xlink:href="pii:S0223523420305249/fx29" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0205" role="short">Image 29</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10.4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">9.5</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>7o</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx30" xlink:href="pii:S0223523420305249/fx30" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0210" role="short">Image 30</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx31" xlink:href="pii:S0223523420305249/fx31" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0215" role="short">Image 31</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">29.0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">8.0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">9.9</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>7p</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx32" xlink:href="pii:S0223523420305249/fx32" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0220" role="short">Image 32</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx33" xlink:href="pii:S0223523420305249/fx33" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0225" role="short">Image 33</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">12.0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">42.5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">28.7</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>7q</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx34" xlink:href="pii:S0223523420305249/fx34" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0230" role="short">Image 34</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx35" xlink:href="pii:S0223523420305249/fx35" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0235" role="short">Image 35</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10.6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">13.2</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>7r</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx36" xlink:href="pii:S0223523420305249/fx36" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0240" role="short">Image 36</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx37" xlink:href="pii:S0223523420305249/fx37" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0245" role="short">Image 37</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">8.8</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">36.2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.2</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>7s</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx38" xlink:href="pii:S0223523420305249/fx38" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0250" role="short">Image 38</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx39" xlink:href="pii:S0223523420305249/fx39" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0255" role="short">Image 39</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.7</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>7t</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx40" xlink:href="pii:S0223523420305249/fx40" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0260" role="short">Image 40</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx41" xlink:href="pii:S0223523420305249/fx41" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0265" role="short">Image 41</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">49.3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">78.9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">44.2</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>7u</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx42" xlink:href="pii:S0223523420305249/fx42" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0270" role="short">Image 42</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx43" xlink:href="pii:S0223523420305249/fx43" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0275" role="short">Image 43</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">15.4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.9</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>7v</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx44" xlink:href="pii:S0223523420305249/fx44" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0280" role="short">Image 44</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx45" xlink:href="pii:S0223523420305249/fx45" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0285" role="short">Image 45</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10.4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">30.6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">8.0</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>7w</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx46" xlink:href="pii:S0223523420305249/fx46" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0290" role="short">Image 46</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx47" xlink:href="pii:S0223523420305249/fx47" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0295" role="short">Image 47</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">10.4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">50.1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.9</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>7x</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx48" xlink:href="pii:S0223523420305249/fx48" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0300" role="short">Image 48</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx49" xlink:href="pii:S0223523420305249/fx49" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0305" role="short">Image 49</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">26.7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">7.5</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>7y</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx50" xlink:href="pii:S0223523420305249/fx50" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0310" role="short">Image 50</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx51" xlink:href="pii:S0223523420305249/fx51" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0315" role="short">Image 51</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">76.3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">245.2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">160.4</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>7z</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx52" xlink:href="pii:S0223523420305249/fx52" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0320" role="short">Image 52</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx53" xlink:href="pii:S0223523420305249/fx53" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0325" role="short">Image 53</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">17.7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.5</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>7ma</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx54" xlink:href="pii:S0223523420305249/fx54" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0330" role="short">Image 54</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx55" xlink:href="pii:S0223523420305249/fx55" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0335" role="short">Image 55</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">17.8</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">22.2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">30.0</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>7 mb</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx56" xlink:href="pii:S0223523420305249/fx56" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0340" role="short">Image 56</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <inline-figure baseline="0.0">
                              <link locator="fx57" xlink:href="pii:S0223523420305249/fx57" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></link>
                              <alt-text id="alttext0345" role="short">Image 57</alt-text>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.6</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.0</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">
                           <bold>1</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">/</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.7</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl1fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0015" view="all">The data are mean values from at least two independent experiments in which the variation is less than 20%.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl2" rowsep="0">
               <ce:label>Table 2</ce:label>
               <ce:caption id="cap0060">
                  <ce:simple-para id="tspara0015" view="all">Antiproliferative effects of compounds against BaF3 and a panel of Trk and Trk mutant-transformed transformed BaF3 cells <ce:cross-ref id="crosref0380" refid="tbl2fna">
                        <ce:sup loc="post">a</ce:sup>
                     </ce:cross-ref>.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0350" role="short">Table 2</ce:alt-text>
               <tgroup cols="6">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <colspec colname="col5" colnum="5"/></colspec>
                  <colspec colname="col6" colnum="6"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Cell models (IC<inf loc="post">50</inf>: μM)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">7a</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">7k</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">7m</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">7 mb</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1, LOXO-101</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">BaF3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">nd <cross-ref id="crosref0385" refid="tbl2fnb">
                              <sup loc="post">b</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">nd</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.489</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.116</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">>10</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">BaF3-CD74-NTRK1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.133</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.133</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.035</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.015</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.016</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">BaF3-ETV6-NTRK2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.161</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.169</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.034</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.022</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.040</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">BaF3-ETV6-NTRK3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.125</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.118</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.014</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.009</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.013</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">BaF3-CD74-NTRK1-G595R</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">nd</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">nd</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">nd</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.144</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.539</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">BaF3-ETV6-NTRK2-G639R</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">nd</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">nd</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">nd</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.503</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">2.240</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">BaF3-ETV6-NTRK3-G623R</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">nd</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">nd</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">nd</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.243</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.201</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">BaF3-CD74-NTRK1-G667C</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">nd</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">nd</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">nd</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.031</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.184</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">BaF3-ETV6-NTRK3-G696A</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">nd</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">nd</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">nd</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.018</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.054</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl2fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0020" view="all">The data were means from at least three independent experiments.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl2fnb">
                  <ce:label>b</ce:label>
                  <ce:note-para id="ntpara0025" view="all">nd = Not determined.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl3" rowsep="0">
               <ce:label>Table 3</ce:label>
               <ce:caption id="cap0065">
                  <ce:simple-para id="tspara0020" view="all">The <ce:italic>K</ce:italic>
                     <ce:inf loc="post">d</ce:inf> determination of Compound <ce:bold>7</ce:bold>
                     <ce:bold>mb</ce:bold> against primary “Off-Target” Kinases.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0355" role="short">Table 3</ce:alt-text>
               <tgroup cols="4">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <colspec colname="col4" colnum="4"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Kinase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <italic>K</italic>
                           <inf loc="post">d</inf> (nM) <cross-ref id="crosref0390" refid="tbl3fna">
                              <sup loc="post">a</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Kinase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <italic>K</italic>
                           <inf loc="post">d</inf> (nM) <cross-ref id="crosref0395" refid="tbl3fna">
                              <sup loc="post">a</sup>
                           </cross-ref>
                        </entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ALK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">150</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JAK3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">170</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ARK5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">140</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">MUSK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">110</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AURKC</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">570</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PHKG1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">12</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">FAK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">200</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">RET</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">55</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">FGFR1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">76</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">ROS1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">13</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">FLT1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">120</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">TIE1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">770</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">FLT3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">190</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">TNK2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">21</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">FLT4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">45</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">TrkA</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.6</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JAK1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">130</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">TrkB</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.1</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">JAK2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">5.5</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">TrkC</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">4.9</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl3fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0030" view="all">The binding affinities (Kd) were evaluated by using DiscoveRx’s platform.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" colsep="0" frame="topbot" id="tbl4" rowsep="0">
               <ce:label>Table 4</ce:label>
               <ce:caption id="cap0070">
                  <ce:simple-para id="tspara0025" view="all">Pharmacokinetic profile of compound <ce:bold>7</ce:bold>
                     <ce:bold>mb</ce:bold> in rats.</ce:simple-para>
               </ce:caption>
               <ce:alt-text id="alttext0360" role="short">Table 4</ce:alt-text>
               <tgroup cols="3">
                  <colspec colname="col1" colnum="1"/></colspec>
                  <colspec colname="col2" colnum="2"/></colspec>
                  <colspec colname="col3" colnum="3"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" role="rowgroup">Parameters</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" nameend="col3" namest="col2" role="colgroup">7mb</entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">po (10 mg/kg)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">iv (2 mg/kg)</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AUC<inf loc="post">(0−∞)</inf> (μM·h)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.62</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">3.69</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">C<inf loc="post">max</inf> (μM)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">0.36</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">6.77</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">T<inf loc="post">1/2</inf>(h)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.13</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.39</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">CL (L/h/kg)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">–</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">1.44</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">BA (%)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">8.79</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">/</entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
         </ce:floats>
         <head>
            <ce:dochead id="dhead0010">
               <ce:textfn>Research paper</ce:textfn>
            </ce:dochead>
            <ce:title id="title0010">Design, synthesis, and Structure–Activity Relationships (SAR) of 3-vinylindazole derivatives as new selective tropomyosin receptor kinases (Trk) inhibitors</ce:title>
            <ce:author-group id="augrp0010">
               <ce:author id="au1" author-id="S0223523420305249-2dd063431b8dec5fa8c6ab67af6f940d">
                  <ce:given-name>Yunxin</ce:given-name>
                  <ce:surname>Duan</ce:surname>
                  <ce:cross-ref id="crosref0010" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0015" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au2" author-id="S0223523420305249-42d5bfac962b7be21b4e849789f8a273">
                  <ce:given-name>Jie</ce:given-name>
                  <ce:surname>Wang</ce:surname>
                  <ce:cross-ref id="crosref0020" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0025" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au3" author-id="S0223523420305249-d1204ca6699b007c3ef68508e15f4be1">
                  <ce:given-name>Sihua</ce:given-name>
                  <ce:surname>Zhu</ce:surname>
                  <ce:cross-ref id="crosref0030" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au4" author-id="S0223523420305249-1b410e4db9be01f51aba1839179b2f7a">
                  <ce:given-name>Zheng-Chao</ce:given-name>
                  <ce:surname>Tu</ce:surname>
                  <ce:cross-ref id="crosref0035" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0040" refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au5" author-id="S0223523420305249-d891010f04cbf5dbc029becbf187493f">
                  <ce:given-name>Zhang</ce:given-name>
                  <ce:surname>Zhang</ce:surname>
                  <ce:cross-ref id="crosref0045" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0050" refid="cor2">
                     <ce:sup loc="post">∗∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au6" author-id="S0223523420305249-2ad47c5edbf4b0ffaa4e1f3e0c03c5c7">
                  <ce:given-name>Shingpan</ce:given-name>
                  <ce:surname>Chan</ce:surname>
                  <ce:cross-ref id="crosref0055" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0060" refid="cor3">
                     <ce:sup loc="post">∗∗∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au7" author-id="S0223523420305249-e5d7d5d3b566f7bdd99c30e97a749579">
                  <ce:given-name>Ke</ce:given-name>
                  <ce:surname>Ding</ce:surname>
                  <ce:cross-ref id="crosref0065" refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="crosref0070" refid="cor1">
                     <ce:sup loc="post">∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation id="aff1" affiliation-id="S0223523420305249-fe14c52cad5ee86c58368ecf68a9aa06">
                  <ce:label>a</ce:label>
                  <ce:textfn>International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemistry Drug Development, School of Pharmacy, Jinan University, No. 601 Huangpu Avenue West, Guangzhou, 510632, China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education (MOE)</sa:organization>
                     <sa:organization>Guangzhou City Key Laboratory of Precision Chemistry Drug Development</sa:organization>
                     <sa:organization>School of Pharmacy</sa:organization>
                     <sa:organization>Jinan University</sa:organization>
                     <sa:address-line>No. 601 Huangpu Avenue West</sa:address-line>
                     <sa:city>Guangzhou</sa:city>
                     <sa:postal-code>510632</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0010">International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemistry Drug Development, School of Pharmacy, Jinan University, No. 601 Huangpu Avenue West, Guangzhou, 510632, China</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff2" affiliation-id="S0223523420305249-3d0b5f62407ee1059389cf9eba50c042">
                  <ce:label>b</ce:label>
                  <ce:textfn>Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou Science Park, Guangzhou, 510530, China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Guangzhou Institutes of Biomedicine and Health</sa:organization>
                     <sa:organization>Chinese Academy of Sciences</sa:organization>
                     <sa:address-line>#190 Kaiyuan Avenue</sa:address-line>
                     <sa:address-line>Guangzhou Science Park</sa:address-line>
                     <sa:city>Guangzhou</sa:city>
                     <sa:postal-code>510530</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0015">Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, #190 Kaiyuan Avenue, Guangzhou Science Park, Guangzhou, 510530, China</ce:source-text>
               </ce:affiliation>
               <ce:correspondence id="cor1">
                  <ce:label>∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:correspondence id="cor2">
                  <ce:label>∗∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:correspondence id="cor3">
                  <ce:label>∗∗∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:footnote id="fn1">
                  <ce:label>1</ce:label>
                  <ce:note-para id="ntpara0010" view="all">These authors contributed equally.</ce:note-para>
               </ce:footnote>
            </ce:author-group>
            <ce:date-received day="1" month="4" year="2020"/></ce:date-received>
            <ce:date-revised day="7" month="6" year="2020"/></ce:date-revised>
            <ce:date-accepted day="7" month="6" year="2020"/></ce:date-accepted>
            <ce:abstract id="abs0010" xml:lang="en" view="all" class="author"><ce:abstract-sec id="abssec0010" view="all">
                  <ce:simple-para id="abspara0010" view="all">Neurotrophic receptor tyrosine kinase (NTRK) fusions are oncogenic drivers for a variety of adult and pediatric tumors, validated by the US FDA approval of small molecular Trk inhibitors Larotrectinib (<ce:bold>1</ce:bold>, LOXO-101) and Entrectinib (<ce:bold>2</ce:bold>). However, gene mutation mediated resistance becomes a major challenge for Trk inhibitor therapies. Herein, we report the design, synthesis and Structure–Activity Relationship investigation of a series of 3-vinylindazole derivatives as new Trk inhibitors with low nanomolar potencies. A representative compound, <ce:bold>7</ce:bold>
                     <ce:bold>mb</ce:bold>, binds to TrkA/B/C with <ce:italic>K</ce:italic>
                     <ce:inf loc="post">d</ce:inf> values of 1.6, 3.1 and 4.9 nM, and suppresses their kinase functions with IC<ce:inf loc="post">50</ce:inf> values of 1.6, 2.9 and 2.0 nM, respectively, but is obviously less potent for the majority of a panel of 403 wild-type kinases in a KINOMEscan selectivity investigation. The compound also potently suppresses proliferation of a panel of BaF3 cells stably transformed with NTRK fusions with IC<ce:inf loc="post">50</ce:inf> values in low nM ranges. Additionally, the compound exhibits strong inhibition against the Larotrectinib-resistant cells with NTRK1-G667C or NTRK3-G696A mutations with IC<ce:inf loc="post">50</ce:inf> values of 0.031 and 0.018 μM, respectively. Although the relatively poor oral bioavailability of <ce:bold>7</ce:bold>
                     <ce:bold>mb</ce:bold> will limit its further development, this compound may be utilized a lead molecule for further structural optimization.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
            <ce:abstract class="graphical" id="abs0015" view="all">
               <ce:section-title id="sectitle0015">Graphical abstract</ce:section-title>
               <ce:abstract-sec id="abssec0015" view="all">
                  <ce:simple-para id="abspara0015" view="all">
                     <ce:display>
                        <ce:figure id="undfig1">
                           <ce:alt-text id="alttext0010" role="short">Image 1</ce:alt-text>
                           <ce:link locator="fx1" xlink:href="pii:S0223523420305249/fx1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
                        </ce:figure>
                     </ce:display>
                  </ce:simple-para>
               </ce:abstract-sec>
            </ce:abstract>
            
            <ce:keywords id="kwrds0010" xml:lang="en" view="all" class="keyword">
               <ce:section-title id="sectitle0025">Keywords</ce:section-title>
               <ce:keyword id="kwrd0010">
                  <ce:text>Tropomyosin receptor kinase (Trk)</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0015">
                  <ce:text>Neurotrophic receptor tyrosine kinase gene (NTRK)</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0020">
                  <ce:text>Fusion</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0025">
                  <ce:text>Inhibitor</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0030">
                  <ce:text>Resistance</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0035">
                  <ce:text>Mutation</ce:text>
               </ce:keyword>
            </ce:keywords>
         </head>
         <body view="all">
            <ce:nomenclature id="nomen0010" view="all">
               <ce:section-title id="sectitle0030">Abbreviations</ce:section-title>
               <ce:def-list id="dlist0010">
                  <ce:def-term id="d0010">TRK</ce:def-term>
                  <ce:def-description id="defdis0010">
                     <ce:para id="p0025" view="all">tropomyosin receptor kinases</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0015">NTRK</ce:def-term>
                  <ce:def-description id="defdis0015">
                     <ce:para id="p0030" view="all">neurotrophin receptor kinase</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0020">FDA</ce:def-term>
                  <ce:def-description id="defdis0020">
                     <ce:para id="p0035" view="all">food and drug administration</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0025">IC<ce:inf loc="post">50</ce:inf>
                  </ce:def-term>
                  <ce:def-description id="defdis0025">
                     <ce:para id="p0040" view="all">half-maximal (50%) inhibitory concentration of a substance</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0030">BDNF</ce:def-term>
                  <ce:def-description id="defdis0030">
                     <ce:para id="p0045" view="all">brain-derived neurotrophic factor</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0035">NGF</ce:def-term>
                  <ce:def-description id="defdis0035">
                     <ce:para id="p0050" view="all">nerve growth factor</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0040">NT-4</ce:def-term>
                  <ce:def-description id="defdis0040">
                     <ce:para id="p0055" view="all">Neurotrophin-4</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0045">NT-3</ce:def-term>
                  <ce:def-description id="defdis0045">
                     <ce:para id="p0060" view="all">Neurotrophin-3</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0050">MAPK</ce:def-term>
                  <ce:def-description id="defdis0050">
                     <ce:para id="p0065" view="all">mitogen-activated protein kinase</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0055">PI3K</ce:def-term>
                  <ce:def-description id="defdis0055">
                     <ce:para id="p0070" view="all">phosphatidylinositol 3 kinase</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0060">Akt</ce:def-term>
                  <ce:def-description id="defdis0060">
                     <ce:para id="p0075" view="all">protein kinase B</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0065">PLC-γ</ce:def-term>
                  <ce:def-description id="defdis0065">
                     <ce:para id="p0080" view="all">phospholipase C-γ</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0070">MASC</ce:def-term>
                  <ce:def-description id="defdis0070">
                     <ce:para id="p0085" view="all">mammary analogue secretory carcinoma</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0075">SBC</ce:def-term>
                  <ce:def-description id="defdis0075">
                     <ce:para id="p0090" view="all">secretory breast carcinoma</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0085">xDFG</ce:def-term>
                  <ce:def-description id="defdis0085">
                     <ce:para id="p0100" view="all">X-aspartate-phenylalanine-glycine</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0090">PDB</ce:def-term>
                  <ce:def-description id="defdis0090">
                     <ce:para id="p0105" view="all">protein data bank</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0095">VEGFR</ce:def-term>
                  <ce:def-description id="defdis0095">
                     <ce:para id="p0110" view="all">vascular endothelial growth factor receptor</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0100">ROS1</ce:def-term>
                  <ce:def-description id="defdis0100">
                     <ce:para id="p0115" view="all">proto-oncogene tyrosine-protein kinase 1</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0105">ALK</ce:def-term>
                  <ce:def-description id="defdis0105">
                     <ce:para id="p0120" view="all">anaplastic lymphoma kinase</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0110">ARK5</ce:def-term>
                  <ce:def-description id="defdis0110">
                     <ce:para id="p0125" view="all">AMPK-related protein kinase 5</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0115">AURKC</ce:def-term>
                  <ce:def-description id="defdis0115">
                     <ce:para id="p0130" view="all">aurora kinase C</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0120">FAK</ce:def-term>
                  <ce:def-description id="defdis0120">
                     <ce:para id="p0135" view="all">focal adhesion kinase</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0125">FGFR1</ce:def-term>
                  <ce:def-description id="defdis0125">
                     <ce:para id="p0140" view="all">fibroblast growth factor receptor 1</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0130">FLT1</ce:def-term>
                  <ce:def-description id="defdis0130">
                     <ce:para id="p0145" view="all">fms-like tyrosine kinase 1</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0135">FLT3</ce:def-term>
                  <ce:def-description id="defdis0135">
                     <ce:para id="p0150" view="all">fms-like tyrosine kinase 3</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0140">FLT4</ce:def-term>
                  <ce:def-description id="defdis0140">
                     <ce:para id="p0155" view="all">fms-like tyrosine kinase 4</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0145">JAK1</ce:def-term>
                  <ce:def-description id="defdis0145">
                     <ce:para id="p0160" view="all">Janus kinase 1</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0150">JAK2</ce:def-term>
                  <ce:def-description id="defdis0150">
                     <ce:para id="p0165" view="all">Janus kinase 2</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0155">JAK3</ce:def-term>
                  <ce:def-description id="defdis0155">
                     <ce:para id="p0170" view="all">Janus kinase 3</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0160">MUSK</ce:def-term>
                  <ce:def-description id="defdis0160">
                     <ce:para id="p0175" view="all">muscle associated receptor tyrosine kinase</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0165">PHKG1</ce:def-term>
                  <ce:def-description id="defdis0165">
                     <ce:para id="p0180" view="all">phosphorylase kinase catalytic subunit gamma 1</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0170">RET</ce:def-term>
                  <ce:def-description id="defdis0170">
                     <ce:para id="p0185" view="all">ret proto-oncogene</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0175">TIE1</ce:def-term>
                  <ce:def-description id="defdis0175">
                     <ce:para id="p0190" view="all">tyrosine kinase with immunoglobulin like and EGF like domains 1</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0180">TNK2</ce:def-term>
                  <ce:def-description id="defdis0180">
                     <ce:para id="p0195" view="all">tyrosine kinase non receptor 2</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0185">PK</ce:def-term>
                  <ce:def-description id="defdis0185">
                     <ce:para id="p0200" view="all">pharmacokinetic</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0190">SD rats</ce:def-term>
                  <ce:def-description id="defdis0190">
                     <ce:para id="p0205" view="all">Sprague−Dawley rats</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0195">ESI-MS</ce:def-term>
                  <ce:def-description id="defdis0195">
                     <ce:para id="p0210" view="all">electrospray ionization mass spectrometry</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0200">HPLC</ce:def-term>
                  <ce:def-description id="defdis0200">
                     <ce:para id="p0215" view="all">high-performance liquid chromatography</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0205">LC-MS</ce:def-term>
                  <ce:def-description id="defdis0205">
                     <ce:para id="p0220" view="all">liquid chromatography–mass spectrometry</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0210">HRMS</ce:def-term>
                  <ce:def-description id="defdis0210">
                     <ce:para id="p0225" view="all">high-resolution mass spectrometry</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0215">DCM</ce:def-term>
                  <ce:def-description id="defdis0215">
                     <ce:para id="p0230" view="all">dichloromethane</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0220">MeOH</ce:def-term>
                  <ce:def-description id="defdis0220">
                     <ce:para id="p0235" view="all">methanol</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0225">EtOH</ce:def-term>
                  <ce:def-description id="defdis0225">
                     <ce:para id="p0240" view="all">ethanol</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0230">PE</ce:def-term>
                  <ce:def-description id="defdis0230">
                     <ce:para id="p0245" view="all">petroleum ether</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0235">EA</ce:def-term>
                  <ce:def-description id="defdis0235">
                     <ce:para id="p0250" view="all">ethyl acetate</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0240">TFA</ce:def-term>
                  <ce:def-description id="defdis0240">
                     <ce:para id="p0255" view="all">trifluoroacetic acid</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0245">DIPEA</ce:def-term>
                  <ce:def-description id="defdis0245">
                     <ce:para id="p0260" view="all">
                        <ce:italic>N</ce:italic>,<ce:italic>N</ce:italic>-Diisopropylethylamine</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0250">DIAD</ce:def-term>
                  <ce:def-description id="defdis0250">
                     <ce:para id="p0265" view="all">diisopropyl azodiformate</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0255">THF</ce:def-term>
                  <ce:def-description id="defdis0255">
                     <ce:para id="p0270" view="all">tetrahydrofuran</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0260">THP</ce:def-term>
                  <ce:def-description id="defdis0260">
                     <ce:para id="p0275" view="all">2-tetrahydropyranyl</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0265">DHP</ce:def-term>
                  <ce:def-description id="defdis0265">
                     <ce:para id="p0280" view="all">3,4-dihydropyran</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0270">p-TSA</ce:def-term>
                  <ce:def-description id="defdis0270">
                     <ce:para id="p0285" view="all">p-toluenesulfonic acid</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0275">P(o-tol)<ce:inf loc="post">3</ce:inf>
                  </ce:def-term>
                  <ce:def-description id="defdis0275">
                     <ce:para id="p0290" view="all">tri(o-tolyl)phosphine</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0280">BINAP</ce:def-term>
                  <ce:def-description id="defdis0280">
                     <ce:para id="p0295" view="all">(±)-2,2′-Bis(diphenylphosphino)-1,1′-binaphthalene</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0290">SEMCl</ce:def-term>
                  <ce:def-description id="defdis0290">
                     <ce:para id="p0305" view="all">2-(trimethylsilyl)ethoxymethyl chloride</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0295">TBAB</ce:def-term>
                  <ce:def-description id="defdis0295">
                     <ce:para id="p0310" view="all">tetrabutylammonium bromide</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0300">TBAF</ce:def-term>
                  <ce:def-description id="defdis0300">
                     <ce:para id="p0315" view="all">tetrabutylammonium fluoride</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0305">DMF</ce:def-term>
                  <ce:def-description id="defdis0305">
                     <ce:para id="p0320" view="all">
                        <ce:italic>N</ce:italic>,<ce:italic>N</ce:italic>-Dimethylformamide</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0310">LiHMDS</ce:def-term>
                  <ce:def-description id="defdis0310">
                     <ce:para id="p0325" view="all">Lithium hexamethyldisilazide</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0315">TBSCl</ce:def-term>
                  <ce:def-description id="defdis0315">
                     <ce:para id="p0330" view="all">tertbutyldimethylsilyl chloride</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0320">rt</ce:def-term>
                  <ce:def-description id="defdis0320">
                     <ce:para id="p0335" view="all">room temperature</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0325">TEA</ce:def-term>
                  <ce:def-description id="defdis0325">
                     <ce:para id="p0340" view="all">triethylamine</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0330">HATU</ce:def-term>
                  <ce:def-description id="defdis0330">
                     <ce:para id="p0345" view="all">1-[Bis(dimethylamino)methylene]-1<ce:italic>H</ce:italic>-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0335">TLC</ce:def-term>
                  <ce:def-description id="defdis0335">
                     <ce:para id="p0350" view="all">thin-layer chromatography</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0340">NMR</ce:def-term>
                  <ce:def-description id="defdis0340">
                     <ce:para id="p0355" view="all">nuclear magnetic resonance</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0345">TMS</ce:def-term>
                  <ce:def-description id="defdis0345">
                     <ce:para id="p0360" view="all">tetramethylsilane</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0350">DMSO</ce:def-term>
                  <ce:def-description id="defdis0350">
                     <ce:para id="p0365" view="all">dimethylsulfoxide</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0355">ATP</ce:def-term>
                  <ce:def-description id="defdis0355">
                     <ce:para id="p0370" view="all">Adenosine Triphosphate</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0360">CCK-8</ce:def-term>
                  <ce:def-description id="defdis0360">
                     <ce:para id="p0375" view="all">cell counting kit-8</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0365">SDS-PAGE</ce:def-term>
                  <ce:def-description id="defdis0365">
                     <ce:para id="p0380" view="all">sodium dodecyl sulfate-polyacrylamide gel electrophoresis</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0370">GAPDH</ce:def-term>
                  <ce:def-description id="defdis0370">
                     <ce:para id="p0385" view="all">glyceraldehyde 3-phosphate dehydrogenase</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0375">TBST</ce:def-term>
                  <ce:def-description id="defdis0375">
                     <ce:para id="p0390" view="all">Tris-Buffered Saline Tween-20</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0380">PVDF</ce:def-term>
                  <ce:def-description id="defdis0380">
                     <ce:para id="p0395" view="all">polyvinylidene fluoride</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0385">BSA</ce:def-term>
                  <ce:def-description id="defdis0385">
                     <ce:para id="p0400" view="all">albumin from bovine serum</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0390">TBS</ce:def-term>
                  <ce:def-description id="defdis0390">
                     <ce:para id="p0405" view="all">tris buffered saline.</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0395">HRP</ce:def-term>
                  <ce:def-description id="defdis0395">
                     <ce:para id="p0410" view="all">horseradish peroxidase</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0400">FBS</ce:def-term>
                  <ce:def-description id="defdis0400">
                     <ce:para id="p0415" view="all">fetal bovine serum</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0405">CMC-Na</ce:def-term>
                  <ce:def-description id="defdis0405">
                     <ce:para id="p0420" view="all">carboxymethylcellulose sodium</ce:para>
                  </ce:def-description>
                  <ce:def-term id="d0410">DAS</ce:def-term>
                  <ce:def-description id="defdis0410">
                     <ce:para id="p0425" view="all">Drug and Statistics</ce:para>
                  </ce:def-description>
               </ce:def-list>
            </ce:nomenclature>
            <ce:sections>
               <ce:section id="sec1" role="introduction" view="all">
                  <ce:label>1</ce:label>
                  <ce:section-title id="sectitle0035">Introduction</ce:section-title>
                  <ce:para id="p0430" view="all">Tropomyosin receptor kinases (Trks) belong to the transmembrane receptor tyrosine kinase superfamily. Three isoforms (i.e. TrkA, TrkB and TrkC), which are encoded by NTRK1, NTRK2 and NTRK3 genes (neurotrophic receptor tyrosine kinase 1/2/3 genes), respectively, have been identified to date. These receptor kinases are primarily expressed in human neuronal tissues and play critical roles in regulating physiological functions of mammalian central and peripheral nervous system through activation of neurophin proteins including nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), neurotrophin 3 (NT3) and neurotrophin 4 (NT4) [<ce:cross-ref id="crosref0075" refid="bib1">1</ce:cross-ref>,<ce:cross-ref id="crosref0080" refid="bib2">2</ce:cross-ref>]. Upon binding with different neurotrophins, Trks are dimerized and autophosphorylated to trigger downstream signal transduction pathways involving mitogen-activated protein kinase (MAPK), phosphatidylinositol 3 kinase (PI3K)/AKT, and phospholipase C-γ (PLC-γ)/PKC, which consequently modulate cell growth, proliferation, survival and differentiation in nervous system [<ce:cross-ref id="crosref0085" refid="bib2">2</ce:cross-ref>,<ce:cross-ref id="crosref0090" refid="bib3">3</ce:cross-ref>].</ce:para>
                  <ce:para id="p0435" view="all">NTRK1 was first identified as a proto-oncogene in colon cancer in 1982 [<ce:cross-refs id="crosrefs0010" refid="bib4 bib5 bib6">4–6</ce:cross-refs>]. NTRK somatic mutations, activating splice variants, and Trk overexpression have been detected in a variety of human cancers including colorectal cancer, lung cancers, melanoma, acute myeloid leukaemia, neuroblastoma, breast cancer, cutaneous cancers and others [<ce:cross-ref id="crosref0095" refid="bib7">7</ce:cross-ref>]. Intrachromosomal or interchromosomal rearrangements, in which 3ʹ sequences of NTRK are juxtaposed to 5ʹ sequences of partner genes, are the most common mechanisms of abnormal Trk activation [<ce:cross-ref id="crosref0100" refid="bib8">8</ce:cross-ref>]. The fusion oncogenes induce ligand-independent activation of Trk kinases mediated by constitutive expression of promoter and oligomerization of the partner genes [<ce:cross-ref id="crosref0105" refid="bib7">7</ce:cross-ref>]. Since the first identification of TPM3(tropomyosin 3)-NTRK1 fusion in human colorectal cancer [<ce:cross-ref id="crosref0110" refid="bib9">9</ce:cross-ref>], a vast number of NTRK fusions (e.g., LMNA(Lamin A/C)-NTRK1, CD74(Cluster of Differentiation 74)-NTRK1, QKI(KH domain containing RNA binding)-NTRK2, ETV6(E26 transformation-specific variant 6 gene)-NTRK3) have been characterized as the oncogenic drivers of multiple adult and pediatric tumors [<ce:cross-ref id="crosref0115" refid="bib7">7</ce:cross-ref>,<ce:cross-ref id="crosref0120" refid="bib10">10</ce:cross-ref>]. For instance, ETV6-NTRK3 fusion is pathognomonically detected in approximate 90% of some rare cancer types including mammary analogue secretory carcinoma (MASC) [<ce:cross-ref id="crosref0125" refid="bib11">11</ce:cross-ref>], secretory breast carcinoma (SBC) [<ce:cross-ref id="crosref0130" refid="bib12">12</ce:cross-ref>], and infantile fibrosarcoma [<ce:cross-ref id="crosref0135" refid="bib13">13</ce:cross-ref>]. NTRK1 fusion oncogenes have also been identified in a subpopulation of different cancers, including 12.3% of thyroid cancer [<ce:cross-ref id="crosref0140" refid="bib14">14</ce:cross-ref>], 1.25% of glioblastoma [<ce:cross-ref id="crosref0145" refid="bib15">15</ce:cross-ref>,<ce:cross-ref id="crosref0150" refid="bib16">16</ce:cross-ref>], 3.3% of lung cancer and others [<ce:cross-ref id="crosref0155" refid="bib17">17</ce:cross-ref>].</ce:para>
                  <ce:para id="p0440" view="all">Given the significant evidence for the crucial roles of NTRK in cancer, a number of selective or nonselective small molecular Trk inhibitors have been developed (<ce:cross-ref id="crosref0160" refid="fig1">Fig. 1</ce:cross-ref>
                     <ce:float-anchor refid="fig1"/></ce:float-anchor>) [<ce:cross-refs id="crosrefs0015" refid="bib18 bib19 bib20">18–20</ce:cross-refs>]. Several Trk-targeted radioligands for positron emission tomography (PET) imaging diagnosis were reported [<ce:cross-refs id="crosrefs0020" refid="bib21 bib22 bib23">21–23</ce:cross-refs>]. Larotrectinib (<ce:bold>1</ce:bold>, LOXO-101) and Entrectinib (<ce:bold>2</ce:bold>) have been recently approved by U.S. Food and Drug Administration (FDA) for adult and pediatric patients with solid tumors harboring NTRK gene fusions [<ce:cross-ref id="crosref0165" refid="bib24">24</ce:cross-ref>,<ce:cross-ref id="crosref0170" refid="bib25">25</ce:cross-ref>]. Belizatinib (<ce:bold>3</ce:bold>) is a novel, potent ALK (anaplastic lymphoma kinase)/pan-Trk dual inhibitor under Phase Ⅰ/Ⅱ clinical investigation for patients with advanced solid tumors and lymphomas [<ce:cross-ref id="crosref0175" refid="bib26">26</ce:cross-ref>]. Multi-kinase inhibitor drugs <ce:bold>4</ce:bold> (Cabozantinib) [<ce:cross-ref id="crosref0180" refid="bib27">27</ce:cross-ref>,<ce:cross-ref id="crosref0185" refid="bib28">28</ce:cross-ref>] and <ce:bold>5</ce:bold> (Ponatinib) [<ce:cross-ref id="crosref0190" refid="bib27">27</ce:cross-ref>,<ce:cross-ref id="crosref0195" refid="bib29">29</ce:cross-ref>] were also reported to demonstrate strong or moderate inhibitory potencies against Trk kinases. Both drug <ce:bold>1</ce:bold> and <ce:bold>2</ce:bold> achieved significant clinical benefit for NTRK fusion positive cancer patients. For instance, drug <ce:bold>1</ce:bold> has demonstrated an overall response rate (ORR) of 79% (n = 121; 95% Confidence Interval (CI), 72–85), including 16% complete responses (CR) and 63% partial responses (PR) per investigator assessment in adult and pediatric patients with NTRK fusions [<ce:cross-refs id="crosrefs0025" refid="bib30 bib31 bib32">30–32</ce:cross-refs>]. Despite significantly clinical success of the FDA approved Trk inhibitors, acquired resistance unfortunately occurs and becomes a major clinical challenge [<ce:cross-ref id="crosref0200" refid="bib33">33</ce:cross-ref>]. For instance, Gly<ce:sup loc="post">595</ce:sup> to Arg<ce:sup loc="post">595</ce:sup> (G595R) and Gly<ce:sup loc="post">667</ce:sup> to Cys<ce:sup loc="post">667</ce:sup> (G667C) point mutations of TrkA, which are located in the solvent front region and the xDFG motif in activation loop of TrkA kinase domain, respectively, are the primary mechanism of clinically acquired resistance, by creating steric hindrance between the side chains of amino acid residues and <ce:bold>1</ce:bold> or <ce:bold>2</ce:bold> [<ce:cross-ref id="crosref0205" refid="bib33">33</ce:cross-ref>]. G623R and G696A substitutions of TrkC are independently paralogous to the TrkA<ce:sup loc="post">G595R</ce:sup> and TRKA<ce:sup loc="post">G667C</ce:sup> mutants, respectively [<ce:cross-ref id="crosref0210" refid="bib31">31</ce:cross-ref>]. Because of the limited number of patients carrying NTRK2 fusion genes, point mutation in TrkB has not been reported from clinic yet [<ce:cross-ref id="crosref0215" refid="bib7">7</ce:cross-ref>,<ce:cross-ref id="crosref0220" refid="bib11">11</ce:cross-ref>]. Encouragingly, a next-generation Trk Inhibitor LOXO-195 (<ce:bold>6</ce:bold>) was developed to exhibit potent suppression on the resistant Trk mutants both <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic> [<ce:cross-ref id="crosref0225" refid="bib34">34</ce:cross-ref>]. This compound has been advanced into phase II clinical trial for previously treated adult and pediatric solid tumor patients with NTRK fusion (NCT03215511) [<ce:cross-ref id="crosref0230" refid="bib34">34</ce:cross-ref>]. However, no therapeutic agent for the Trk mutated resistant patients is approved to date, it is highly valuable to discover new Trk inhibitors with differentiate chemical structures.</ce:para>
                  <ce:para id="p0445" view="all">Herein, we report the design and synthesis of a series of 3-vinylindazole derivatives as new selective pan-Trk inhibitors which suppressed proliferation of the NTRK1-G667C or NTRK3-G696A mutated Larotrectinib-resistant cells with low nM IC<ce:inf loc="post">50</ce:inf> potencies.</ce:para>
               </ce:section>
               <ce:section id="sec2" view="all">
                  <ce:label>2</ce:label>
                  <ce:section-title id="sectitle0040">Molecular design</ce:section-title>
                  <ce:para id="p0450" view="all">Compound <ce:bold>2</ce:bold> is a multi-kinase inhibitor approved by US FDA for advanced solid tumors with NTRK, ROS1 (c-ros oncogene 1) and ALK fusions. Co-crystal structure of <ce:bold>2</ce:bold> with TrkA clearly revealed that the aminoindazole moiety in molecule <ce:bold>2</ce:bold> formed three key hydrogen bonds with the backbone of Glu590 and Met592 in hinge region of the kinase (PDB: <ce:inter-ref id="PC_linkbxTf9ChSTr" xlink:href="pdb:5KVT" xlink:type="simple">5KVT</ce:inter-ref>, <ce:cross-ref id="crosref0235" refid="fig2">Fig. 2</ce:cross-ref>
                     <ce:float-anchor refid="fig2"/></ce:float-anchor>A). The 3, 5-difluorobenzyl moiety is optimally located downward in a hydrophobic pocket and one of the fluorine atoms was in close proximity to Gly667 to facilitate the strong Trk binding potency, while the <ce:italic>N</ce:italic>-methylpiperazine group was oriented toward the solvent front region and tetrahydropyranyl moiety occupied the sugar binding site. It has been well documented that an ATP competitive kinase inhibitor typically forms one to three hydrogen bonds with backbone of residues in the hinge region, increasing numbers of corresponding hydrogen bonds may have negative impact on the kinome selectivity [<ce:cross-ref id="crosref0240" refid="bib35">35</ce:cross-ref>]. Thus, we initially utilized a 2-vinylpyridine moiety, which was adopted from the fragment of an FDA-approved VEGER inhibitor axitinib, to mimic the orientation of the benzamide moiety in <ce:bold>2</ce:bold> and decrease numbers of hydrogen bonds with the hinge region, aiming to improve the target selectivity. A preliminary computational study suggested that the designed molecule <ce:bold>7a</ce:bold> would bind with TrkA in a similar binding mode to that of drug <ce:bold>2</ce:bold>, with two hydrogen bonds with the hinge region (<ce:cross-ref id="crosref0245" refid="fig2">Fig. 2</ce:cross-ref>B and C).</ce:para>
               </ce:section>
               <ce:section id="sec3" view="all">
                  <ce:label>3</ce:label>
                  <ce:section-title id="sectitle0045">Chemistry</ce:section-title>
                  <ce:para id="p0455" view="all">Syntheses of the designed compounds <ce:bold>7a</ce:bold>-<ce:bold>7d</ce:bold>, and <ce:bold>7g</ce:bold>-<ce:bold>7h</ce:bold> were outlined in <ce:cross-ref id="crosref0250" refid="sch1">Scheme 1</ce:cross-ref>
                     <ce:float-anchor refid="sch1"/></ce:float-anchor>. Intermediate <ce:bold>9b</ce:bold> and <ce:bold>10b</ce:bold> were prepared by utilizing Suzuki coupling reaction [<ce:cross-refs id="crosrefs0030" refid="bib36 bib36a bib36b">36</ce:cross-refs>] followed by deprotection with TFA. Intermediate <ce:bold>11a</ce:bold> was afforded by a palladium-catalyzed coupling reaction, while <ce:bold>12a</ce:bold> was produced by Sonogashira coupling reaction [<ce:cross-ref id="crosref0255" refid="bib37">37</ce:cross-ref>]. Reduction of <ce:bold>12a</ce:bold> led to another intermediate <ce:bold>13a</ce:bold>. Compound <ce:bold>14c</ce:bold> was synthesized by cyclization through three step reactions. Iodination of <ce:bold>9b</ce:bold>, <ce:bold>10b</ce:bold>, <ce:bold>11a</ce:bold>-<ce:bold>13a</ce:bold> and <ce:bold>14c</ce:bold>, followed by protection of the THP group, Heck coupling reaction [<ce:cross-ref id="crosref0260" refid="bib38">38</ce:cross-ref>] and deprotection with TFA led to compounds <ce:bold>7a</ce:bold>-<ce:bold>7d</ce:bold>, and <ce:bold>7g</ce:bold>-<ce:bold>7h</ce:bold>.</ce:para>
                  <ce:para id="p0460" view="all">Compounds <ce:bold>7j</ce:bold>, <ce:bold>7m</ce:bold>, <ce:bold>7o</ce:bold>, <ce:bold>7q</ce:bold>-<ce:bold>7z</ce:bold> were synthesized according to the protocol described in <ce:cross-ref id="crosref0265" refid="sch2">Scheme 2</ce:cross-ref>
                     <ce:float-anchor refid="sch2"/></ce:float-anchor>. Iodination of <ce:bold>15</ce:bold>, followed by protection of the THP group, Heck coupling reaction and nitro reduction obtained the key intermediate <ce:bold>15d</ce:bold>. Amidation of <ce:bold>15d</ce:bold> with 3, 5-difluorobenzoyl chloride produced <ce:bold>15q</ce:bold>. Reductive amination of <ce:bold>15d</ce:bold> with commercially available aromatic aldehydes led to a series of intermediates <ce:bold>15e</ce:bold>-<ce:bold>15o</ce:bold>. <ce:italic>N</ce:italic>-methylation of <ce:bold>15e</ce:bold> with CH<ce:inf loc="post">3</ce:inf>I and strong base provided <ce:bold>15p</ce:bold>. Final compounds <ce:bold>7j</ce:bold>, <ce:bold>7m</ce:bold>, <ce:bold>7o</ce:bold>, <ce:bold>7q</ce:bold>-<ce:bold>7z</ce:bold> were obtained by removing THP group from <ce:bold>15e</ce:bold>-<ce:bold>15q</ce:bold>.</ce:para>
                  <ce:para id="p0465" view="all">The syntheses of compounds <ce:bold>7i</ce:bold>, <ce:bold>7k</ce:bold>, <ce:bold>7l</ce:bold>, <ce:bold>7n</ce:bold>, and <ce:bold>7p</ce:bold> were outlined in <ce:cross-ref id="crosref0270" refid="sch3">Scheme 3</ce:cross-ref>
                     <ce:float-anchor refid="sch3"/></ce:float-anchor>. Protecting the hydroxyl of <ce:bold>16</ce:bold> and <ce:bold>17</ce:bold> produced <ce:bold>16a</ce:bold> and <ce:bold>17a</ce:bold>. Then iodination of <ce:bold>16a</ce:bold> and <ce:bold>17a</ce:bold>, followed by protection of the THP group, led to <ce:bold>16c</ce:bold> and <ce:bold>17c</ce:bold>. Removing TBS group from <ce:bold>16c</ce:bold> led to <ce:bold>16d</ce:bold>. <ce:bold>16f</ce:bold> was synthesized via nucleophilic substitution reaction and Heck reaction from <ce:bold>16d</ce:bold>. A Heck reaction between <ce:bold>17c</ce:bold> and 2-vinylpyridine generated the <ce:bold>17d</ce:bold>, which was subsequently deprotected with TBAF to obtain <ce:bold>17e</ce:bold>. <ce:bold>17f</ce:bold> was synthesized from <ce:bold>17e</ce:bold> and 3, 5-difluorophenol by Mitsunobu reaction [<ce:cross-ref id="crosref0275" refid="bib39">39</ce:cross-ref>]. The treatment of <ce:bold>17e</ce:bold> with Dess-Martin periodinane afforded <ce:bold>17g</ce:bold>, which was further reductive aminated to produce <ce:bold>17h</ce:bold>. <ce:italic>N</ce:italic>-methylation of <ce:bold>17h</ce:bold> gave <ce:bold>17i</ce:bold>. The procedure of obtaining intermediate <ce:bold>18d</ce:bold> was similar to synthetic route of <ce:bold>17d</ce:bold>. <ce:bold>18d</ce:bold> was hydrolyzed under base conditions to yield <ce:bold>18e</ce:bold> by further acidification, which was condensed with 3,5-difluoroaniline to afford <ce:bold>18f</ce:bold>. Removal of the THP group of <ce:bold>16f</ce:bold>, <ce:bold>17f</ce:bold>, <ce:bold>17h</ce:bold>, <ce:bold>17i</ce:bold> and <ce:bold>18f</ce:bold> produced <ce:bold>7i</ce:bold>, <ce:bold>7k</ce:bold>, <ce:bold>7l</ce:bold>, <ce:bold>7n</ce:bold>, and <ce:bold>7p</ce:bold>.</ce:para>
                  <ce:para id="p0470" view="all">Syntheses of <ce:bold>7e</ce:bold>, <ce:bold>7f</ce:bold>, and <ce:bold>7ma</ce:bold>-<ce:bold>7mb</ce:bold> were depicted in <ce:cross-ref id="crosref0280" refid="sch4">Scheme 4</ce:cross-ref>
                     <ce:float-anchor refid="sch4"/></ce:float-anchor>. Iodination, protection of N–H with different groups, Heck coupling reaction, Buchwald-Hartwig amination reaction [<ce:cross-refs id="crosrefs0035" refid="bib40b bib40 bib40a">40</ce:cross-refs>], followed by deprotection with TFA, led to the <ce:bold>7e</ce:bold>, <ce:bold>7f</ce:bold>, and <ce:bold>7ma-7mb</ce:bold>.</ce:para>
               </ce:section>
               <ce:section id="sec4" role="results" view="all">
                  <ce:label>4</ce:label>
                  <ce:section-title id="sectitle0050">Results and discussion</ce:section-title>
                  <ce:para id="p0475" view="all">The TrkA/B/C inhibitory activities of the designed molecules were preliminarily screened by utilizing fluorescence resonance energy transfer (FRET)-based Z′-Lyte kinase assays [<ce:cross-ref id="crosref0285" refid="bib41">41</ce:cross-ref>]. The cellular growth inhibition was further determined against a panel of BaF3 cells stably transformed with TrkA/B/C, respectively, for the representative compounds with promising kinase inhibitory potencies. FDA approved drug <ce:bold>1</ce:bold> was included as a positive reference compound to exhibit 2.9, 2.3 and 1.7 nM IC<ce:inf loc="post">50</ce:inf> values in kinase assays, and suppressed the proliferation of BaF3 cells harboring TrkA/B/C with IC<ce:inf loc="post">50</ce:inf> values of 0.016, 0.040 and 0.013 μM, respectively (<ce:cross-ref id="crosref0290" refid="tbl1">Table 1</ce:cross-ref>
                     <ce:float-anchor refid="tbl1"/></ce:float-anchor> and <ce:cross-ref id="crosref0295" refid="tbl2">Table 2</ce:cross-ref>
                     <ce:float-anchor refid="tbl2"/></ce:float-anchor>). Encouragingly, our first designed compound <ce:bold>7a</ce:bold> displayed comparable kinase inhibitory potencies with that of drug <ce:bold>1</ce:bold> with IC<ce:inf loc="post">50</ce:inf> values of 7.6, 1.3 and 1.9 nM against TrkA, TrkB and TrkC (<ce:cross-ref id="crosref0300" refid="tbl1">Table 1</ce:cross-ref>), respectively, providing a promising lead compound for further structural optimization.</ce:para>
                  <ce:para id="p0480" view="all">Our docking results suggested the 3, 5-difluorobenzene moiety might contribute greatly to the TrkA/B/C inhibitory potency, therefore we first performed structural modification on the linker which bridged the hydrophobic 3, 5-difluorobenzene moiety and 1<ce:italic>H</ce:italic>-indazole scaffold (<ce:cross-ref id="crosref0305" refid="tbl1">Table 1</ce:cross-ref>). It was shown that length and chemical type of the linker had significant impact on Trks inhibitory potency of a compound. For instance, when the methylene (-CH<ce:inf loc="post">2</ce:inf>-) linker in <ce:bold>7a</ce:bold> was replaced with a traditional bioisostere such as a sulfur (-S-, <ce:bold>7c</ce:bold>), oxygen (-O-, <ce:bold>7d</ce:bold>), –NH–(<ce:bold>7e</ce:bold>) or –N(Me)- (<ce:bold>7f</ce:bold>) moiety, the resulting compounds exhibited 3–60 fold less potencies. The zero-linking molecule (<ce:italic>E</ce:italic>)-5-(3, 5-difluorophenyl)-3-(2-(pyridin-2-yl)vinyl)-1<ce:italic>H</ce:italic>-indazole (<ce:bold>7b</ce:bold>) displayed IC<ce:inf loc="post">50</ce:inf> values of 253.6, 728.8 and 533.9 nM against TrkA, TrkB and TrkC, while introduction of an ethylene (–CH<ce:inf loc="post">2</ce:inf>CH<ce:inf loc="post">2</ce:inf>–) linker (<ce:bold>7g</ce:bold>) significantly improved the kinase inhibitory potency with corresponding IC<ce:inf loc="post">50</ce:inf> values of 3.7, 8.5 and 12.4 nM, respectively. However, when the –CH<ce:inf loc="post">2</ce:inf>CH<ce:inf loc="post">2</ce:inf>- linker in <ce:bold>7g</ce:bold> was replaced by a linear ethynyl (-C<ce:glyph name="tbnd"/></ce:glyph>C-, <ce:bold>7h</ce:bold>), retro-amide (-NHC(=O)-, 7<ce:bold>i</ce:bold>), or amide (-C(=O) NH-, <ce:bold>7j</ce:bold>) group, the resulting compounds displayed obviously less potencies. Particularly, compound <ce:bold>7h</ce:bold> almost totally abolished the TrkA/B/C inhibitory activity with IC<ce:inf loc="post">50</ce:inf> values of >1000, >1000 and >450 nM, respectively. Further investigation also suggested that the –CH<ce:inf loc="post">2</ce:inf>CH<ce:inf loc="post">2</ce:inf>- linker in <ce:bold>7g</ce:bold> could be replaced by a methenoxy (–CH<ce:inf loc="post">2</ce:inf>O–, <ce:bold>7k</ce:bold>) or methenamino (–CH<ce:inf loc="post">2</ce:inf>NH–, <ce:bold>7m</ce:bold>) moiety to improve the Trks inhibition activities. For instance, <ce:bold>7m</ce:bold> demonstrated IC<ce:inf loc="post">50</ce:inf> values of 1.5, 8.3, and 2.7 nM, against TrkA, B and C, respectively, which are 2–4 folds more potent than <ce:bold>7g</ce:bold>, while the corresponding counterparts with reverse linker, i.e. –OCH<ce:inf loc="post">2</ce:inf>- (<ce:bold>7l</ce:bold>) and –NHCH<ce:inf loc="post">2</ce:inf>- (<ce:bold>7n</ce:bold>), are less potent. The results also showed that methylation of –NH– moieties in <ce:bold>7m</ce:bold> or <ce:bold>7n</ce:bold> resulted in 2–10 fold potency loss. Collectively, methenoxy (–CH<ce:inf loc="post">2</ce:inf>O–) and methenamino (–CH<ce:inf loc="post">2</ce:inf>NH–) moieties seemed to be the optical linkers for this class of Trks inhibitors, which agreed with recent data from 3-aryl-indazole based Trk inhibitors [<ce:cross-ref id="crosref0310" refid="bib42">42</ce:cross-ref>]. Compounds <ce:bold>7k</ce:bold> and <ce:bold>7m</ce:bold> are the two most potent molecules obtained from the first-run structural optimization.</ce:para>
                  <ce:para id="p0485" view="all">In order to validate the great contribution of 3, 5-difluorobenzene moiety to TrkA/B/C inhibitory potency, new molecules were also designed and synthesized by varying the substituents in the western phenyl ring of <ce:bold>7m</ce:bold>. It was found that removal of the difluoro substituents (<ce:bold>7q</ce:bold>) caused 7- and 5- fold potency loss against TrkA and TrkC, respectively. Unexpectedly, <ce:bold>7q</ce:bold> exhibited a 7.5- fold improved TrkB inhibitory activity with an IC<ce:inf loc="post">50</ce:inf> value of 1.1 nM. Although the <ce:italic>meta</ce:italic>-monofluoro- substituted compound <ce:bold>7s</ce:bold> displayed similar potency to that of <ce:bold>7m</ce:bold>, the <ce:italic>ortho</ce:italic>-fluoro- (<ce:bold>7r</ce:bold>) or <ce:italic>para</ce:italic>-fluoro- (<ce:bold>7t</ce:bold>) substitution caused obvious potency loss. These results clearly implied the importance of a fluoro group in <ce:italic>meta</ce:italic>-position of the phenyl ring for Trk inhibition. Keeping the critical 3-fluorine in <ce:bold>7m</ce:bold> unchanged, the 5-chloro (<ce:bold>7u</ce:bold>), 5-bromo (<ce:bold>7v</ce:bold>), 5-methyl (<ce:bold>7w</ce:bold>), 5-methoxyl (<ce:bold>7x</ce:bold>), 5-trifluoromethyl (<ce:bold>7y</ce:bold>) or 5- cyano (<ce:bold>7z</ce:bold>) substituted compounds were designed and synthesized. The results showed that this position is tolerated to a wide range of substituents to retain strong Trk inhibition. Most of the new molecules exhibited low nM IC<ce:inf loc="post">50</ce:inf> values against the kinases, with an exception that compound <ce:bold>7y</ce:bold> was 30–60 fold less potent than the parental molecule <ce:bold>7m</ce:bold>. It was also noteworthy that <ce:bold>7z</ce:bold> was almost equally potent to <ce:bold>7m</ce:bold>, but its poor solubility made it less attractive for further investigation (data not shown).</ce:para>
                  <ce:para id="p0490" view="all">Careful analysis of the predicted binding model of <ce:bold>7m</ce:bold> with TrkA (PDB: <ce:inter-ref id="PC_linkrjwGSKHcdJ" xlink:href="pdb:5KVT" xlink:type="simple">5KVT</ce:inter-ref>) suggested that there was an additional small lipophilic cavity comprised of Phe521, Val524 and Lys544 (<ce:cross-ref id="crosref0315" refid="fig3">Fig. 3</ce:cross-ref>
                     <ce:float-anchor refid="fig3"/></ce:float-anchor>A). Occupying this pocket with a small hydrophobic group might provide a rational strategy for activity improvement. Consequently, compounds (<ce:bold>7ma</ce:bold> and <ce:bold>7</ce:bold>
                     <ce:bold>mb</ce:bold>) with methyl substitutions were designed and synthesized (<ce:cross-ref id="crosref0320" refid="fig3">Fig. 3</ce:cross-ref>B). Biological evaluation revealed that (<ce:italic>R</ce:italic>)<ce:italic>-</ce:italic> enantiomer <ce:bold>7</ce:bold>
                     <ce:bold>mb</ce:bold> demonstrated better kinase inhibition than the <ce:italic>S</ce:italic>- isomer <ce:bold>7ma</ce:bold>, with IC<ce:inf loc="post">50</ce:inf> values of 1.6, 2.9 and 2.0 nM against TrkA, TrkB and TrkC, respectively. Whereas the <ce:italic>S</ce:italic>- isomer <ce:bold>7ma</ce:bold> was approximately 10–15 folds less potent with corresponding IC<ce:inf loc="post">50</ce:inf> values of 17.8, 22.2 and 30.0 nM, respectively. Thus, compound <ce:bold>7</ce:bold>
                     <ce:bold>mb</ce:bold> represented one of the most promising compounds in this series with equal potency to that of FDA approved drug <ce:bold>1</ce:bold>.</ce:para>
                  <ce:para id="p0495" view="all">The kinase inhibition activities of this series of new Trk inhibitors were further validated by evaluation of cellular growth suppressive effects of the representative molecules (i.e. <ce:bold>7a</ce:bold>, <ce:bold>7k, 7m</ce:bold> and <ce:bold>7</ce:bold>
                     <ce:bold>mb</ce:bold>) against a panel of BaF3 murine cells stably transformed with NTRK oncogenic fusions including CD74-NTRK1, ETV6-NTRK2 and ETV6-NTRK3 (<ce:cross-ref id="crosref0325" refid="tbl2">Table 2</ce:cross-ref>). It was shown that the positive drug <ce:bold>1</ce:bold> exhibited strong antiproliferative activities against these cells with IC<ce:inf loc="post">50</ce:inf> values of 0.016, 0.040 and 0.013 μM, respectively, but did not show obvious inhibition against the growth of BaF3 parental cells. Compounds <ce:bold>7a</ce:bold> and <ce:bold>7k</ce:bold> demonstrated similar kinase inhibition potencies to drug <ce:bold>1</ce:bold>, but they exhibited 3–10 folds less antiproliferative activities. The relatively poor cellular potencies of compounds <ce:bold>7a</ce:bold> and <ce:bold>7k</ce:bold> might be due to their low cellular membrane permeability. Encouragingly, compounds <ce:bold>7m</ce:bold> and <ce:bold>7</ce:bold>
                     <ce:bold>mb</ce:bold> exhibited strong antiproliferation activities against the NTRK transformed cells with IC<ce:inf loc="post">50</ce:inf> values of 0.035, 0.034, 0.014 and 0.015, 0.022, 0.009 μM, respectively. Thus, compound <ce:bold>7</ce:bold>
                     <ce:bold>mb</ce:bold> represents a highly promising lead compound with similar cellular potency to that of drug <ce:bold>1</ce:bold> in both biochemical kinase and cell growth inhibition assays.</ce:para>
                  <ce:para id="p0500" view="all">TrkA<ce:sup loc="post">G595R</ce:sup>, TrkA<ce:sup loc="post">G667C</ce:sup>, TrkC<ce:sup loc="post">G623R</ce:sup> and TrkC<ce:sup loc="post">G696A</ce:sup> mutations have been identified as the major mechanism of clinically acquired resistance against the current Trk inhibitor therapies [<ce:cross-ref id="crosref0330" refid="bib11">11</ce:cross-ref>,<ce:cross-ref id="crosref0335" refid="bib33">33</ce:cross-ref>]. We further evaluated potential suppressive effects of compound <ce:bold>7</ce:bold>
                     <ce:bold>mb</ce:bold> against the proliferation of BaF3 cells with TrkA<ce:sup loc="post">G595R</ce:sup>, TrkB<ce:sup loc="post">G639R</ce:sup>, TrkC<ce:sup loc="post">G623R</ce:sup>, TrkA<ce:sup loc="post">G667C</ce:sup> or TrkC<ce:sup loc="post">G696A</ce:sup> resistant mutants. It was shown that drug <ce:bold>1</ce:bold> demonstrated obviously decreased potencies against all of these resistant cells with IC<ce:inf loc="post">50</ce:inf> values of 0.539, 2.240, 1.201, 0.184, and 0.054 μM. Although compound <ce:bold>7</ce:bold>
                     <ce:bold>mb</ce:bold> could not overcome the solvent front mutations induced resistance (i.e. TrkA<ce:sup loc="post">G595R</ce:sup>, TrkB<ce:sup loc="post">G639R</ce:sup>, TrkC<ce:sup loc="post">G623R</ce:sup>), it exhibited strong suppression on the growth of BaF3 cells harboring the xDFG motif mutations (i.e. BaF3-CD74-NTRK1-G667C and BaF3-ETV6-NTRK3-G696A cells) with an IC<ce:inf loc="post">50</ce:inf> values of 0.031 and 0.018 μM, respectively.</ce:para>
                  <ce:para id="p0505" view="all">Inhibitory effects of compound <ce:bold>7</ce:bold>
                     <ce:bold>mb</ce:bold> on activation of TrkA, TrkB and TrkC and their downstream signals were further investigated in BaF3-CD74-NTRK1, BaF3-ETV6-NTRK2, BaF3-ETV6-NTRK3 cells, respectively. As shown in <ce:cross-ref id="crosref0340" refid="fig4">Fig. 4</ce:cross-ref>
                     <ce:float-anchor refid="fig4"/></ce:float-anchor>, compound <ce:bold>7</ce:bold>
                     <ce:bold>mb</ce:bold> dose-dependently inhibited the phosphorylation of TrkA/B/C and their downstream signaling molecules ERK, AKT, and PLC-γ1 in BaF3-CD74-NTRK1, BaF3-ETV6-NTRK2 and BaF3-ETV6-NTRK3 cells. Interestingly, the compound also induced partial degradation of Trk protein in BaF3-ETV6-NTRK2, BaF3-ETV6-NTRK3 cells, and the protein degradation of TrkC could also observed upon drug <ce:bold>1</ce:bold> treatment in BaF3-ETV6-NTRK3 cells (Supporting Information). However, the mechanism behind these phenomena remains elusive.</ce:para>
                  <ce:para id="p0510" view="all">We further utilized an active-site-dependent competition binding assay (conducted by DiscoveRx, San Diego, CA) to determine the binding affinity of compound <ce:bold>7</ce:bold>
                     <ce:bold>mb</ce:bold> with Trks [<ce:cross-ref id="crosref0345" refid="bib43">43</ce:cross-ref>]. It was shown that <ce:bold>7</ce:bold>
                     <ce:bold>mb</ce:bold> tightly bound to ATP-binding site of TrkA, TrkB, and TrkC with binding constant (<ce:italic>K</ce:italic>
                     <ce:inf loc="post">d</ce:inf>) values of 1.6, 3.1 and 4.9 nM, respectively. A kinase selectivity profiling study was also conducted against a panel of 468 kinases (containing 65 mutated kinases and 403 nonmutated kinases) at 1.0 μM to evaluate the target selectivity of <ce:bold>7</ce:bold>
                     <ce:bold>mb</ce:bold> by using DiscoveRx screening platform [<ce:cross-ref id="crosref0350" refid="bib43">43</ce:cross-ref>]. The results showed that <ce:bold>7</ce:bold>
                     <ce:bold>mb</ce:bold> exhibited good target selectivity with S(1), S(10), and S(35) scores of 0.012, 0.050, and 0.087, respectively (Supporting Information). The major potential “off targets” (inhibition >90%, ctrl < 10%, <ce:cross-ref id="crosref0355" refid="fig5">Fig. 5</ce:cross-ref>
                     <ce:float-anchor refid="fig5"/></ce:float-anchor>) included ALK, AMPK-related protein kinase 5 (ARK5), aurora kinase C (AURKC), focal adhesion kinase (FAK), fibroblast growth factor receptor 1 (FGFR1), fms-like tyrosine kinase 1 (FLT1), fms-like tyrosine kinase 3 (FLT3), fms-like tyrosine kinase 4 (FLT4), janus kinase 1 (JAK1), janus kinase 2 (JAK2), janus kinase 3 (JAK3), muscle associated receptor tyrosine kinase (MUSK), phosphorylase kinase catalytic subunit gamma 1 (PHKG1), ret proto-oncogene (RET), ROS1, tyrosine kinase with immunoglobulin like and EGF like domains 1 (TIE1) and tyrosine kinase non receptor 2 (TNK2) etc. Additionally, <ce:bold>7</ce:bold>
                     <ce:bold>mb</ce:bold> also exhibited potential suppression on several oncogenic mutations of FLT3 and RET, such as FLT3-D835H, FLT3-K663Q, FLT3-N841I, RET-M918T, RET-V804L, RET-V804M etc. The <ce:italic>K</ce:italic>
                     <ce:inf loc="post">d</ce:inf> values of compound <ce:bold>7</ce:bold>
                     <ce:bold>mb</ce:bold> with these “off targets” were also determined (<ce:cross-ref id="crosref0360" refid="tbl3">Table 3</ce:cross-ref>
                     <ce:float-anchor refid="tbl3"/></ce:float-anchor>). In addition to Trk, compound <ce:bold>7</ce:bold>
                     <ce:bold>mb</ce:bold> displayed moderate or strong binding affinities with most of the “off-targets” (e.g. FGFR1, FLT3, FLT4, JAK1, JAK2, JAK3, PHKG1, RET, ROS1 and TNK2) with <ce:italic>K</ce:italic>
                     <ce:inf loc="post">d</ce:inf> values below 100 nM. JAK2 is the only off-target of <ce:bold>7</ce:bold>
                     <ce:bold>mb</ce:bold> with similar binding affinity (a <ce:italic>K</ce:italic>
                     <ce:inf loc="post">d</ce:inf> value of 5.5 nM) to that of Trks. These data collectively implied the reasonable target selectivity of compound <ce:bold>7</ce:bold>
                     <ce:bold>mb</ce:bold>.</ce:para>
                  <ce:para id="p0515" view="all">Given its promising and target selectivity, the pharmacokinetic (PK) parameters of <ce:bold>7</ce:bold>
                     <ce:bold>mb</ce:bold> were further determined in Sprague−Dawley (SD) rats (<ce:cross-ref id="crosref0365" refid="tbl4">Table 4</ce:cross-ref>
                     <ce:float-anchor refid="tbl4"/></ce:float-anchor>). It was shown that compound <ce:bold>7</ce:bold>
                     <ce:bold>mb</ce:bold> demonstrated a relatively short half-life of 1.39 h and a low oral bioavailability of 8.79% in rats. Although the insufficient PK parameters will limit its further development, compound <ce:bold>7</ce:bold>
                     <ce:bold>mb</ce:bold> may be utilized a lead molecule for further structural optimization.</ce:para>
               </ce:section>
               <ce:section id="sec5" role="conclusion" view="all">
                  <ce:label>5</ce:label>
                  <ce:section-title id="sectitle0055">Conclusion</ce:section-title>
                  <ce:para id="p0520" view="all">A series of 3-vinylindazole derivatives were designed and synthesized as new selective Trk inhibitors. The representative compound <ce:bold>7</ce:bold>
                     <ce:bold>mb</ce:bold> exhibited IC<ce:inf loc="post">50</ce:inf> values of 1.6, 2.9 and 2.0 nM against the TrkA, B and C, respectively, and dose-dependently inhibited phosphorylation of TrkA/B/C and their downstream signal proteins in BaF3 cells with NTRK fusions. The compound also potently suppresses the proliferation of a panel of BaF3 cells stably transformed with NTRK fusions with IC<ce:inf loc="post">50</ce:inf> values in low nM ranges. Additionally, the compound exhibits strong inhibition against the Larotrectinib-resistant cells with NTRK1-G667C or NTRK3-G696A mutations with IC<ce:inf loc="post">50</ce:inf> values of 0.031 and 0.018 μM, respectively. Although the relatively poor oral bioavailability of <ce:bold>7</ce:bold>
                     <ce:bold>mb</ce:bold> will limit its further development, this compound may be utilized a lead molecule for further structural optimization.</ce:para>
               </ce:section>
               <ce:section id="sec6" view="all">
                  <ce:label>6</ce:label>
                  <ce:section-title id="sectitle0060">Experiment section</ce:section-title>
                  <ce:section id="sec6.1" view="all">
                     <ce:label>6.1</ce:label>
                     <ce:section-title id="sectitle0065">General methods for chemistry</ce:section-title>
                     <ce:para id="p0525" view="all">If not otherwise specified, reagents and solvents were all obtained from commercial sources (e.g., Bide Pharmatech Ltd, China) and used without further purification. All chemical reactions were monitored by thin-layer chromatography (TLC) plates purchased from Qingdao Haiyang Chemical Ltd, China, and visualized under UV light (254 or 365 nm). The crude materials were purified by flash column chromatography packed with 200–300 mesh silica gel to afford products. <ce:sup loc="post">1</ce:sup>H NMR and <ce:sup loc="post">13</ce:sup>C NMR spectra were recorded on a Bruker AVANCE AV-400 spectrometer (Bruker Company, Germany) at 400 MHz and 101 MHz, respectively. Low-resolution electrospray ionization (ESI) mass spectra of compounds were performed on an Agilent 1200 HPLC-MSD mass spectrometer (Agilent Technologies, America), while high-resolution ESI-MS mass spectra were recorded on an Applied Biosystems Q-STAR Elite ESI-LC-MS/MS mass spectrometer. Purity of all final compounds was assayed to be >95% by utilizing an Agilent 1260 HPLC system (column: Diamonsil C18, 5.0 μm, 4.6 × 250 mm<ce:sup loc="post">2</ce:sup>; detector: PDA-100 photodiode array; injector: ASI-100 autoinjector; pump: p-680A; mobile phase: methanol/H<ce:inf loc="post">2</ce:inf>O (v/v, triethylamine was added as needed); low rate, 1.0 mL/min; UV wavelength, 254 nM; injection volume, 5 μL).</ce:para>
                     <ce:section id="sec6.1.1" view="all">
                        <ce:label>6.1.1</ce:label>
                        <ce:section-title id="sectitle0070">General procedure A for 3-Iodoindazole derivatives</ce:section-title>
                        <ce:para id="p0530" view="all">To a solution of indazole derivatives (1.0 equiv) in DMF was added I<ce:inf loc="post">2</ce:inf> (1.5 equiv) and K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> (2.0 equiv). The reaction mixture was stirred at room temperature overnight and quenched with saturated Na<ce:inf loc="post">2</ce:inf>S<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">3</ce:inf> solution, then filtered. The precipitate was washed with H<ce:inf loc="post">2</ce:inf>O and dried to afford a series of 3-iodoindazole derivatives. (yield, 80–95%).</ce:para>
                     </ce:section>
                     <ce:section id="sec6.1.2" view="all">
                        <ce:label>6.1.2</ce:label>
                        <ce:section-title id="sectitle0075">General procedure B for THP protection</ce:section-title>
                        <ce:para id="p0535" view="all">DHP (3.0 equiv) was added dropwise to a mixture of 1<ce:italic>H</ce:italic>-indazole intermediate (1.0 equiv) and p-TSA (0.05 equiv) in DCM. The reaction mixture was stirred at 0 °C overnight then concentrated in vacuo<ce:italic>.</ce:italic> The mixture was extracted by EtOAc and washed with H<ce:inf loc="post">2</ce:inf>O followed by brine. The organic layers were dried over anhydrous Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>, filtered and evaporated. The crude material was purified by silica gel column chromatography to afford THP-protected intermediates. (yield, 60–80%).</ce:para>
                     </ce:section>
                     <ce:section id="sec6.1.3" view="all">
                        <ce:label>6.1.3</ce:label>
                        <ce:section-title id="sectitle0080">General procedure C for Heck coupling reaction</ce:section-title>
                        <ce:para id="p0540" view="all">To a solution of intermediates (1.0 equiv) in DMF was added vinyl derivatives (1.5 equiv), Pd(OAc)<ce:inf loc="post">2</ce:inf> (0.05 equiv), P(o-tol)<ce:inf loc="post">3</ce:inf> (0.1 equiv), and DIEA (3.0 equiv). The reaction mixture was stirred at 90 °C overnight under argon and cooled to room temperature, then extracted by EtOAc and washed with H<ce:inf loc="post">2</ce:inf>O followed by brine. The organic layers were dried over anhydrous Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>, filtered and evaporated. The crude material was purified by silica gel column chromatography to afford product. (yield, 40–60%).</ce:para>
                     </ce:section>
                     <ce:section id="sec6.1.4" view="all">
                        <ce:label>6.1.4</ce:label>
                        <ce:section-title id="sectitle0085">General procedure D for THP deprotection</ce:section-title>
                        <ce:para id="p0545" view="all">To a solution of THP-protected intermediate (1.0 equiv) in DCM was added TFA. The reaction mixture was stirred at room temperature overnight and concentrated in vacuo, then neutralized to pH 6–7 with saturated NaHCO<ce:inf loc="post">3</ce:inf> solution. The solution was extracted by EtOAc and washed with H<ce:inf loc="post">2</ce:inf>O followed by brine. The organic layer was dried over anhydrous Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>, filtered and evaporated. The crude material was purified by silica gel column chromatography to afford product. (yield, 60–70%).</ce:para>
                        <ce:para id="p0550" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-5-(3,5-difluorobenzyl)-3-(2-(pyridin-2-yl)vinyl)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>7a</ce:bold>). Compound <ce:bold>7a</ce:bold> was obtained by following general procedure D as yellow solid. (yield, 65%; TLC, PE: EA = 1:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.2) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 13.28 (s, 1H), 8.61 (d, <ce:italic>J</ce:italic> = 6.7 Hz, 1H), 8.14 (s, 1H), 7.97 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.83 (td, <ce:italic>J</ce:italic> = 7.7, 1.8 Hz, 1H), 7.68 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.57 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.51 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 1H), 7.33–7.25 (m, 2H), 7.10–6.99 (m, 3H), 4.13 (s, 2H). <ce:sup loc="post">13</ce:sup>C NMR (101 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 163.67 (d, <ce:italic>J</ce:italic> = 13.1 Hz, 1C), 161.23 (d, <ce:italic>J</ce:italic> = 14.1 Hz, 1C), 155.02, 149.43, 146.73 (t, <ce:italic>J</ce:italic> = 9.1 Hz, 1C), 141.49, 140.30, 136.97, 133.02, 128.45, 127.83, 124.19, 122.44, 122.40, 121.18, 120.10, 111.82 (d, <ce:italic>J</ce:italic> = 25.3 Hz, 1C), 111.75 (d, <ce:italic>J</ce:italic> = 11.1 Hz, 1C), 110.86, 101.41 (t, <ce:italic>J</ce:italic> = 25.3 Hz, 1C), 40.51. HRMS (ESI) for C<ce:inf loc="post">21</ce:inf>H<ce:inf loc="post">15</ce:inf>F<ce:inf loc="post">2</ce:inf>N<ce:inf loc="post">3</ce:inf> [M + H]<ce:sup loc="post">+</ce:sup>, calcd: 348.1307, found: 348.1301. HPLC analysis: MeOH: H<ce:inf loc="post">2</ce:inf>O (85:15), 7.589 min; purity, 99.49%.</ce:para>
                        <ce:para id="p0555" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-5-(3,5-difluorophenyl)-3-(2-(pyridin-2-yl)vinyl)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>7b</ce:bold>). Compound <ce:bold>7b</ce:bold> was obtained by following general procedure D as yellow solid. (yield, 58%; TLC, PE: EA = 1:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.2) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 13.43 (s, 1H), 8.61 (d, <ce:italic>J</ce:italic> = 3.1 Hz, 1H), 8.52 (s, 1H), 8.05 (d, <ce:italic>J</ce:italic> = 16.3 Hz, 1H), 7.86–7.77 (m, 2H), 7.75–7.58 (m, 5H), 7.32–7.18 (m, 2H). <ce:sup loc="post">13</ce:sup>C NMR (101 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 164.19 (d, <ce:italic>J</ce:italic> = 14.1 Hz, 1C), 161.75 (d, <ce:italic>J</ce:italic> = 14.1 Hz, 1C), 155.07, 149.53, 144.38 (t, <ce:italic>J</ce:italic> = 9.1 Hz, 1C), 142.58, 141.19, 136.81, 131.05, 129.15, 125.85, 123.45, 122.74, 122.47, 121.63, 119.10, 111.17, 110.21 (d, <ce:italic>J</ce:italic> = 26.3 Hz, 1C), 110.14 (d, <ce:italic>J</ce:italic> = 12.1 Hz, 1C), 102.10 (t, <ce:italic>J</ce:italic> = 25.3 Hz, 1C). HRMS (ESI) for C<ce:inf loc="post">20</ce:inf>H<ce:inf loc="post">13</ce:inf>F<ce:inf loc="post">2</ce:inf>N<ce:inf loc="post">3</ce:inf> [M + H]<ce:sup loc="post">+</ce:sup>, calcd: 334.1150, found: 334.1138. HPLC analysis: MeOH: H<ce:inf loc="post">2</ce:inf>O (85:15), 8.004 min; purity, 96.10%.</ce:para>
                        <ce:para id="p0560" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-5-((3,5-difluorophenyl)thio)-3-(2-(pyridin-2-yl)vinyl)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>7c</ce:bold>). Compound <ce:bold>7c</ce:bold> was obtained by following general procedure D as yellow solid. (yield, 56%; TLC, PE: EA = 1:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.2) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 13.61 (s, 1H), 8.60 (d, <ce:italic>J</ce:italic> = 3.0 Hz, 1H), 8.55 (s, 1H), 8.00 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.82 (td, <ce:italic>J</ce:italic> = 7.6, 1.9 Hz, 1H), 7.76–7.69 (m, 2H), 7.63 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.53 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H), 7.32–7.25 (m, 1H), 7.09–7.00 (m, 1H), 6.83–6.73 (m, 2H). <ce:sup loc="post">13</ce:sup>C NMR (101 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 163.95 (d, <ce:italic>J</ce:italic> = 13.1 Hz, 1C), 161.48 (d, <ce:italic>J</ce:italic> = 13.1 Hz, 1C), 154.86, 149.50, 143.76 (t, <ce:italic>J</ce:italic> = 9.1 Hz, 1C), 142.23, 141.40, 136.85, 132.60, 129.61, 128.53, 123.33, 122.70, 122.56, 121.92, 121.32, 112.63, 109.45 (d, <ce:italic>J</ce:italic> = 28.3 Hz, 1C), 109.37 (d, <ce:italic>J</ce:italic> = 12.1 Hz, 1C), 101.11 (t, <ce:italic>J</ce:italic> = 26.3 Hz, 1C). HRMS (ESI) for C<ce:inf loc="post">20</ce:inf>H<ce:inf loc="post">13</ce:inf>F<ce:inf loc="post">2</ce:inf>N<ce:inf loc="post">3</ce:inf>S [M + H]<ce:sup loc="post">+</ce:sup>, calcd: 366.0871, found: 366.0859. HPLC analysis: MeOH: H<ce:inf loc="post">2</ce:inf>O (85:15), 11.988 min; purity, 97.87%.</ce:para>
                        <ce:para id="p0565" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-5-(3,5-difluorophenoxy)-3-(2-(pyridin-2-yl)vinyl)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>7d</ce:bold>). Compound <ce:bold>7d</ce:bold> was obtained by following general procedure D as beige solid. (yield, 59%; TLC, PE: EA = 1:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.2) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 13.43 (s, 1H), 8.58 (d, <ce:italic>J</ce:italic> = 5.8 Hz, 1H), 8.03 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 7.95 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.79 (td, <ce:italic>J</ce:italic> = 7.6, 1.8 Hz, 1H), 7.66 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 2H), 7.54 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.28–7.20 (m, 2H), 6.99–6.90 (m, 1H), 6.72–6.64 (m, 2H). <ce:sup loc="post">13</ce:sup>C NMR (101 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 164.42 (d, <ce:italic>J</ce:italic> = 16.2 Hz, 1C), 161.99 (d, <ce:italic>J</ce:italic> = 16.2 Hz, 1C), 160.96 (t, <ce:italic>J</ce:italic> = 14.1 Hz, 1C), 155.00, 149.50, 148.73, 142.05, 139.14, 136.80, 128.82, 123.66, 122.67, 122.41, 121.28, 120.78, 112.50, 111.72, 100.83 (d, <ce:italic>J</ce:italic> = 28.3 Hz, 1C), 100.75 (d, <ce:italic>J</ce:italic> = 12.1 Hz, 1C), 97.91 (t, <ce:italic>J</ce:italic> = 27.3 Hz, 1C). HRMS (ESI) for C<ce:inf loc="post">20</ce:inf>H<ce:inf loc="post">13</ce:inf>F<ce:inf loc="post">2</ce:inf>N<ce:inf loc="post">3</ce:inf>O [M + H]<ce:sup loc="post">+</ce:sup>, calcd: 350.1099, found: 350.1082. HPLC analysis: MeOH: H<ce:inf loc="post">2</ce:inf>O (85:15), 8.918 min; purity, 96.17%.</ce:para>
                        <ce:para id="p0570" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-<ce:italic>N</ce:italic>-(3,5-difluorophenyl)-3-(2-(pyridin-2-yl)vinyl)-1<ce:italic>H</ce:italic>-indazol-5-amine</ce:bold> (<ce:bold>7e</ce:bold>). To a solution of <ce:bold>20c</ce:bold> (200 mg, 0.42 mmol) in THF (10 mL) was added tetrabutylammonium fluoride (1.0 M solution in THF, 2.1 mL, 2.1 mmol) and ethylenediamine (126 mg, 2.1 mmol). The mixture was stirred at 60 °C for 3 h and cooled to room temperature. Then extracted by EtOAc and washed with H<ce:inf loc="post">2</ce:inf>O followed by brine. The organic layers were dried over anhydrous Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>, filtered and evaporated. The crude material was purified by silica gel column chromatography (40–50% EtOAc in petroleum ether) to afford final product <ce:bold>7e</ce:bold> as red solid. (106 mg; yield, 73%; TLC, PE: EA = 1:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.1) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 13.34 (s, 1H), 8.74–8.53 (m, 2H), 7.97 (d, <ce:italic>J</ce:italic> = 16.3 Hz, 1H), 7.91–7.77 (m, 2H), 7.71 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.59 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H), 7.48 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.34–7.20 (m, 2H), 6.61–6.38 (m, 3H). <ce:sup loc="post">13</ce:sup>C NMR (101 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 164.78 (d, <ce:italic>J</ce:italic> = 16.2 Hz, 1C), 162.38 (d, <ce:italic>J</ce:italic> = 16.2 Hz, 1C), 154.84, 149.02, 148.83, 141.18, 138.51, 137.32, 135.03, 127.70, 124.59, 122.90, 122.41, 122.27, 121.55, 111.72, 111.51, 96.68, 96.40, 92.64 (t, <ce:italic>J</ce:italic> = 26.3 Hz, 1C). HRMS (ESI) for C<ce:inf loc="post">20</ce:inf>H<ce:inf loc="post">14</ce:inf>F<ce:inf loc="post">2</ce:inf>N<ce:inf loc="post">4</ce:inf> [M + H]<ce:sup loc="post">+</ce:sup>, calcd: 349.1259, found: 349.1248. HPLC analysis: MeOH: H<ce:inf loc="post">2</ce:inf>O (85:15), 6.948 min; purity, 99.44%.</ce:para>
                        <ce:para id="p0575" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-<ce:italic>N</ce:italic>-(3,5-difluorophenyl)-<ce:italic>N</ce:italic>-methyl-3-(2-(pyridin-2-yl)vinyl)-1<ce:italic>H</ce:italic>-indazol-5-amine</ce:bold> (<ce:bold>7f</ce:bold>). Compound <ce:bold>7f</ce:bold> was synthesized from <ce:bold>20d</ce:bold> by a procedure similar to that of <ce:bold>7e</ce:bold> as white solid. (yield, 75%; TLC, PE: EA = 1:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.2) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 13.43 (s, 1H), 8.58 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H), 8.10 (d, <ce:italic>J</ce:italic> = 2.0 Hz, 1H), 7.97 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.79 (td, <ce:italic>J</ce:italic> = 7.6, 1.9 Hz, 1H), 7.72–7.62 (m, 2H), 7.55 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.30–7.21 (m, 2H), 6.48–6.38 (m, 1H), 6.30–6.18 (m, 2H), 3.34 (s, 3H). <ce:sup loc="post">13</ce:sup>C NMR (101 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 164.73 (d, <ce:italic>J</ce:italic> = 14.1 Hz, 1C), 162.36 (d, <ce:italic>J</ce:italic> = 15.2 Hz, 1C), 155.11, 152.37, 149.66, 142.20, 140.82, 139.86, 137.06, 129.05, 126.55, 123.91, 122.71, 122.65, 121.88, 118.63, 112.46, 96.61, 96.32, 91.82 (t, <ce:italic>J</ce:italic> = 26.3 Hz, 1C), 40.92. HRMS (ESI) for C<ce:inf loc="post">21</ce:inf>H<ce:inf loc="post">16</ce:inf>F<ce:inf loc="post">2</ce:inf>N<ce:inf loc="post">4</ce:inf> [M + H]<ce:sup loc="post">+</ce:sup>, calcd: 363.1416, found: 363.1401. HPLC analysis: MeOH: H<ce:inf loc="post">2</ce:inf>O (85:15), 9.514 min; purity, 99.69%.</ce:para>
                        <ce:para id="p0580" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-5-(3,5-difluorophenethyl)-3-(2-(pyridin-2-yl)vinyl)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>7g</ce:bold>). Compound <ce:bold>7g</ce:bold> was obtained by following general procedure D as white solid. (yield, 60%; TLC, PE: EA = 1:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.2) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 13.22 (s, 1H), 8.60 (d, <ce:italic>J</ce:italic> = 4.7 Hz, 1H), 8.01 (s, 1H), 7.95 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.82 (td, <ce:italic>J</ce:italic> = 7.7, 1.9 Hz, 1H), 7.67 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.56–7.46 (m, 2H), 7.35–7.23 (m, 2H), 7.10–6.98 (m, 3H), 3.11–2.95 (m, 4H). <ce:sup loc="post">13</ce:sup>C NMR (101 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 163.78 (d, <ce:italic>J</ce:italic> = 13.1 Hz, 1C), 161.34 (d, <ce:italic>J</ce:italic> = 13.1 Hz, 1C), 155.20, 149.68, 146.64 (t, <ce:italic>J</ce:italic> = 9.1 Hz, 1C), 141.52, 140.47, 137.21, 134.32, 128.61, 128.00, 124.52, 122.65, 122.61, 121.23, 119.62, 111.93 (d, <ce:italic>J</ce:italic> = 24.2 Hz, 1C), 111.87 (d, <ce:italic>J</ce:italic> = 12.1 Hz, 1C), 110.60, 101.45 (t, <ce:italic>J</ce:italic> = 25.3 Hz, 1C), 37.33, 36.59. HRMS (ESI) for C<ce:inf loc="post">22</ce:inf>H<ce:inf loc="post">17</ce:inf>F<ce:inf loc="post">2</ce:inf>N<ce:inf loc="post">3</ce:inf> [M + H]<ce:sup loc="post">+</ce:sup>, calcd: 362.1463, found: 362.1453. HPLC analysis: MeOH: H<ce:inf loc="post">2</ce:inf>O (85:15), 8.349 min; purity, 100.00%.</ce:para>
                        <ce:para id="p0585" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-5-((3,5-difluorophenyl)ethynyl)-3-(2-(pyridin-2-yl)vinyl)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>7h</ce:bold>). Compound <ce:bold>7h</ce:bold> was obtained by following general procedure D as yellow solid. (yield, 64%; TLC, PE: EA = 1:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.2) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 13.54 (s, 1H), 8.61 (d, <ce:italic>J</ce:italic> = 6.7 Hz, 1H), 8.50 (s, 1H), 7.98 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.82 (td, <ce:italic>J</ce:italic> = 7.6, 1.8 Hz, 1H), 7.73 (d, <ce:italic>J</ce:italic> = 7.6 Hz, 1H), 7.67–7.59 (m, 2H), 7.57 (dd, <ce:italic>J</ce:italic> = 8.6, 1.4 Hz, 1H), 7.40–7.32 (m, 3H), 7.31–7.25 (m, 1H). <ce:sup loc="post">13</ce:sup>C NMR (101 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 163.62 (d, <ce:italic>J</ce:italic> = 14.1 Hz, 1C), 161.16 (d, <ce:italic>J</ce:italic> = 14.1 Hz, 1C), 154.87, 149.54, 142.31, 140.93, 136.86, 129.62, 129.38, 125.65 (t, <ce:italic>J</ce:italic> = 12.1 Hz, 1C), 125.11, 123.45, 122.72, 122.56, 120.78, 114.66 (d, <ce:italic>J</ce:italic> = 27.3 Hz, 1C), 114.58 (d, <ce:italic>J</ce:italic> = 11.1 Hz, 1C), 114.02, 111.38, 104.80 (t, <ce:italic>J</ce:italic> = 26.3 Hz, 1C), 92.58, 85.95. HRMS (ESI) for C<ce:inf loc="post">22</ce:inf>H<ce:inf loc="post">13</ce:inf>F<ce:inf loc="post">2</ce:inf>N<ce:inf loc="post">3</ce:inf> [M + H]<ce:sup loc="post">+</ce:sup>, calcd: 358.1150, found: 358.1133. HPLC analysis: MeOH: H<ce:inf loc="post">2</ce:inf>O (85:15), 12.954 min; purity, 97.93%.</ce:para>
                        <ce:para id="p0590" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-<ce:italic>N</ce:italic>-(3,5-difluorophenyl)-3-(2-(pyridin-2-yl)vinyl)-1<ce:italic>H</ce:italic>-indazole-5-carboxamide</ce:bold> (<ce:bold>7i</ce:bold>). Compound <ce:bold>7i</ce:bold> was obtained by following general procedure D as yellow solid. (yield, 61%; TLC, PE: EA = 1:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.2) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 13.62 (s, 1H), 10.71 (s, 1H), 8.83 (s, 1H), 8.63 (d, <ce:italic>J</ce:italic> = 4.9 Hz, 1H), 8.05 (d, <ce:italic>J</ce:italic> = 16.3 Hz, 1H), 7.98 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 7.88–7.81 (m, 1H), 7.75–7.66 (m, 3H), 7.66–7.58 (m, 2H), 7.37–7.25 (m, 1H), 7.04–6.92 (m, 1H). <ce:sup loc="post">13</ce:sup>C NMR (101 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 166.44, 163.86 (d, <ce:italic>J</ce:italic> = 16.2 Hz, 1C), 161.44 (d, <ce:italic>J</ce:italic> = 15.2 Hz, 1C), 154.81, 149.72, 143.38, 142.76, 142.10, 137.31, 129.92, 127.46, 126.44, 123.28, 122.99, 122.96, 121.30, 120.54, 110.97, 103.34, 103.05, 98.81 (t, <ce:italic>J</ce:italic> = 26.3 Hz, 1C). HRMS (ESI) for C<ce:inf loc="post">21</ce:inf>H<ce:inf loc="post">14</ce:inf>F<ce:inf loc="post">2</ce:inf>N<ce:inf loc="post">4</ce:inf>O [M + H]<ce:sup loc="post">+</ce:sup>, calcd: 377.1208, found: 377.1194. HPLC analysis: MeOH: H<ce:inf loc="post">2</ce:inf>O (85:15), 6.535 min; purity, 99.35%.</ce:para>
                        <ce:para id="p0595" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-3,5-difluoro-<ce:italic>N</ce:italic>-(3-(2-(pyridin-2-yl)vinyl)-1<ce:italic>H</ce:italic>-indazol-5-yl)benzamide</ce:bold> (<ce:bold>7j</ce:bold>). Compound <ce:bold>7j</ce:bold> was obtained by following general procedure D as yellow solid. (yield, 58%; TLC, PE: EA = 1:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.2) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 13.35 (s, 1H), 10.54 (s, 1H), 8.64–8.56 (m, 2H), 7.95 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.84–7.72 (m, 4H), 7.68 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.62 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 1H), 7.59–7.51 (m, 1H), 7.48 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.30–7.24 (m, 1H). <ce:sup loc="post">13</ce:sup>C NMR (101 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 163.54 (d, <ce:italic>J</ce:italic> = 12.1 Hz, 1C), 162.81, 161.09 (d, <ce:italic>J</ce:italic> = 13.1 Hz, 1C), 155.06, 149.57, 141.44, 138.89, 138.46 (t, <ce:italic>J</ce:italic> = 8.1 Hz, 1C), 136.88, 132.55, 128.55, 124.13, 122.37, 121.88, 121.61, 120.67, 111.48, 111.22 (d, <ce:italic>J</ce:italic> = 27.3 Hz, 1C), 111.14 (d, <ce:italic>J</ce:italic> = 12.1 Hz, 1C), 110.99, 106.97 (t, <ce:italic>J</ce:italic> = 26.3 Hz, 1C). HRMS (ESI) for C<ce:inf loc="post">21</ce:inf>H<ce:inf loc="post">14</ce:inf>F<ce:inf loc="post">2</ce:inf>N<ce:inf loc="post">4</ce:inf>O [M + H]<ce:sup loc="post">+</ce:sup>, calcd: 377.1208, found: 377.1195. HPLC analysis: MeOH: H<ce:inf loc="post">2</ce:inf>O (85:15), 5.298 min; purity, 99.78%.</ce:para>
                        <ce:para id="p0600" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-5-((3,5-difluorobenzyl)oxy)-3-(2-(pyridin-2-yl)vinyl)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>7k</ce:bold>). Compound <ce:bold>7k</ce:bold> was obtained by following general procedure D as beige solid. (yield, 66%; TLC, PE: EA = 1:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.2) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 13.23 (s, 1H), 8.60 (dd, <ce:italic>J</ce:italic> = 5.0, 1.8 Hz, 1H), 7.96 (d, <ce:italic>J</ce:italic> = 16.3 Hz, 1H), 7.81 (td, <ce:italic>J</ce:italic> = 7.6, 1.8 Hz, 1H), 7.65 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 2H), 7.56–7.44 (m, 2H), 7.32–7.14 (m, 5H), 5.28 (s, 2H). <ce:sup loc="post">13</ce:sup>C NMR (101 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 163.75 (d, <ce:italic>J</ce:italic> = 13.1 Hz, 1C), 161.30 (d, <ce:italic>J</ce:italic> = 12.1 Hz, 1C), 155.14, 153.25, 149.52, 142.11, 141.21, 137.31, 136.81, 127.91, 123.99, 122.49, 122.29, 121.22, 118.49, 111.74, 110.62, 110.37, 103.14 (t, <ce:italic>J</ce:italic> = 25.3 Hz, 1C), 101.99, 68.51. HRMS (ESI) for C<ce:inf loc="post">21</ce:inf>H<ce:inf loc="post">15</ce:inf>F<ce:inf loc="post">2</ce:inf>N<ce:inf loc="post">3</ce:inf>O [M + H]<ce:sup loc="post">+</ce:sup>, calcd: 364.1256, found: 364.1243. HPLC analysis: MeOH: H<ce:inf loc="post">2</ce:inf>O (85:15), 7.451 min; purity, 100.00%.</ce:para>
                        <ce:para id="p0605" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-5-((3,5-difluorophenoxy)methyl)-3-(2-(pyridin-2-yl)vinyl)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>7l</ce:bold>). Compound <ce:bold>7l</ce:bold> was obtained by following general procedure D as brown solid. (yield, 57%; TLC, PE: EA = 1:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.2) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 13.53 (s, 1H), 8.60 (dd, <ce:italic>J</ce:italic> = 5.2, 1.6 Hz, 1H), 8.33 (s, 1H), 7.96 (d, <ce:italic>J</ce:italic> = 16.3 Hz, 1H), 7.82 (td, <ce:italic>J</ce:italic> = 7.7, 1.9 Hz, 1H), 7.68 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.64–7.55 (m, 2H), 7.49 (d, <ce:italic>J</ce:italic> = 10.0 Hz, 1H), 7.31–7.23 (m, 1H), 6.91–6.83 (m, 2H), 6.82–6.76 (m, 1H), 5.27 (s, 2H). <ce:sup loc="post">13</ce:sup>C NMR (101 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 164.40 (d, <ce:italic>J</ce:italic> = 16.1 Hz, 1C), 161.98 (d, <ce:italic>J</ce:italic> = 16.1 Hz, 1C), 160.65 (t, <ce:italic>J</ce:italic> = 14.1 Hz, 1C), 154.98, 149.54, 141.94, 141.17, 136.91, 128.97, 128.93, 127.25, 124.02, 122.48 (2C), 120.95, 120.71, 110.86, 99.23 (d, <ce:italic>J</ce:italic> = 28.3 Hz, 1C), 99.15 (d, <ce:italic>J</ce:italic> = 12.1 Hz, 1C), 96.21 (t, <ce:italic>J</ce:italic> = 26.3 Hz, 1C), 70.74. HRMS (ESI) for C<ce:inf loc="post">21</ce:inf>H<ce:inf loc="post">15</ce:inf>F<ce:inf loc="post">2</ce:inf>N<ce:inf loc="post">3</ce:inf>O [M + H]<ce:sup loc="post">+</ce:sup>, calcd: 364.1256, found: 364.1229. HPLC analysis: MeOH: H<ce:inf loc="post">2</ce:inf>O (85:15), 7.627 min; purity, 100.00%.</ce:para>
                        <ce:para id="p0610" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-<ce:italic>N</ce:italic>-(3,5-difluorobenzyl)-3-(2-(pyridin-2-yl)vinyl)-1<ce:italic>H</ce:italic>-indazol-5-amine</ce:bold> (<ce:bold>7m</ce:bold>). Compound <ce:bold>7m</ce:bold> was obtained by following general procedure D as yellow solid. (yield, 60%; TLC, PE: EA = 1:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.1) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 12.95 (s, 1H), 8.57 (d, <ce:italic>J</ce:italic> = 3.8 Hz, 1H), 7.85 (d, <ce:italic>J</ce:italic> = 16.3 Hz, 1H), 7.79 (td, <ce:italic>J</ce:italic> = 7.7, 1.9 Hz, 1H), 7.54 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.34 (d, <ce:italic>J</ce:italic> = 9.7 Hz, 1H), 7.27–7.18 (m, 4H), 7.12–7.04 (m, 1H), 6.97–6.89 (m, 2H), 6.36 (t, <ce:italic>J</ce:italic> = 6.2 Hz, 1H), 4.43 (d, <ce:italic>J</ce:italic> = 6.1 Hz, 2H). <ce:sup loc="post">13</ce:sup>C NMR (101 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 163.79 (d, <ce:italic>J</ce:italic> = 13.1 Hz, 1C), 161.35 (d, <ce:italic>J</ce:italic> = 13.1 Hz, 1C), 155.27, 149.53, 145.93 (t, <ce:italic>J</ce:italic> = 8.1 Hz, 1C), 143.40, 140.01, 136.77, 135.83, 126.94, 124.88, 122.16, 122.05, 121.85, 117.85, 111.28, 110.38 (d, <ce:italic>J</ce:italic> = 25.3 Hz, 1C), 110.32 (d, <ce:italic>J</ce:italic> = 12.1 Hz, 1C), 102.06 (t, <ce:italic>J</ce:italic> = 25.3 Hz, 1C), 98.01, 46.48. HRMS (ESI) for C<ce:inf loc="post">21</ce:inf>H<ce:inf loc="post">16</ce:inf>F<ce:inf loc="post">2</ce:inf>N<ce:inf loc="post">4</ce:inf> [M + H]<ce:sup loc="post">+</ce:sup>, calcd: 363.1416, found: 363.1404. HPLC analysis: MeOH: H<ce:inf loc="post">2</ce:inf>O (85:15), 5.549 min; purity, 96.66%.</ce:para>
                        <ce:para id="p0615" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-3,5-difluoro-<ce:italic>N</ce:italic>-((3-(2-(pyridin-2-yl)vinyl)-1<ce:italic>H</ce:italic>-indazol-5-yl)methyl)aniline</ce:bold> (<ce:bold>7n</ce:bold>). Compound <ce:bold>7n</ce:bold> was obtained by following general procedure D as beige solid. (yield, 61%; TLC, PE: EA = 1:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.1) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 13.27 (s, 1H), 8.61 (d, <ce:italic>J</ce:italic> = 3.1 Hz, 1H), 8.17 (s, 1H), 7.95 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.82 (td, <ce:italic>J</ce:italic> = 7.7, 1.9 Hz, 1H), 7.65 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 7.60–7.51 (m, 2H), 7.42 (d, <ce:italic>J</ce:italic> = 10.0 Hz, 1H), 7.31–7.22 (m, 1H), 6.93 (t, <ce:italic>J</ce:italic> = 5.9 Hz, 1H), 6.31 (dd, <ce:italic>J</ce:italic> = 11.0, 2.4 Hz, 2H), 6.25–6.15 (m, 1H), 4.42 (d, <ce:italic>J</ce:italic> = 5.8 Hz, 2H). <ce:sup loc="post">13</ce:sup>C NMR (101 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 164.76 (d, <ce:italic>J</ce:italic> = 17.2 Hz, 1C), 162.37 (d, <ce:italic>J</ce:italic> = 17.2 Hz, 1C), 154.99, 151.40 (t, <ce:italic>J</ce:italic> = 14.1 Hz, 1C), 149.50, 141.48, 140.77, 136.95, 132.15, 128.54, 126.59, 124.19, 122.42, 122.37, 120.92, 119.12, 110.69, 95.06, 94.79, 90.26 (t, <ce:italic>J</ce:italic> = 27.3 Hz, 1C), 46.53. HRMS (ESI) for C<ce:inf loc="post">21</ce:inf>H<ce:inf loc="post">16</ce:inf>F<ce:inf loc="post">2</ce:inf>N<ce:inf loc="post">4</ce:inf> [M + H]<ce:sup loc="post">+</ce:sup>, calcd: 363.1416, found: 363.1400. HPLC analysis: MeOH: H<ce:inf loc="post">2</ce:inf>O (80:20), 8.385 min; purity, 97.85%.</ce:para>
                        <ce:para id="p0620" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-<ce:italic>N</ce:italic>-(3,5-difluorobenzyl)-<ce:italic>N</ce:italic>-methyl-3-(2-(pyridin-2-yl)vinyl)-1<ce:italic>H</ce:italic>-indazol-5-amine</ce:bold> (<ce:bold>7o</ce:bold>). Compound <ce:bold>7o</ce:bold> was obtained by following general procedure D as red solid. (yield, 59%; TLC, PE: EA = 1:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.2) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 13.03 (s, 1H), 8.58 (dd, <ce:italic>J</ce:italic> = 5.1, 1.7 Hz, 1H), 7.92 (d, <ce:italic>J</ce:italic> = 16.3 Hz, 1H), 7.79 (td, <ce:italic>J</ce:italic> = 7.6, 1.9 Hz, 1H), 7.62 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.42 (d, <ce:italic>J</ce:italic> = 9.1 Hz, 1H), 7.36 (d, <ce:italic>J</ce:italic> = 16.3 Hz, 1H), 7.27–7.21 (m, 1H), 7.17 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 7.14–7.05 (m, 2H), 7.02–6.96 (m, 2H), 4.65 (s, 2H), 3.08 (s, 3H). <ce:sup loc="post">13</ce:sup>C NMR (101 MHz, Chloroform-<ce:italic>d</ce:italic>) δ 164.77 (d, <ce:italic>J</ce:italic> = 12.1 Hz, 1C), 162.29 (d, <ce:italic>J</ce:italic> = 12.1 Hz, 1C), 155.86, 149.57, 145.82, 143.81 (t, <ce:italic>J</ce:italic> = 9.1 Hz, 1C), 142.48, 136.92, 128.79, 124.15, 123.01, 122.29, 122.23, 118.01, 111.04, 109.93 (d, <ce:italic>J</ce:italic> = 25.3 Hz, 1C), 109.87 (d, <ce:italic>J</ce:italic> = 12.1 Hz, 1C), 102.61 (t, <ce:italic>J</ce:italic> = 25.3 Hz, 1C), 101.99, 58.18, 39.85. HRMS (ESI) for C<ce:inf loc="post">22</ce:inf>H<ce:inf loc="post">18</ce:inf>F<ce:inf loc="post">2</ce:inf>N<ce:inf loc="post">4</ce:inf> [M + H]<ce:sup loc="post">+</ce:sup>, calcd: 377.1572, found: 377.1565. HPLC analysis: MeOH: H<ce:inf loc="post">2</ce:inf>O (85:15), 8.644 min; purity, 97.23%.</ce:para>
                        <ce:para id="p0625" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-3,5-difluoro-<ce:italic>N</ce:italic>-methyl-<ce:italic>N</ce:italic>-((3-(2-(pyridin-2-yl)vinyl)-1<ce:italic>H</ce:italic>-indazol-5-yl)methyl)aniline</ce:bold> (<ce:bold>7p</ce:bold>). Compound <ce:bold>7p</ce:bold> was obtained by following general procedure D as beige solid. (yield, 63%; TLC, PE: EA = 1:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.2) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 13.28 (s, 1H), 8.60 (d, <ce:italic>J</ce:italic> = 3.0 Hz, 1H), 8.05–7.88 (m, 2H), 7.81 (td, <ce:italic>J</ce:italic> = 7.7, 1.8 Hz, 1H), 7.62 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 7.56–7.46 (m, 2H), 7.33–7.20 (m, 2H), 6.53–6.40 (m, 2H), 6.37–6.27 (m, 1H), 4.75 (s, 2H), 3.06 (s, 3H). <ce:sup loc="post">13</ce:sup>C NMR (101 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 164.86 (d, <ce:italic>J</ce:italic> = 17.2 Hz, 1C), 162.47 (d, <ce:italic>J</ce:italic> = 17.2 Hz, 1C), 154.98, 151.54 (d, <ce:italic>J</ce:italic> = 14.1 Hz, 1C), 149.57, 141.41, 140.74, 136.87, 131.19, 128.61, 125.70, 123.98, 122.41, 122.38, 120.99, 118.56, 110.94, 95.20 (d, <ce:italic>J</ce:italic> = 30.3 Hz, 1C), 95.11 (d, <ce:italic>J</ce:italic> = 21.2 Hz, 1C), 90.43 (t, <ce:italic>J</ce:italic> = 26.3 Hz, 1C), 55.22, 38.71. HRMS (ESI) for C<ce:inf loc="post">22</ce:inf>H<ce:inf loc="post">18</ce:inf>F<ce:inf loc="post">2</ce:inf>N<ce:inf loc="post">4</ce:inf> [M + H]<ce:sup loc="post">+</ce:sup>, calcd: 377.1572, found: 377.1562. HPLC analysis: MeOH: H<ce:inf loc="post">2</ce:inf>O (80:20), 12.448 min; purity, 99.20%.</ce:para>
                        <ce:para id="p0630" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-<ce:italic>N</ce:italic>-benzyl-3-(2-(pyridin-2-yl)vinyl)-1<ce:italic>H</ce:italic>-indazol-5-amine</ce:bold> (<ce:bold>7q</ce:bold>). Compound <ce:bold>7q</ce:bold> was obtained by following general procedure D as brown solid. (yield, 54%; TLC, PE: EA = 1:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.1) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 12.92 (s, 1H), 8.58 (dd, <ce:italic>J</ce:italic> = 4.8, 1.8 Hz, 1H), 7.87 (d, <ce:italic>J</ce:italic> = 16.3 Hz, 1H), 7.79 (td, <ce:italic>J</ce:italic> = 7.7, 1.9 Hz, 1H), 7.55 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 7.51–7.45 (m, 2H), 7.39–7.30 (m, 3H), 7.30–7.19 (m, 3H), 7.01–6.93 (m, 2H), 6.21 (s, 1H), 4.38 (s, 2H). <ce:sup loc="post">13</ce:sup>C NMR (101 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 155.31, 149.48, 144.04, 140.31, 139.97, 136.81, 135.71, 128.30 (2C), 127.53 (2C), 126.79, 126.70, 125.00, 122.08, 121.99, 121.93, 117.98, 111.10, 97.71, 47.44. HRMS (ESI) for C<ce:inf loc="post">21</ce:inf>H<ce:inf loc="post">18</ce:inf>N<ce:inf loc="post">4</ce:inf> [M + H]<ce:sup loc="post">+</ce:sup>, calcd: 327.1604, found: 327.1594. HPLC analysis: MeOH: H<ce:inf loc="post">2</ce:inf>O (80:20), 6.686 min; purity, 97.78%.</ce:para>
                        <ce:para id="p0635" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-<ce:italic>N</ce:italic>-(2-fluorobenzyl)-3-(2-(pyridin-2-yl)vinyl)-1<ce:italic>H</ce:italic>-indazol-5-amine</ce:bold> (<ce:bold>7r</ce:bold>). Compound <ce:bold>7r</ce:bold> was obtained by following general procedure D as yellow solid. (yield, 61%; TLC, PE: EA = 1:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.1) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 12.92 (s, 1H), 8.58 (dd, <ce:italic>J</ce:italic> = 4.8, 1.8 Hz, 1H), 7.87 (d, <ce:italic>J</ce:italic> = 16.3 Hz, 1H), 7.80 (td, <ce:italic>J</ce:italic> = 7.7, 1.9 Hz, 1H), 7.59–7.48 (m, 2H), 7.35–7.21 (m, 5H), 7.20–7.14 (m, 1H), 7.02–6.92 (m, 2H), 6.16 (s, 1H), 4.42 (s, 2H). <ce:sup loc="post">13</ce:sup>C NMR (101 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 161.80, 159.37, 155.31, 149.50, 143.71, 139.99, 136.86, 135.78, 129.98 (d, <ce:italic>J</ce:italic> = 5.1 Hz, 1C), 128.85, (d, <ce:italic>J</ce:italic> = 8.1 Hz, 1C), 126.81, 126.66, 124.99, 124.38 (d, <ce:italic>J</ce:italic> = 3.0 Hz, 1C), 122.03, 121.92, 117.82, 115.24, (d, <ce:italic>J</ce:italic> = 21.2 Hz, 1C), 111.22, 97.40, 40.74. HRMS (ESI) for C<ce:inf loc="post">21</ce:inf>H<ce:inf loc="post">17</ce:inf>FN<ce:inf loc="post">4</ce:inf> [M + H]<ce:sup loc="post">+</ce:sup>, calcd: 345.1510, found: 345.1493. HPLC analysis: MeOH: H<ce:inf loc="post">2</ce:inf>O (80:20), 6.676 min; purity, 97.55%.</ce:para>
                        <ce:para id="p0640" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-<ce:italic>N</ce:italic>-(3-fluorobenzyl)-3-(2-(pyridin-2-yl)vinyl)-1<ce:italic>H</ce:italic>-indazol-5-amine</ce:bold> (<ce:bold>7s</ce:bold>). Compound <ce:bold>7s</ce:bold> was obtained by following general procedure D as yellow solid. (yield, 59%; TLC, PE: EA = 1:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.1) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 12.93 (s, 1H), 8.58 (d, <ce:italic>J</ce:italic> = 3.1 Hz, 1H), 7.86 (d, <ce:italic>J</ce:italic> = 16.3 Hz, 1H), 7.78 (td, <ce:italic>J</ce:italic> = 7.6, 1.9 Hz, 1H), 7.55 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 7.42–7.26 (m, 5H), 7.25–7.21 (m, 1H), 7.08–7.01 (m, 1H), 6.98–6.93 (m, 2H), 6.27 (s, 1H), 4.42 (d, <ce:italic>J</ce:italic> = 4.5 Hz, 2H). <ce:sup loc="post">13</ce:sup>C NMR (101 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 163.62, 161.20, 155.29, 149.51, 143.77, 143.72, 140.00, 136.79, 135.77, 130.25 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 1C), 126.89, 124.94, 123.47 (d, <ce:italic>J</ce:italic> = 3.0 Hz, 1C), 122.13 (d, <ce:italic>J</ce:italic> = 11.1 Hz, 1C), 121.91, 117.91, 114.10 (d, <ce:italic>J</ce:italic> = 21.2 Hz, 1C), 113.52 (d, <ce:italic>J</ce:italic> = 21.2 Hz, 1C), 111.20, 97.89, 46.79. HRMS (ESI) for C<ce:inf loc="post">21</ce:inf>H<ce:inf loc="post">17</ce:inf>FN<ce:inf loc="post">4</ce:inf> [M + H]<ce:sup loc="post">+</ce:sup>, calcd: 345.1510, found: 345.1504. HPLC analysis: MeOH: H<ce:inf loc="post">2</ce:inf>O (85:15), 5.108 min; purity, 97.27%.</ce:para>
                        <ce:para id="p0645" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-<ce:italic>N</ce:italic>-(4-fluorobenzyl)-3-(2-(pyridin-2-yl)vinyl)-1<ce:italic>H</ce:italic>-indazol-5-amine</ce:bold> (<ce:bold>7t</ce:bold>). Compound <ce:bold>7t</ce:bold> was obtained by following general procedure D as yellow solid. (yield, 63%; TLC, PE: EA = 1:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.1) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 12.91 (s, 1H), 8.58 (dd, <ce:italic>J</ce:italic> = 4.9, 1.8 Hz, 1H), 7.86 (d, <ce:italic>J</ce:italic> = 16.3 Hz, 1H), 7.79 (td, <ce:italic>J</ce:italic> = 7.6, 1.9 Hz, 1H), 7.56 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 7.54–7.47 (m, 2H), 7.32 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 7.29–7.21 (m, 2H), 7.20–7.13 (m, 2H), 6.98–6.92 (m, 2H), 6.20 (s, 1H), 4.36 (s, 2H). <ce:sup loc="post">13</ce:sup>C NMR (101 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 162.32, 159.91, 155.31, 149.47, 143.85, 139.97, 136.83, 136.44, 136.41, 135.72, 129.40 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 1C), 126.83, 124.95, 122.07 (d, <ce:italic>J</ce:italic> = 7.1 Hz, 1C), 121.92, 117.94, 115.11, 114.90, 111.13, 97.78, 46.61. HRMS (ESI) for C<ce:inf loc="post">21</ce:inf>H<ce:inf loc="post">17</ce:inf>FN<ce:inf loc="post">4</ce:inf> [M + H]<ce:sup loc="post">+</ce:sup>, calcd: 345.1510, found: 345.1482. HPLC analysis: MeOH: H<ce:inf loc="post">2</ce:inf>O (80:20), 6.536 min; purity, 97.75%.</ce:para>
                        <ce:para id="p0650" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-<ce:italic>N</ce:italic>-(3-chloro-5-fluorobenzyl)-3-(2-(pyridin-2-yl)vinyl)-1<ce:italic>H</ce:italic>-indazol-5-amine</ce:bold> (<ce:bold>7u</ce:bold>). Compound <ce:bold>7u</ce:bold> was obtained by following general procedure D as red solid. (yield, 58%; TLC, PE: EA = 1:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.1) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 12.93 (s, 1H), 8.58 (dd, <ce:italic>J</ce:italic> = 5.0, 1.8 Hz, 1H), 7.85 (d, <ce:italic>J</ce:italic> = 16.3 Hz, 1H), 7.79 (td, <ce:italic>J</ce:italic> = 7.7, 1.8 Hz, 1H), 7.55 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 7.42 (s, 1H), 7.37–7.21 (m, 5H), 6.97–6.91 (m, 2H), 6.34 (s, 1H), 4.43 (d, <ce:italic>J</ce:italic> = 4.8 Hz, 2H). <ce:sup loc="post">13</ce:sup>C NMR (101 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 163.52, 161.06, 155.22, 149.49, 145.82 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 1C), 143.34, 140.01, 136.79, 135.84, 133.89 (d, <ce:italic>J</ce:italic> = 11.1 Hz, 1C), 126.90, 124.92, 123.49 (d, <ce:italic>J</ce:italic> = 3.0 Hz, 1C), 122.25 (d, <ce:italic>J</ce:italic> = 20.2 Hz, 1C), 121.84, 117.85, 114.31 (d, <ce:italic>J</ce:italic> = 25.3 Hz, 1C), 113.19 (d, <ce:italic>J</ce:italic> = 21.2 Hz, 1C), 111.31, 98.01, 46.27. HRMS (ESI) for C<ce:inf loc="post">21</ce:inf>H<ce:inf loc="post">16</ce:inf>ClFN<ce:inf loc="post">4</ce:inf> [M + H]<ce:sup loc="post">+</ce:sup>, calcd: 379.1120, found: 379.1108. HPLC analysis: MeOH: H<ce:inf loc="post">2</ce:inf>O (80:20), 9.509 min; purity, 98.53%.</ce:para>
                        <ce:para id="p0655" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-<ce:italic>N</ce:italic>-(3-bromo-5-fluorobenzyl)-3-(2-(pyridin-2-yl)vinyl)-1<ce:italic>H</ce:italic>-indazol-5-amine</ce:bold> (<ce:bold>7v</ce:bold>). Compound <ce:bold>7v</ce:bold> was obtained by following general procedure D as brown solid. (yield, 62%; TLC, PE: EA = 1:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.1) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 12.94 (s, 1H), 8.58 (dd, <ce:italic>J</ce:italic> = 4.9, 1.8 Hz, 1H), 7.86 (d, <ce:italic>J</ce:italic> = 16.3 Hz, 1H), 7.80 (td, <ce:italic>J</ce:italic> = 7.7, 1.8 Hz, 1H), 7.61–7.53 (m, 2H), 7.43–7.30 (m, 3H), 7.30–7.20 (m, 2H), 6.99–6.89 (m, 2H), 6.35 (s, 1H), 4.43 (s, 2H). <ce:sup loc="post">13</ce:sup>C NMR (101 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 163.48, 161.01, 155.16, 149.42, 146.07 (d, <ce:italic>J</ce:italic> = 7.1 Hz, 1C), 143.33, 139.99, 136.86, 135.82, 126.81, 126.39 (d, <ce:italic>J</ce:italic> = 2.0 Hz, 1C), 124.97, 122.30 (d, <ce:italic>J</ce:italic> = 24.2 Hz, 1C), 121.95, 121.85, 117.84, 117.05 (d, <ce:italic>J</ce:italic> = 25.3 Hz, 1C), 113.58 (d, <ce:italic>J</ce:italic> = 21.2 Hz, 1C), 111.31, 97.98, 46.18. HRMS (ESI) for C<ce:inf loc="post">21</ce:inf>H<ce:inf loc="post">16</ce:inf>BrFN<ce:inf loc="post">4</ce:inf> [M + H]<ce:sup loc="post">+</ce:sup>, calcd: 423.0615, found: 423.0600. HPLC analysis: MeOH: H<ce:inf loc="post">2</ce:inf>O (80:20), 10.191 min; purity, 97.80%.</ce:para>
                        <ce:para id="p0660" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-<ce:italic>N</ce:italic>-(3-fluoro-5-methylbenzyl)-3-(2-(pyridin-2-yl)vinyl)-1<ce:italic>H</ce:italic>-indazol-5-amine</ce:bold> (<ce:bold>7w</ce:bold>). Compound <ce:bold>7w</ce:bold> was obtained by following general procedure D as brown solid. (yield, 58%; TLC, PE: EA = 1:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.1) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 12.91 (s, 1H), 8.57 (d, <ce:italic>J</ce:italic> = 4.8 Hz, 1H), 7.85 (d, <ce:italic>J</ce:italic> = 16.3 Hz, 1H), 7.79 (td, <ce:italic>J</ce:italic> = 7.7, 1.8 Hz, 1H), 7.55 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.33 (d, <ce:italic>J</ce:italic> = 9.1 Hz, 1H), 7.29–7.20 (m, 2H), 7.15 (s, 1H), 7.07 (d, <ce:italic>J</ce:italic> = 9.9 Hz, 1H), 6.94 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 2H), 6.87 (d, <ce:italic>J</ce:italic> = 10.0 Hz, 1H), 6.24 (s, 1H), 4.35 (s, 2H), 2.30 (s, 3H). <ce:sup loc="post">13</ce:sup>C NMR (101 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 163.58, 161.17, 155.28, 149.47, 143.76, 143.34 (d, <ce:italic>J</ce:italic> = 7.1 Hz, 1C), 140.22 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 1C), 139.94, 136.78, 135.73, 126.85, 125.00, 124.08, 122.05, 121.86, 117.90, 114.01 (d, <ce:italic>J</ce:italic> = 21.2 Hz, 1C), 111.13 (m, 2C), 97.79, 46.85, 20.89. HRMS (ESI) for C<ce:inf loc="post">22</ce:inf>H<ce:inf loc="post">19</ce:inf>FN<ce:inf loc="post">4</ce:inf> [M + H]<ce:sup loc="post">+</ce:sup>, calcd: 359.1667, found: 359.1651. HPLC analysis: MeOH: H<ce:inf loc="post">2</ce:inf>O (80:20), 8.110 min; purity, 98.33%.</ce:para>
                        <ce:para id="p0665" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-<ce:italic>N</ce:italic>-(3-fluoro-5-methoxybenzyl)-3-(2-(pyridin-2-yl)vinyl)-1<ce:italic>H</ce:italic>-indazol-5-amine</ce:bold> (<ce:bold>7x</ce:bold>). Compound <ce:bold>7x</ce:bold> was obtained by following general procedure D as yellow solid. (yield, 55%; TLC, PE: EA = 1:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.1) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 12.92 (s, 1H), 8.58 (dd, <ce:italic>J</ce:italic> = 4.9, 1.8 Hz, 1H), 7.85 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.79 (td, <ce:italic>J</ce:italic> = 7.7, 1.8 Hz, 1H), 7.54 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 7.33 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 7.27–7.20 (m, 2H), 6.97–6.90 (m, 3H), 6.87 (d, <ce:italic>J</ce:italic> = 9.1 Hz, 1H), 6.67 (dt, <ce:italic>J</ce:italic> = 11.0, 2.4 Hz, 1H), 6.28 (s, 1H), 4.36 (s, 2H), 3.75 (s, 3H). <ce:sup loc="post">13</ce:sup>C NMR (101 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 163.34, 160.89, 155.17, 149.34, 145.91 (d, <ce:italic>J</ce:italic> = 7.1 Hz, 1C), 143.31, 140.01, 136.82, 135.87, 131.05, 130.65 (m, 1C), 126.76, 124.96, 122.16 (d, <ce:italic>J</ce:italic> = 12.1 Hz, 1C), 121.82, 120.22, 118.43 (d, <ce:italic>J</ce:italic> = 21.2 Hz, 1C), 117.87, 111.33 (d, <ce:italic>J</ce:italic> = 23.2 Hz, 1C), 110.87, 98.02, 46.27. HRMS (ESI) for C<ce:inf loc="post">22</ce:inf>H<ce:inf loc="post">19</ce:inf>FN<ce:inf loc="post">4</ce:inf>O [M + H]<ce:sup loc="post">+</ce:sup>, calcd: 375.1616, found: 375.1604. HPLC analysis: MeOH: H<ce:inf loc="post">2</ce:inf>O (80:20), 6.929 min; purity, 97.83%.</ce:para>
                        <ce:para id="p0670" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-<ce:italic>N</ce:italic>-(3-fluoro-5-(trifluoromethyl)benzyl)-3-(2-(pyridin-2-yl)vinyl)-1<ce:italic>H</ce:italic>-indazol-5-amine</ce:bold> (<ce:bold>7y</ce:bold>). Compound <ce:bold>7y</ce:bold> was obtained by following general procedure D as yellow solid. (yield, 62%; TLC, PE: EA = 1:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.1) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 12.95 (s, 1H), 8.57 (dd, <ce:italic>J</ce:italic> = 4.9, 1.8 Hz, 1H), 7.86 (d, <ce:italic>J</ce:italic> = 16.3 Hz, 1H), 7.79 (td, <ce:italic>J</ce:italic> = 7.7, 1.8 Hz, 1H), 7.74 (s, 1H), 7.64 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H), 7.58–7.49 (m, 2H), 7.35 (d, <ce:italic>J</ce:italic> = 9.2 Hz, 1H), 7.30–7.21 (m, 2H), 6.95 (d, <ce:italic>J</ce:italic> = 9.3 Hz, 2H), 6.40 (s, 1H), 4.52 (s, 2H). <ce:sup loc="post">13</ce:sup>C NMR (101 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 163.34, 160.89, 155.17, 149.34, 145.91 (d, <ce:italic>J</ce:italic> = 7.1 Hz, 1C), 143.31, 140.01, 136.82, 135.87, 130.65 (q, <ce:italic>J</ce:italic> = 9.1 Hz, 1C), 126.76, 124.96, 122.16, 122.09 (d, <ce:italic>J</ce:italic> = 270.7 Hz, 1C), 121.83, 120.22, 118.43 (d, <ce:italic>J</ce:italic> = 21.2 Hz, 1C), 117.88, 111.35 (d, <ce:italic>J</ce:italic> = 23.2 Hz, 1C), 110.87, 98.02, 46.27. HRMS (ESI) for C<ce:inf loc="post">22</ce:inf>H<ce:inf loc="post">16</ce:inf>F<ce:inf loc="post">4</ce:inf>N<ce:inf loc="post">4</ce:inf> [M + H]<ce:sup loc="post">+</ce:sup>, calcd: 413.1384, found: 413.1366. HPLC analysis: MeOH: H<ce:inf loc="post">2</ce:inf>O (80:20), 9.153 min; purity, 99.17%.</ce:para>
                        <ce:para id="p0675" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-3-fluoro-5-(((3-(2-(pyridin-2-yl)vinyl)-1<ce:italic>H</ce:italic>-indazol-5-yl)amino)methyl)benzonitrile</ce:bold> (<ce:bold>7z</ce:bold>). Compound <ce:bold>7z</ce:bold> was obtained by following general procedure D as brown solid. (yield, 65%; TLC, PE: EA = 1:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.1) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 12.94 (s, 1H), 8.61–8.55 (m, 1H), 7.88–7.81 (m, 2H), 7.78 (td, <ce:italic>J</ce:italic> = 7.7, 1.9 Hz, 1H), 7.73–7.66 (m, 2H), 7.56 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 7.35 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 7.28–7.20 (m, 2H), 6.97–6.90 (m, 2H), 6.36 (t, <ce:italic>J</ce:italic> = 6.1 Hz, 1H), 4.48 (d, <ce:italic>J</ce:italic> = 5.8 Hz, 2H). <ce:sup loc="post">13</ce:sup>C NMR (101 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 163.06, 160.61, 155.23, 149.50, 146.03 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 1C), 143.17, 140.03, 136.76, 135.89, 127.55 (d, <ce:italic>J</ce:italic> = 3.0 Hz, 1C), 127.01, 124.84, 122.17 (d, <ce:italic>J</ce:italic> = 12.1 Hz, 1C), 121.81, 119.70 (d, <ce:italic>J</ce:italic> = 22.2 Hz, 1C), 117.88, 117.80 (d, <ce:italic>J</ce:italic> = 3.0 Hz, 1C), 117.66 (d, <ce:italic>J</ce:italic> = 25.3 Hz, 1C), 112.72 (d, <ce:italic>J</ce:italic> = 10.1 Hz, 1C), 111.37, 98.07, 46.09. HRMS (ESI) for C<ce:inf loc="post">22</ce:inf>H<ce:inf loc="post">16</ce:inf>FN<ce:inf loc="post">5</ce:inf> [M + H]<ce:sup loc="post">+</ce:sup>, calcd: 370.1463, found: 370.1446. HPLC analysis: MeOH: H<ce:inf loc="post">2</ce:inf>O (80:20), 5.479 min; purity, 98.77%.</ce:para>
                        <ce:para id="p0680" view="all">
                           <ce:bold>(<ce:italic>S</ce:italic>,<ce:italic>E</ce:italic>)-<ce:italic>N</ce:italic>-(1-(3,5-difluorophenyl)ethyl)-3-(2-(pyridin-2-yl)vinyl)-1<ce:italic>H</ce:italic>-indazol-5-amine</ce:bold> (<ce:bold>7ma</ce:bold>). Compound <ce:bold>7ma</ce:bold> was obtained by following general procedure D as yellow solid. (yield, 63%; TLC, PE: EA = 1:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.1) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 12.92 (s, 1H), 8.58 (d, <ce:italic>J</ce:italic> = 4.8 Hz, 1H), 7.87–7.76 (m, 2H), 7.50 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 7.31 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 1H), 7.24 (d, <ce:italic>J</ce:italic> = 7.0 Hz, 3H), 7.15 (d, <ce:italic>J</ce:italic> = 16.3 Hz, 1H), 7.00 (t, <ce:italic>J</ce:italic> = 9.1 Hz, 1H), 6.92 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 1H), 6.82 (s, 1H), 6.23 (d, <ce:italic>J</ce:italic> = 6.6 Hz, 1H), 4.70 (p, <ce:italic>J</ce:italic> = 6.6 Hz, 1H), 1.47 (d, <ce:italic>J</ce:italic> = 6.7 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (101 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 163.89 (d, <ce:italic>J</ce:italic> = 13.1 Hz, 1C), 161.44 (d, <ce:italic>J</ce:italic> = 13.1 Hz, 1C), 155.20, 151.93 (t, <ce:italic>J</ce:italic> = 8.1 Hz, 1C), 149.55, 142.74, 140.01, 136.81, 135.75, 126.93, 125.15, 122.19, 122.07, 121.62, 117.96, 111.17, 109.28 (d, <ce:italic>J</ce:italic> = 25.3 Hz, 1C), 109.22 (d, <ce:italic>J</ce:italic> = 12.1 Hz, 1C), 101.94 (t, <ce:italic>J</ce:italic> = 26.3 Hz, 1C), 99.05, 52.20, 24.14 HRMS (ESI) for C<ce:inf loc="post">22</ce:inf>H<ce:inf loc="post">18</ce:inf>F<ce:inf loc="post">2</ce:inf>N<ce:inf loc="post">4</ce:inf> [M + H]<ce:sup loc="post">+</ce:sup>, calcd: 377.1572, found: 377.1560. HPLC analysis: MeOH: H<ce:inf loc="post">2</ce:inf>O (80:20), 8.396 min; purity, 98.65%.</ce:para>
                        <ce:para id="p0685" view="all">
                           <ce:bold>(<ce:italic>R</ce:italic>,<ce:italic>E</ce:italic>)-<ce:italic>N</ce:italic>-(1-(3,5-difluorophenyl)ethyl)-3-(2-(pyridin-2-yl)vinyl)-1<ce:italic>H</ce:italic>-indazol-5-amine</ce:bold> (<ce:bold>7</ce:bold>
                           <ce:bold>mb</ce:bold>). Compound <ce:bold>7</ce:bold>
                           <ce:bold>mb</ce:bold> was obtained by following general procedure D as yellow solid. (yield, 60%; TLC, PE: EA = 1:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.1) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 12.89 (s, 1H), 8.58 (dd, <ce:italic>J</ce:italic> = 5.2, 1.8 Hz, 1H), 7.85–7.77 (m, 2H), 7.51 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 7.31 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 1H), 7.27–7.21 (m, 3H), 7.16 (d, <ce:italic>J</ce:italic> = 16.3 Hz, 1H), 7.04–6.97 (m, 1H), 6.92 (dd, <ce:italic>J</ce:italic> = 8.9, 2.0 Hz, 1H), 6.83 (s, 1H), 6.22 (d, <ce:italic>J</ce:italic> = 7.0 Hz, 1H), 4.70 (p, <ce:italic>J</ce:italic> = 6.7 Hz, 1H), 1.47 (d, <ce:italic>J</ce:italic> = 6.7 Hz, 3H). <ce:sup loc="post">13</ce:sup>C NMR (101 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 163.86 (d, <ce:italic>J</ce:italic> = 13.1 Hz, 1C), 161.42 (d, <ce:italic>J</ce:italic> = 13.1 Hz, 1C), 155.18, 151.90 (t, <ce:italic>J</ce:italic> = 8.1 Hz, 1C), 149.52, 142.71, 139.98, 136.78, 135.73, 126.90, 125.12, 122.15, 122.04, 121.60, 117.92, 111.13, 109.25 (d, <ce:italic>J</ce:italic> = 25.3 Hz, 1C), 109.18 (d, <ce:italic>J</ce:italic> = 11.1 Hz, 1C), 101.90 (t, <ce:italic>J</ce:italic> = 26.3 Hz, 1C), 99.04, 52.18, 24.10. HRMS (ESI) for C<ce:inf loc="post">22</ce:inf>H<ce:inf loc="post">18</ce:inf>F<ce:inf loc="post">2</ce:inf>N<ce:inf loc="post">4</ce:inf> [M + H]<ce:sup loc="post">+</ce:sup>, calcd: 377.1572, found: 377.1561. HPLC analysis: MeOH: H<ce:inf loc="post">2</ce:inf>O (80:20), 8.673 min; purity, 100.00%.</ce:para>
                        <ce:para id="p0690" view="all">
                           <ce:bold>5-(3,5-difluorobenzyl)-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>9a</ce:bold>). A solution of compound <ce:bold>8</ce:bold> (1 g, 3.0 mmol), 3,5-difluorobenzyl bromide (1.05 g, 6.0 mmol), Na<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> (650 mg, 6.0 mmol) in THF (20 mL) and H<ce:inf loc="post">2</ce:inf>O (4 mL) was added Pd(PPh<ce:inf loc="post">3</ce:inf>)<ce:inf loc="post">4</ce:inf> (352 mg, 0.3 mmol). The mixture was stirred at 70 °C under argon overnight and cooled to room temperature. Then extracted by EtOAc and washed with H<ce:inf loc="post">2</ce:inf>O followed by brine. The organic layers were dried over anhydrous Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>, filtered and evaporated. The crude material was purified by silica gel column chromatography (5–10% EtOAc in petroleum ether) to afford product <ce:bold>9a</ce:bold> as colorless oil. (650 mg; yield, 73%; TLC, PE: EA = 20:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 8.05 (s, 1H), 7.65 (d, <ce:italic>J</ce:italic> = 9.1 Hz, 2H), 7.32 (dd, <ce:italic>J</ce:italic> = 8.5, 1.7 Hz, 1H), 7.06–6.96 (m, 3H), 5.80 (dd, <ce:italic>J</ce:italic> = 9.7, 2.6 Hz, 1H), 4.07 (s, 2H), 3.91–3.81 (m, 1H), 3.76–3.66 (m, 1H), 2.44–2.31 (m, 1H), 2.07–1.89 (m, 2H), 1.81–1.66 (m, 1H), 1.62–1.52 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 329.0 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0695" view="all">
                           <ce:bold>5-(3,5-difluorobenzyl)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>9b</ce:bold>). <ce:bold>9a</ce:bold> was treated by the general procedure D to obtain <ce:bold>9b</ce:bold> as white solid. (yield, 77%; TLC, PE: EA = 5:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.2) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 13.01 (s, 1H), 8.01 (d, <ce:italic>J</ce:italic> = 1.0 Hz, 1H), 7.63 (s, 1H), 7.47 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 1H), 7.24 (dd, <ce:italic>J</ce:italic> = 8.6, 1.6 Hz, 1H), 7.05–6.95 (m, 3H), 4.05 (s, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 245.1 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0700" view="all">
                           <ce:bold>5-(3,5-difluorobenzyl)-3-iodo-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>9c</ce:bold>). <ce:bold>9c</ce:bold> was obtained according to general procedure A as white solid. (yield, 85%; TLC, PE: EA = 5:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 13.45 (s, 1H), 7.48 (d, <ce:italic>J</ce:italic> = 9.3 Hz, 1H), 7.35–7.31 (m, 2H), 7.07–6.98 (m, 3H), 4.10 (s, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 369.0 [M - H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0705" view="all">
                           <ce:bold>5-(3,5-difluorobenzyl)-3-iodo-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>9d</ce:bold>). <ce:bold>9d</ce:bold> was obtained according to general procedure B as colorless oil. (yield, 70%; TLC, PE: EA = 25:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 7.65 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H), 7.41–7.33 (m, 2H), 7.02–6.92 (m, 3H), 5.75 (dd, <ce:italic>J</ce:italic> = 9.7, 2.3 Hz, 1H), 4.07 (s, 2H), 3.86–3.77 (m, 1H), 3.70–3.60 (m, 1H), 2.40–2.27 (m, 1H), 1.99–1.85 (m, 2H), 1.72–1.58 (m, 1H), 1.58–1.42 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 477.0 [M + Na]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0710" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-5-(3,5-difluorobenzyl)-3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>9e</ce:bold>). <ce:bold>9e</ce:bold> was obtained according to general procedure C as yellow solid. (yield, 54%; TLC, PE:EA = 5:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 8.61 (d, <ce:italic>J</ce:italic> = 4.0 Hz, 1H), 8.15 (s, 1H), 7.93 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.83 (td, <ce:italic>J</ce:italic> = 7.7, 1.9 Hz, 1H), 7.73–7.67 (m, 2H), 7.59 (d, <ce:italic>J</ce:italic> = 16.3 Hz, 1H), 7.38 (dd, <ce:italic>J</ce:italic> = 8.7, 1.5 Hz, 1H), 7.32–7.26 (m, 1H), 7.10–6.99 (m, 3H), 5.86 (dd, <ce:italic>J</ce:italic> = 9.7, 2.5 Hz, 1H), 4.14 (s, 2H), 3.92–3.85 (m, 1H), 3.79–3.68 (m, 1H), 2.48–2.36 (m, 1H), 2.10–1.93 (m, 2H), 1.83–1.67 (m, 1H), 1.65–1.53 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 432.2 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0715" view="all">
                           <ce:bold>5-(3,5-difluorophenyl)-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>10a</ce:bold>). Compound <ce:bold>10a</ce:bold> was synthesized from <ce:bold>9</ce:bold> by a procedure similar to that of <ce:bold>9a</ce:bold> as colorless oil. (yield, 66%; TLC, PE: EA = 20:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 8.18 (s, 1H), 8.16 (s, 1H), 7.81 (d, <ce:italic>J</ce:italic> = 3.0 Hz, 2H), 7.49 (dd, <ce:italic>J</ce:italic> = 9.2, 2.2 Hz, 2H), 7.24–7.16 (m, 1H), 5.90 (dd, <ce:italic>J</ce:italic> = 9.7, 2.5 Hz, 1H), 3.93–3.85 (m, 1H), 3.81–3.72 (m, 1H), 2.47–2.35 (m, 1H), 2.07–1.95 (m, 2H), 1.83–1.69 (m, 1H), 1.65–1.54 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 315.1 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0720" view="all">
                           <ce:bold>5-(3,5-difluorophenyl)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>10b</ce:bold>). <ce:bold>10a</ce:bold> was treated by the general procedure D to obtain <ce:bold>10b</ce:bold> as yellow solid. (yield, 70%; TLC, PE: EA = 5:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.2) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 13.20 (s, 1H), 8.15 (d, <ce:italic>J</ce:italic> = 4.1 Hz, 2H), 7.73 (dd, <ce:italic>J</ce:italic> = 8.7, 1.8 Hz, 1H), 7.63 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 7.51–7.42 (m, 2H), 7.22–7.14 (m, 1H). MS (ESI), <ce:italic>m/z</ce:italic>: 231.1[M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0725" view="all">
                           <ce:bold>5-(3,5-difluorophenyl)-3-iodo-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>10c</ce:bold>). <ce:bold>10c</ce:bold> was obtained according to general procedure A as yellow solid. (yield, 85%; TLC, PE: EA = 5:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 13.63 (s, 1H), 7.80 (dd, <ce:italic>J</ce:italic> = 8.7, 1.8 Hz, 1H), 7.74 (s, 1H), 7.65 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 7.56–7.48 (m, 2H), 7.25–7.17 (m, 1H). MS (ESI), <ce:italic>m/z</ce:italic>: 355.0 [M - H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0730" view="all">
                           <ce:bold>5-(3,5-difluorophenyl)-3-iodo-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>10d</ce:bold>). <ce:bold>10d</ce:bold> was obtained according to general procedure B as yellow oil. (yield, 72%; TLC, PE: EA = 25:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 7.89 (dd, <ce:italic>J</ce:italic> = 8.9, 1.7 Hz, 1H), 7.86 (d, <ce:italic>J</ce:italic> = 9.8 Hz, 1H), 7.75 (s, 1H), 7.55 (dd, <ce:italic>J</ce:italic> = 8.7, 2.7 Hz, 2H), 7.27–7.19 (m, 1H), 5.91 (dd, <ce:italic>J</ce:italic> = 9.7, 2.3 Hz, 1H), 3.93–3.84 (m, 1H), 3.81–3.70 (m, 1H), 2.43–2.31 (m, 1H), 2.07–1.94 (m, 2H), 1.81–1.67 (m, 1H), 1.63–1.53 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 463.0 [M + Na]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0735" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-5-(3,5-difluorophenyl)-3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>10e</ce:bold>). <ce:bold>10e</ce:bold> was obtained according to general procedure C as yellow solid. (yield, 49%; TLC, PE: EA = 5:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 8.62 (d, <ce:italic>J</ce:italic> = 6.5 Hz, 1H), 8.53 (s, 1H), 8.03 (d, <ce:italic>J</ce:italic> = 16.3 Hz, 1H), 7.88–7.80 (m, 3H), 7.74 (d, <ce:italic>J</ce:italic> = 6.6 Hz, 1H), 7.69 (d, <ce:italic>J</ce:italic> = 16.3 Hz, 1H), 7.66–7.60 (m, 2H), 7.33–7.27 (m, 1H), 7.27–7.19 (m, 1H), 5.95 (dd, <ce:italic>J</ce:italic> = 9.6, 2.4 Hz, 1H), 3.96–3.88 (m, 1H), 3.85–3.70 (m, 1H), 2.48–2.40 (m, 1H), 2.12–1.99 (m, 2H), 1.85–1.71 (m, 1H), 1.66–1.57 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 418.3 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0740" view="all">
                           <ce:bold>5-((3,5-difluorophenyl)thio)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>11a</ce:bold>). A solution of compound <ce:bold>11</ce:bold> (2 g, 8.2 mmol), 3,5-difluorobenzenethiol (1.32 g, 9.0 mmol), CsOH·H<ce:inf loc="post">2</ce:inf>O (2.75 g, 16.4 mmol) in DMF (30 mL) was added Pd<ce:inf loc="post">2</ce:inf>(dba)<ce:inf loc="post">3</ce:inf> (375 mg, 0.4 mmol) and Xantphos (475 mg, 0.8 mmol). The mixture was stirred at 80 °C under argon overnight and cooled to room temperature. Then extracted by EtOAc and washed with H<ce:inf loc="post">2</ce:inf>O followed by brine. The organic layers were dried over anhydrous Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>, filtered and evaporated. The crude material was purified by silica gel column chromatography (15–20% EtOAc in petroleum ether) to afford product <ce:bold>11a</ce:bold> as yellow solid. (1.3 g; yield, 60%; TLC, PE: EA = 5:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.2) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, Chloroform-<ce:italic>d</ce:italic>) δ 8.15 (s, 1H), 8.05–8.00 (m, 1H), 7.59 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H), 7.52 (dd, <ce:italic>J</ce:italic> = 8.7, 1.6 Hz, 1H), 6.63–6.51 (m, 3H). MS (ESI), <ce:italic>m/z</ce:italic>: 261.0 [M - H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0745" view="all">
                           <ce:bold>5-((3,5-difluorophenyl)thio)-3-iodo-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>11b</ce:bold>). <ce:bold>11b</ce:bold> was obtained according to general procedure A as yellow solid. (yield, 80%; TLC, PE: EA = 5:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 13.69 (s, 1H), 7.69 (d, <ce:italic>J</ce:italic> = 9.4 Hz, 2H), 7.52 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 7.09–7.01 (m, 1H), 6.81–6.73 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 386.9 [M - H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0750" view="all">
                           <ce:bold>5-((3,5-difluorophenyl)thio)-3-iodo-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>11c</ce:bold>). <ce:bold>11c</ce:bold> was obtained according to general procedure B as white solid. (yield, 67%; TLC, PE: EA = 25:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 7.89 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 1H), 7.67 (d, <ce:italic>J</ce:italic> = 1.0 Hz, 1H), 7.60 (dd, <ce:italic>J</ce:italic> = 8.8, 1.7 Hz, 1H), 7.09–7.02 (m, 1H), 6.83–6.75 (m, 2H), 5.90 (dd, <ce:italic>J</ce:italic> = 9.7, 2.4 Hz, 1H), 3.92–3.84 (m, 1H), 3.78–3.69 (m, 1H), 2.41–2.29 (m, 1H), 2.06–1.94 (m, 2H), 1.81–1.66 (m, 1H), 1.62–1.52 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 473.0 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0755" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-5-((3,5-difluorophenyl)thio)-3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>11d</ce:bold>). <ce:bold>11d</ce:bold> was obtained according to general procedure C as yellow solid. (yield, 49%; TLC, PE: EA = 5:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 8.61 (d, <ce:italic>J</ce:italic> = 3.1 Hz, 1H), 8.55 (d, <ce:italic>J</ce:italic> = 1.6 Hz, 1H), 8.00–7.90 (m, 2H), 7.82 (td, <ce:italic>J</ce:italic> = 7.6, 1.9 Hz, 1H), 7.74 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.68–7.57 (m, 2H), 7.32–7.25 (m, 1H), 7.10–7.02 (m, 1H), 6.84–6.74 (m, 2H), 5.96 (dd, <ce:italic>J</ce:italic> = 9.7, 2.3 Hz, 1H), 3.96–3.88 (m, 1H), 3.84–3.72 (m, 1H), 2.47–2.34 (m, 1H), 2.10–1.98 (m, 2H), 1.83–1.68 (m, 1H), 1.65–1.54 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 450.1 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0760" view="all">
                           <ce:bold>5-((3,5-difluorophenyl)ethynyl)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>12a</ce:bold>). A mixture of compound <ce:bold>11</ce:bold> (1 g, 4.1 mmol), 1-ethynyl-3,5-difluorobenzene (1.14 g, 8.2 mmol), DIPEA (1.59 g, 12.3 mmol) in DMF (15 mL) was added Pd(PPh<ce:inf loc="post">3</ce:inf>)<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf> (288 mg, 0.4 mmol) and CuI (78 mg, 0.4 mmol). The mixture was stirred at 40 °C under argon overnight and cooled to room temperature. Then extracted by EtOAc and washed with H<ce:inf loc="post">2</ce:inf>O followed by brine. The organic layers were dried over anhydrous Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>, filtered and evaporated. The crude material was purified by silica gel column chromatography (30–40% EtOAc in petroleum ether) to afford product <ce:bold>12a</ce:bold> as gray solid. (882 mg; yield, 79%; TLC, PE: EA = 3:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 13.35 (s, 1H), 8.15 (s, 1H), 8.05 (s, 1H), 7.61 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H), 7.50 (dd, <ce:italic>J</ce:italic> = 8.6, 1.5 Hz, 1H), 7.41–7.29 (m, 3H). MS (ESI), <ce:italic>m/z</ce:italic>: 253.0 [M - H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0765" view="all">
                           <ce:bold>5-((3,5-difluorophenyl)ethynyl)-3-iodo-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>12b</ce:bold>). <ce:bold>12b</ce:bold> was obtained according to general procedure A as white solid. (yield, 80%; TLC, PE: EA = 3:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.4) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 13.77 (s, 1H), 7.70 (s, 1H), 7.64 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 7.58 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H), 7.40–7.34 (m, 3H).</ce:para>
                        <ce:para id="p0770" view="all">MS (ESI), <ce:italic>m/z</ce:italic>: 378.9 [M - H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0775" view="all">
                           <ce:bold>5-((3,5-difluorophenyl)ethynyl)-3-iodo-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>12c</ce:bold>). <ce:bold>12c</ce:bold> was obtained according to general procedure B as white solid. (yield, 74%; TLC, PE: EA = 20:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 7.86 (d, <ce:italic>J</ce:italic> = 9.6 Hz, 1H), 7.71 (s, 1H), 7.66 (dd, <ce:italic>J</ce:italic> = 8.8, 1.5 Hz, 1H), 7.42–7.33 (m, 3H), 5.90 (dd, <ce:italic>J</ce:italic> = 9.8, 2.4 Hz, 1H), 3.94–3.84 (m, 1H), 3.80–3.69 (m, 1H), 2.41–2.29 (m, 1H), 2.05–1.93 (m, 2H), 1.80–1.66 (m, 1H), 1.63–1.52 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 465.0 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0780" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-5-((3,5-difluorophenyl)ethynyl)-3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>12d</ce:bold>). <ce:bold>12d</ce:bold> was obtained according to general procedure C as yellow solid. (yield, 52%; TLC, PE: EA = 5:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.2) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 8.62 (d, <ce:italic>J</ce:italic> = 3.9 Hz, 1H), 8.52 (s, 1H), 8.01–7.92 (m, 1H), 7.91–7.81 (m, 2H), 7.76 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H), 7.70–7.63 (m, 2H), 7.43–7.35 (m, 3H), 7.33–7.28 (m, 1H), 5.94 (dd, <ce:italic>J</ce:italic> = 9.7, 2.3 Hz, 1H), 3.98–3.88 (m, 1H), 3.84–3.72 (m, 1H), 2.48–2.36 (m, 1H), 2.11–1.97 (m, 2H), 1.84–1.70 (m, 1H), 1.66–1.55 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 442.2 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0785" view="all">
                           <ce:bold>5-(3,5-difluorophenethyl)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>13a</ce:bold>). To a solution of <ce:bold>12a</ce:bold> (500 mg, 2 mmol) in DMF (5 mL) and ethanol (5 mL) was added 10% Pd/C (50 mg). The mixture was stirred at 60 °C under a balloon of hydrogen overnight and cooled to room temperature. <ce:bold>13a</ce:bold> was obtained as gray solid by filtering mixture and evaporating the filtrate. (468 mg; yield, 92%; TLC, PE: EA = 3:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 13.01 (s, 1H), 7.98 (s, 1H), 7.54 (s, 1H), 7.45 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 1H), 7.24 (d, <ce:italic>J</ce:italic> = 10.0 Hz, 1H), 7.05–6.93 (m, 3H), 3.05–2.86 (m, 4H). MS (ESI), <ce:italic>m/z</ce:italic>: 257.1 [M - H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0790" view="all">
                           <ce:bold>5-(3,5-difluorophenethyl)-3-iodo-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>13b</ce:bold>). <ce:bold>13b</ce:bold> was obtained according to general procedure A as white solid. (yield, 83%; TLC, PE: EA = 5:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 13.43 (s, 1H), 7.47 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 1H), 7.33 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H), 7.24 (s, 1H), 7.07–7.00 (m, 3H), 3.05–2.89 (m, 4H). MS (ESI), <ce:italic>m/z</ce:italic>: 383.0 [M - H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0795" view="all">
                           <ce:bold>5-(3,5-difluorophenethyl)-3-iodo-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>13c</ce:bold>). <ce:bold>13c</ce:bold> was obtained according to general procedure B as white solid. (yield, 76%; TLC, PE: EA = 20:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 7.67 (d, <ce:italic>J</ce:italic> = 9.4 Hz, 1H), 7.41 (dd, <ce:italic>J</ce:italic> = 8.7, 1.6 Hz, 1H), 7.25 (s, 1H), 7.07–6.98 (m, 3H), 5.81 (dd, <ce:italic>J</ce:italic> = 9.9, 2.4 Hz, 1H), 3.91–3.82 (m, 1H), 3.76–3.67 (m, 1H), 3.06–2.90 (m, 4H), 2.41–2.28 (m, 1H), 2.05–1.91 (m, 2H), 1.75–1.70 (m, 1H), 1.59–1.54 (m, 2H).</ce:para>
                        <ce:para id="p0800" view="all">MS (ESI), <ce:italic>m/z</ce:italic>: 491.0 [M + Na]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0805" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-5-(3,5-difluorophenethyl)-3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>13d</ce:bold>). <ce:bold>13d</ce:bold> was obtained according to general procedure C as yellow solid. (yield, 50%; TLC, PE: EA = 5:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.2) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 8.61 (d, <ce:italic>J</ce:italic> = 3.9 Hz, 1H), 8.02 (s, 1H), 7.92 (d, <ce:italic>J</ce:italic> = 16.3 Hz, 1H), 7.83 (td, <ce:italic>J</ce:italic> = 7.6, 1.8 Hz, 1H), 7.72–7.66 (m, 2H), 7.56 (d, <ce:italic>J</ce:italic> = 16.3 Hz, 1H), 7.38 (dd, <ce:italic>J</ce:italic> = 8.6, 1.5 Hz, 1H), 7.32–7.26 (m, 1H), 7.09–6.99 (m, 3H), 5.86 (dd, <ce:italic>J</ce:italic> = 9.8, 2.4 Hz, 1H), 3.95–3.83 (m, 1H), 3.81–3.68 (m, 1H), 3.15–2.93 (m, 4H), 2.48–2.36 (m, 1H), 2.09–1.94 (m, 2H), 1.82–1.68 (m, 1H), 1.64–1.53 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 446.2 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0810" view="all">
                           <ce:bold>4-(3,5-difluorophenoxy)-2-methyl-1-nitrobenzene</ce:bold> (<ce:bold>14a</ce:bold>). To a solution of <ce:bold>14</ce:bold> (5 g, 32.2 mmol), K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> (8.9 g, 64.4 mmol) in DMF (30 mL) was added 3,5-difluorophenol (4.6 g, 35.5 mmol). The reaction mixture was stirred at 80 °C for 4 h and cooled to room temperature. Then extracted by EtOAc and washed with H<ce:inf loc="post">2</ce:inf>O followed by brine. The organic layers were dried over anhydrous Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>, filtered and evaporated. The crude material was purified by silica gel column chromatography (2–5% EtOAc in petroleum ether) to afford product <ce:bold>14a</ce:bold> as white solid. (7.6 g; yield, 89%; TLC, PE: EA = 30:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.2) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 8.10 (d, <ce:italic>J</ce:italic> = 9.0 Hz, 1H), 7.21 (d, <ce:italic>J</ce:italic> = 2.8 Hz, 1H), 7.20–7.13 (m, 1H), 7.10 (dd, <ce:italic>J</ce:italic> = 9.0, 2.8 Hz, 1H), 7.04–6.94 (m, 2H), 2.54 (s, 3H). MS (ESI), <ce:italic>m/z</ce:italic>: 264.1 [M - H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0815" view="all">
                           <ce:bold>4-(3,5-difluorophenoxy)-2-methylaniline</ce:bold> (<ce:bold>14b</ce:bold>). To a solution of <ce:bold>14a</ce:bold> (7 g, 26.4 mmol), NH<ce:inf loc="post">4</ce:inf>Cl (4.24 g, 79.2 mmol) in ethanol (100 mL) and H<ce:inf loc="post">2</ce:inf>O (20 mL) was added Fe powder (7.4 g, 1.32 g) slowly. The reaction mixture was stirred for 3 h at 75 °C and cooled to room temperature. The reaction mixture was filtered through Celite and evaporated. Then extracted by EtOAc and washed with H<ce:inf loc="post">2</ce:inf>O followed by brine. The organic layers were dried over anhydrous Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>, filtered and evaporated. The crude material was purified by silica gel column chromatography (10–15% EtOAc in petroleum ether) to afford product <ce:bold>14b</ce:bold> as colorless oil. (4.4 g; yield, 71%; TLC, PE: EA = 10:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.2) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 6.88–6.61 (m, 4H), 6.51 (d, <ce:italic>J</ce:italic> = 10.7 Hz, 2H), 4.89 (s, 2H), 2.05 (s, 3H). MS (ESI), <ce:italic>m/z</ce:italic>: 236.1 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0820" view="all">
                           <ce:bold>5-(3,5-difluorophenoxy)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>14c</ce:bold>). Compound <ce:bold>14b</ce:bold> (2 g, 8.5 mmol) was dissolved in a solution of 40% fluoroboric acid (20 mL). To the mixture was dropwise added 50% NaNO<ce:inf loc="post">2</ce:inf> (620 mg, 8.9 mmol) solution. The mixture was stirred at 0 °C for 2 h. Then filtered to get precipitate. To a solution of precipitate, CH<ce:inf loc="post">3</ce:inf>COOK (2.5 g, 25.5 mmol) in CHCl<ce:inf loc="post">3</ce:inf> (15 mL) was added 18-crown-6 (237 mg, 0.9 mmol), the reaction mixture was stirred at room temperature overnight. Then extracted by DCM and washed with H<ce:inf loc="post">2</ce:inf>O followed by brine. The organic layers were dried over anhydrous Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>, filtered and evaporated. The crude material was purified by silica gel column chromatography (15–20% EtOAc in petroleum ether) to afford product <ce:bold>14c</ce:bold> as beige solid. (880 mg; 42%; TLC, PE: EA = 5:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 13.24 (s, 1H), 8.07 (s, 1H), 7.63 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 1H), 7.53 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 7.17 (dd, <ce:italic>J</ce:italic> = 8.9, 2.3 Hz, 1H), 6.98–6.89 (m, 1H), 6.69–6.60 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 247.1 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0825" view="all">
                           <ce:bold>5-(3,5-difluorophenoxy)-3-iodo-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>14d</ce:bold>). <ce:bold>14d</ce:bold> was obtained according to general procedure A as yellow solid. (yield, 80%; TLC, PE: EA = 5:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.4) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 13.67 (s, 1H), 7.66 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 1H), 7.26 (dd, <ce:italic>J</ce:italic> = 9.0, 2.3 Hz, 1H), 7.14 (s, 1H), 7.01–6.92 (m, 1H), 6.69 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 371.0 [M - H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0830" view="all">
                           <ce:bold>5-(3,5-difluorophenoxy)-3-iodo-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>14e</ce:bold>). <ce:bold>14e</ce:bold> was obtained according to general procedure B as yellow oil. (yield, 70%; TLC, PE: EA = 20:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 7.87 (dd, <ce:italic>J</ce:italic> = 9.1, 0.7 Hz, 1H), 7.34 (dd, <ce:italic>J</ce:italic> = 9.0, 2.3 Hz, 1H), 7.15 (dd, <ce:italic>J</ce:italic> = 2.3, 0.6 Hz, 1H), 7.03–6.92 (m, 1H), 6.76–6.66 (m, 2H), 5.88 (dd, <ce:italic>J</ce:italic> = 9.8, 2.4 Hz, 1H), 3.92–3.84 (m, 1H), 3.79–3.68 (m, 1H), 2.44–2.29 (m, 1H), 2.08–1.94 (m, 2H), 1.80–1.67 (m, 1H), 1.64–1.53 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 456.9 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0835" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-5-(3,5-difluorophenoxy)-3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>14f</ce:bold>). <ce:bold>14f</ce:bold> was obtained according to general procedure C as yellow solid. (yield, 56%; TLC, PE: EA = 5:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.2) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 8.61–8.56 (m, 1H), 8.05 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 7.97–7.84 (m, 2H), 7.80 (td, <ce:italic>J</ce:italic> = 7.6, 1.8 Hz, 1H), 7.69 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.58 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.31 (dd, <ce:italic>J</ce:italic> = 9.0, 2.2 Hz, 1H), 7.29–7.24 (m, 1H), 6.99–6.92 (m, 1H), 6.75–6.65 (m, 2H), 5.92 (dd, <ce:italic>J</ce:italic> = 9.7, 2.3 Hz, 1H), 3.95–3.88 (m, 1H), 3.82–3.73 (m, 1H), 2.48–2.38 (m, 1H), 2.11–1.99 (m, 2H), 1.82–1.69 (m, 1H), 1.68–1.53 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 456.1 [M + Na]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0840" view="all">
                           <ce:bold>3-iodo-5-nitro-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>15a</ce:bold>). <ce:bold>15a</ce:bold> was obtained according to general procedure A as yellow solid. (yield, 83%; TLC, PE: EA = 5:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.4) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 14.09 (s, 1H), 8.26 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 8.20 (dd, <ce:italic>J</ce:italic> = 9.2, 2.2 Hz, 1H), 7.72 (d, <ce:italic>J</ce:italic> = 9.2 Hz, 1H).</ce:para>
                        <ce:para id="p0845" view="all">
                           <ce:bold>3-iodo-5-nitro-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>15b</ce:bold>). <ce:bold>15b</ce:bold> was obtained according to general procedure B as yellow solid. (yield, 70%; TLC, PE: EA = 20:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.2) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 8.36–8.29 (m, 2H), 8.00 (dd, <ce:italic>J</ce:italic> = 8.8, 1.2 Hz, 1H), 5.98 (dd, <ce:italic>J</ce:italic> = 9.7, 2.3 Hz, 1H), 3.94–3.83 (m, 1H), 3.83–3.71 (m, 1H), 2.43–2.26 (m, 1H), 2.09–1.94 (m, 2H), 1.79–1.69 (m, 1H), 1.64–1.56 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 396.0 [M + Na]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0850" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-5-nitro-3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>15c</ce:bold>). <ce:bold>15c</ce:bold> was obtained according to general procedure C as yellow solid. (yield, 56%; TLC, PE: EA = 10:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.1) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 9.16 (d, <ce:italic>J</ce:italic> = 2.0 Hz, 1H), 8.63 (d, <ce:italic>J</ce:italic> = 4.6 Hz, 1H), 8.32 (dd, <ce:italic>J</ce:italic> = 9.3, 2.1 Hz, 1H), 8.09–7.96 (m, 2H), 7.89–7.79 (m, 2H), 7.69 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.36–7.28 (m, 1H), 6.02 (dd, <ce:italic>J</ce:italic> = 9.6, 2.4 Hz, 1H), 3.95–3.87 (m, 1H), 3.86–3.73 (m, 1H), 2.47–2.35 (m, 1H), 2.12–2.00 (m, 2H), 1.85–1.70 (m, 1H), 1.69–1.55 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 351.1 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0855" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazol-5-amine</ce:bold> (<ce:bold>15d</ce:bold>). <ce:bold>15d</ce:bold> was synthesized from <ce:bold>15c</ce:bold> with a procedure similar to that of <ce:bold>14b</ce:bold> as red solid. (yield, 64%; TLC, PE: EA = 1:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.2) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 8.59 (d, <ce:italic>J</ce:italic> = 4.8 Hz, 1H), 7.87–7.74 (m, 2H), 7.64 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.47 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 7.38 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.29–7.13 (m, 2H), 6.89 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 1H), 5.73 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H), 5.06 (s, 2H), 3.93–3.83 (m, 1H), 3.78–3.64 (m, 1H), 2.46–2.30 (m, 1H), 2.10–1.89 (m, 2H), 1.81–1.66 (m, 1H), 1.62–1.52 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 321.1 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0860" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-<ce:italic>N</ce:italic>-(3,5-difluorobenzyl)-3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazol-5-amine</ce:bold> (<ce:bold>15e</ce:bold>). Compound <ce:bold>15d</ce:bold> (1 g, 3.1 mmol) was dissolved in methanol (10 mL). To the mixture was added catalytic CH<ce:inf loc="post">3</ce:inf>COOH and 3,5-difluorobenzaldehyde (483 mg, 3.4 mmol). The mixture was stirred at room temperature for 1 h. Then filtered to get precipitate. To a solution of precipitate in dichloromethane (10 mL) and methanol (5 mL) was added NaBH<ce:inf loc="post">4</ce:inf> (352 mg, 9.3 mmol) slowly, the reaction mixture was stirred at 0 °C for 6 h. Then quenched with saturated NH<ce:inf loc="post">4</ce:inf>Cl solution, extracted by DCM and washed with H<ce:inf loc="post">2</ce:inf>O followed by brine. The organic layers were dried over anhydrous Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>, filtered and evaporated. The crude material was purified by silica gel column chromatography (25–30% EtOAc in petroleum ether) to afford product <ce:bold>15e</ce:bold> as yellow solid. (585 mg; yield, 42%; TLC, PE: EA = 3:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.2) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 8.59 (d, <ce:italic>J</ce:italic> = 5.8 Hz, 1H), 7.85–7.77 (m, 2H), 7.58 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.52 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 1H), 7.33–7.23 (m, 2H), 7.22–7.16 (m, 2H), 7.07 (tt, <ce:italic>J</ce:italic> = 9.4, 2.4 Hz, 1H), 6.98 (dd, <ce:italic>J</ce:italic> = 9.0, 2.1 Hz, 1H), 6.94 (d, <ce:italic>J</ce:italic> = 2.0 Hz, 1H), 6.43 (t, <ce:italic>J</ce:italic> = 6.2 Hz, 1H), 5.74 (dd, <ce:italic>J</ce:italic> = 9.7, 2.5 Hz, 1H), 4.44 (d, <ce:italic>J</ce:italic> = 6.2 Hz, 2H), 3.93–3.83 (m, 1H), 3.75–3.64 (m, 1H), 2.44–2.31 (m, 1H), 2.07–1.98 (m, 1H), 1.97–1.89 (m, 1H), 1.79–1.66 (m, 1H), 1.62–1.50 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 447.3 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0865" view="all">
                           <ce:bold>15f</ce:bold>-<ce:bold>15o</ce:bold> were obtained following the synthetic procedure of <ce:bold>15e</ce:bold>.</ce:para>
                        <ce:para id="p0870" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-<ce:italic>N</ce:italic>-benzyl-3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazol-5-amine (15f)</ce:bold>.</ce:para>
                        <ce:para id="p0875" view="all">(yield, 48%; TLC, PE: EA = 3:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 8.59 (d, <ce:italic>J</ce:italic> = 7.5 Hz, 1H), 7.85–7.77 (m, 2H), 7.59 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.52–7.44 (m, 3H), 7.37–7.20 (m, 5H), 7.02–6.95 (m, 2H), 6.27 (t, <ce:italic>J</ce:italic> = 6.0 Hz, 1H), 5.73 (dd, <ce:italic>J</ce:italic> = 9.7, 2.5 Hz, 1H), 4.39 (d, <ce:italic>J</ce:italic> = 5.7 Hz, 2H), 3.92–3.83 (m, 1H), 3.76–3.66 (m, 1H), 2.45–2.31 (m, 1H), 2.09–1.98 (m, 1H), 1.98–1.89 (m, 1H), 1.79–1.65 (m, 1H), 1.65–1.51 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 411.2 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0880" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-<ce:italic>N</ce:italic>-(2-fluorobenzyl)-3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazol-5-amine</ce:bold> (<ce:bold>15g</ce:bold>). (yield, 50%; TLC, PE: EA = 3:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 8.60 (d, <ce:italic>J</ce:italic> = 3.4 Hz, 1H), 7.85 (d, <ce:italic>J</ce:italic> = 16.3 Hz, 1H), 7.80 (td, <ce:italic>J</ce:italic> = 7.7, 1.9 Hz, 1H), 7.59 (d, <ce:italic>J</ce:italic> = 7.7 Hz, 1H), 7.55–7.47 (m, 2H), 7.35 (d, <ce:italic>J</ce:italic> = 16.3 Hz, 1H), 7.31–7.20 (m, 3H), 7.20–7.13 (m, 1H), 7.05–6.98 (m, 2H), 6.24 (t, <ce:italic>J</ce:italic> = 6.1 Hz, 1H), 5.73 (dd, <ce:italic>J</ce:italic> = 9.7, 2.6 Hz, 1H), 4.44 (d, <ce:italic>J</ce:italic> = 6.0 Hz, 2H), 3.92–3.82 (m, 1H), 3.75–3.65 (m, 1H), 2.45–2.32 (m, 1H), 2.08–1.88 (m, 2H), 1.80–1.64 (m, 1H), 1.62–1.51 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 429.2 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0885" view="all">
                           <ce:bold>(E)-<ce:italic>N</ce:italic>-(3-fluorobenzyl)-3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazol-5-amine</ce:bold> (<ce:bold>15h</ce:bold>). (yield, 55%; TLC, PE: EA = 3:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 8.58 (ddd, <ce:italic>J</ce:italic> = 4.9, 1.8, 0.9 Hz, 1H), 7.86–7.75 (m, 2H), 7.58 (dt, <ce:italic>J</ce:italic> = 7.9, 1.0 Hz, 1H), 7.55–7.46 (m, 1H), 7.38 (td, <ce:italic>J</ce:italic> = 7.9, 6.0 Hz, 1H), 7.33–7.23 (m, 4H), 7.04 (dddd, <ce:italic>J</ce:italic> = 9.1, 8.0, 2.7, 1.1 Hz, 1H), 7.00–6.94 (m, 2H), 6.34 (t, <ce:italic>J</ce:italic> = 6.1 Hz, 1H), 5.73 (dd, <ce:italic>J</ce:italic> = 9.7, 2.6 Hz, 1H), 4.42 (d, <ce:italic>J</ce:italic> = 6.0 Hz, 2H), 3.92–3.84 (m, 1H), 3.76–3.66 (m, 1H), 2.44–2.30 (m, 1H), 2.03 (d, <ce:italic>J</ce:italic> = 13.5 Hz, 1H), 1.94 (dd, <ce:italic>J</ce:italic> = 13.1, 3.0 Hz, 1H), 1.74 (s, 1H), 1.58 (h, <ce:italic>J</ce:italic> = 4.1 Hz, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 429.2 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0890" view="all">
                           <ce:bold>(E)-<ce:italic>N</ce:italic>-(4-fluorobenzyl)-3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazol-5-amine</ce:bold> (<ce:bold>15i</ce:bold>). (yield, 50%; TLC, PE: EA = 3:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 8.58 (d, <ce:italic>J</ce:italic> = 5.8 Hz, 1H), 7.86–7.75 (m, 2H), 7.58 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.51 (d, <ce:italic>J</ce:italic> = 9.3 Hz, 1H), 7.41–7.34 (m, 1H), 7.33–7.23 (m, 4H), 7.04 (td, <ce:italic>J</ce:italic> = 9.1, 3.3 Hz, 1H), 7.00–6.94 (m, 2H), 6.34 (t, <ce:italic>J</ce:italic> = 6.1 Hz, 1H), 5.73 (dd, <ce:italic>J</ce:italic> = 9.7, 2.6 Hz, 1H), 4.42 (d, <ce:italic>J</ce:italic> = 6.0 Hz, 2H), 3.92–3.84 (m, 1H), 3.76–3.66 (m, 1H), 2.44–2.30 (m, 1H), 2.08–2.00 (m, 1H), 1.97–1.90 (m, 1H), 1.81–1.66 (m, 1H), 1.64–1.52 (m, 2H).</ce:para>
                        <ce:para id="p0895" view="all">MS (ESI), <ce:italic>m/z</ce:italic>: 429.2 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0900" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-<ce:italic>N</ce:italic>-(3-chloro-5-fluorobenzyl)-3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazol-5-amine</ce:bold> (<ce:bold>15j</ce:bold>). (yield, 49%; TLC, PE: EA = 3:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 8.59 (d, <ce:italic>J</ce:italic> = 4.1 Hz, 1H), 7.85–7.76 (m, 2H), 7.59 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 7.52 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 1H), 7.41 (s, 1H), 7.33–7.23 (m, 4H), 7.01–6.93 (m, 2H), 6.41 (t, <ce:italic>J</ce:italic> = 6.3 Hz, 1H), 5.74 (dd, <ce:italic>J</ce:italic> = 9.7, 2.5 Hz, 1H), 4.44 (d, <ce:italic>J</ce:italic> = 6.2 Hz, 2H), 3.93–3.84 (m, 1H), 3.77–3.66 (m, 1H), 2.45–2.31 (m, 1H), 2.09–1.98 (m, 1H), 1.98–1.89 (m, 1H), 1.80–1.66 (m, 1H), 1.63–1.52 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 463.1 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0905" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-<ce:italic>N</ce:italic>-(3-bromo-5-fluorobenzyl)-3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazol-5-amine</ce:bold> (<ce:bold>15k</ce:bold>). (yield, 52%; TLC, PE: EA = 3:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 8.59 (d, <ce:italic>J</ce:italic> = 7.2 Hz, 1H), 7.86–7.76 (m, 2H), 7.59 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 7.55 (s, 1H), 7.52 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 1H), 7.38 (dt, <ce:italic>J</ce:italic> = 8.4, 2.2 Hz, 1H), 7.36–7.27 (m, 2H), 7.27–7.23 (m, 1H), 7.01–6.93 (m, 2H), 6.41 (t, <ce:italic>J</ce:italic> = 6.2 Hz, 1H), 5.74 (dd, <ce:italic>J</ce:italic> = 9.7, 2.5 Hz, 1H), 4.44 (d, <ce:italic>J</ce:italic> = 6.2 Hz, 2H), 3.93–3.83 (m, 1H), 3.76–3.66 (m, 1H), 2.46–2.30 (m, 1H), 2.07–1.98 (m, 1H), 1.97–1.89 (m, 1H), 1.79–1.65 (m, 1H), 1.61–1.51 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 507.1[M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0910" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-<ce:italic>N</ce:italic>-(3-fluoro-5-methylbenzyl)-3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazol-5-amine</ce:bold> (<ce:bold>15l</ce:bold>). (yield, 56%; TLC, PE: EA = 3:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 8.58 (d, <ce:italic>J</ce:italic> = 5.8 Hz, 1H), 7.84–7.77 (m, 2H), 7.59 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.51 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 1H), 7.32–7.23 (m, 2H), 7.14 (s, 1H), 7.06 (d, <ce:italic>J</ce:italic> = 10.1 Hz, 1H), 7.00–6.92 (m, 2H), 6.87 (d, <ce:italic>J</ce:italic> = 9.8 Hz, 1H), 6.31 (t, <ce:italic>J</ce:italic> = 6.0 Hz, 1H), 5.73 (dd, <ce:italic>J</ce:italic> = 9.7, 2.5 Hz, 1H), 4.36 (d, <ce:italic>J</ce:italic> = 6.0 Hz, 2H), 3.94–3.84 (m, 1H), 3.76–3.65 (m, 1H), 2.44–2.31 (m, 1H), 2.29 (s, 3H), 2.07–1.99 (m, 1H), 1.98–1.88 (m, 1H), 1.80–1.65 (m, 1H), 1.62–1.52 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 443.2 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0915" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-<ce:italic>N</ce:italic>-(3-fluoro-5-methoxybenzyl)-3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazol-5-amine</ce:bold> (<ce:bold>15m</ce:bold>). (yield, 50%; TLC, PE: EA = 3:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 8.59 (d, <ce:italic>J</ce:italic> = 4.1 Hz, 1H), 7.87–7.77 (m, 2H), 7.59 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.51 (d, <ce:italic>J</ce:italic> = 9.0 Hz, 1H), 7.33–7.22 (m, 2H), 7.02–6.91 (m, 3H), 6.87 (d, <ce:italic>J</ce:italic> = 9.6 Hz, 1H), 6.67 (dt, <ce:italic>J</ce:italic> = 11.0, 2.4 Hz, 1H), 6.36 (s, 1H), 5.73 (dd, <ce:italic>J</ce:italic> = 9.7, 2.5 Hz, 1H), 4.38 (s, 2H), 3.93–3.83 (m, 1H), 3.79–3.65 (m, 4H), 2.46–2.32 (m, 1H), 2.07–1.98 (m, 1H), 1.97–1.89 (m, 1H), 1.78–1.65 (m, 1H), 1.62–1.50 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 459.2 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0920" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-<ce:italic>N</ce:italic>-(3-fluoro-5-(trifluoromethyl)benzyl)-3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazol-5-amine (15n).</ce:bold> (yield, 55%; TLC, PE: EA = 3:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 8.58 (d, <ce:italic>J</ce:italic> = 5.9 Hz, 1H), 7.86–7.70 (m, 3H), 7.63 (d, <ce:italic>J</ce:italic> = 9.3 Hz, 1H), 7.58 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.55–7.49 (m, 2H), 7.31 (d, <ce:italic>J</ce:italic> = 16.3 Hz, 1H), 7.27–7.22 (m, 1H), 7.02–6.95 (m, 2H), 6.45 (t, <ce:italic>J</ce:italic> = 6.3 Hz, 1H), 5.74 (dd, <ce:italic>J</ce:italic> = 9.7, 2.5 Hz, 1H), 4.53 (d, <ce:italic>J</ce:italic> = 6.2 Hz, 2H), 3.92–3.82 (m, 1H), 3.77–3.64 (m, 1H), 2.45–2.31 (m, 1H), 2.09–1.88 (m, 2H), 1.80–1.63 (m, 1H), 1.63–1.51 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 497.3 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0925" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-3-fluoro-5-(((3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazol-5-yl)amino)methyl)benzonitrile</ce:bold> (<ce:bold>15o</ce:bold>). (yield, 52%; TLC, PE: EA = 3:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 8.59 (d, <ce:italic>J</ce:italic> = 5.8 Hz, 1H), 7.85–7.76 (m, 3H), 7.74–7.65 (m, 2H), 7.60 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.53 (d, <ce:italic>J</ce:italic> = 9.0 Hz, 1H), 7.32–7.23 (m, 2H), 6.98 (dd, <ce:italic>J</ce:italic> = 9.0, 2.0 Hz, 1H), 6.94 (s, 1H), 6.43 (t, <ce:italic>J</ce:italic> = 6.2 Hz, 1H), 5.74 (dd, <ce:italic>J</ce:italic> = 9.7, 2.5 Hz, 1H), 4.49 (d, <ce:italic>J</ce:italic> = 6.1 Hz, 2H), 3.92–3.83 (m, 1H), 3.76–3.66 (m, 1H), 2.44–2.31 (m, 1H), 2.08–1.99 (m, 1H), 1.97–1.89 (m, 1H), 1.81–1.65 (m, 1H), 1.63–1.52 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 454.1 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0930" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-<ce:italic>N</ce:italic>-(3,5-difluorobenzyl)-<ce:italic>N</ce:italic>-methyl-3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazol-5-amine</ce:bold> (<ce:bold>15p</ce:bold>). To a solution of <ce:bold>15e</ce:bold> (400 mg, 0.9 mmol) and CH<ce:inf loc="post">3</ce:inf>I (255 mg, 1.8 mmol) in anhydrous THF (20 mL) was added LiHMDS (1.0 M solution in THF, 2.7 mL, 2.7 mmol). The reaction mixture was stirred at 0 °C for 3 h under argon. Then quenched with saturated NH<ce:inf loc="post">4</ce:inf>Cl solution, extracted by EtOAc and washed with H<ce:inf loc="post">2</ce:inf>O followed by brine. The organic layers were dried over anhydrous Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>, filtered and evaporated. The crude material was purified by silica gel column chromatography (25–30% EtOAc in petroleum ether) to afford product <ce:bold>15p</ce:bold> as yellow oil. (272 mg; yield, 66%; TLC, PE: EA = 3:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.4) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 8.59 (d, <ce:italic>J</ce:italic> = 5.8 Hz, 1H), 7.90 (d, <ce:italic>J</ce:italic> = 16.3 Hz, 1H), 7.80 (td, <ce:italic>J</ce:italic> = 7.6, 1.9 Hz, 1H), 7.65 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.60 (d, <ce:italic>J</ce:italic> = 9.8 Hz, 1H), 7.40 (d, <ce:italic>J</ce:italic> = 16.2 Hz, 1H), 7.30–7.22 (m, 1H), 7.18–7.12 (m, 2H), 7.09 (tt, <ce:italic>J</ce:italic> = 9.3, 2.4 Hz, 1H), 7.01–6.93 (m, 2H), 5.79 (dd, <ce:italic>J</ce:italic> = 9.7, 2.5 Hz, 1H), 4.68 (s, 2H), 3.93–3.83 (m, 1H), 3.76–3.67 (m, 1H), 3.10 (s, 3H), 2.47–2.34 (m, 1H), 2.09–2.00 (m, 1H), 1.99–1.91 (m, 1H), 1.81–1.67 (m, 1H), 1.62–1.53 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 461.2 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0935" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-3,5-difluoro-<ce:italic>N</ce:italic>-(3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazol-5-yl)benzamide</ce:bold> (<ce:bold>15q</ce:bold>). To a solution of <ce:bold>15d</ce:bold> (400 mg, 1.2 mmol) and TEA (365 mg, 3.6 mmol) in anhydrous DCM (15 mL) was added 3,5-difluorobenzoyl chloride (318 mg, 1.8 mmol). The reaction mixture was stirred at 0 °C for 2 h under argon. Then extracted by DCM and washed with H<ce:inf loc="post">2</ce:inf>O followed by brine. The organic layers were dried over anhydrous Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>, filtered and evaporated. The crude material was purified by silica gel column chromatography (25–30% EtOAc in petroleum ether) to afford product <ce:bold>15q</ce:bold> as yellow solid. (402 mg; yield, 70%; TLC, PE: EA = 3:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.2) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 10.54 (s, 1H), 8.66–8.54 (m, 2H), 7.92 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.86–7.70 (m, 6H), 7.57 (tt, <ce:italic>J</ce:italic> = 9.2, 2.4 Hz, 1H), 7.51 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.34–7.25 (m, 1H), 5.89 (dd, <ce:italic>J</ce:italic> = 9.8, 2.3 Hz, 1H), 3.98–3.86 (m, 1H), 3.83–3.71 (m, 1H), 2.48–2.38 (m, 1H), 2.08–1.97 (m, 2H), 1.84–1.70 (m, 1H), 1.67–1.54 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 461.2 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0940" view="all">
                           <ce:bold>5-((tert-butyldimethylsilyl)oxy)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>16a</ce:bold>). To a solution of <ce:bold>16</ce:bold> (3 g, 22.4 mmol) and imidazole (3.1 g, 44.8 mmol) in DMF (30 mL) was added tert-butyldimethylsilyl chloride (5.1 g, 33.6 mmol). The mixture was stirred at room temperature overnight. Then extracted by EtOAc and washed with H<ce:inf loc="post">2</ce:inf>O followed by brine. The organic layers were dried over anhydrous Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>, filtered and evaporated to afford product. The crude material (<ce:bold>16a</ce:bold>) was used directly in next step without further purification. (5 g; yield, 90%; TLC, PE: EA = 10:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 12.92 (s, 1H), 7.92 (t, <ce:italic>J</ce:italic> = 1.3 Hz, 1H), 7.41 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 1H), 7.12 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 6.91 (dd, <ce:italic>J</ce:italic> = 8.8, 2.3 Hz, 1H), 0.96 (s, 9H), 0.18 (s, 6H). MS (ESI), <ce:italic>m/z</ce:italic>: 249.1[M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0945" view="all">
                           <ce:bold>5-((tert-butyldimethylsilyl)oxy)-3-iodo-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>16b</ce:bold>). <ce:bold>16b</ce:bold> was obtained according to general procedure A as white solid. (yield, 93%; TLC, PE: EA = 10:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.4) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 13.40 (s, 1H), 7.45 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 1H), 7.01 (dd, <ce:italic>J</ce:italic> = 8.9, 2.3 Hz, 1H), 6.71 (s, 1H), 0.96 (s, 9H), 0.19 (s, 6H). MS (ESI), <ce:italic>m/z</ce:italic>: 373.0 [M - H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0950" view="all">
                           <ce:bold>5-((tert-butyldimethylsilyl)oxy)-3-iodo-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>16c</ce:bold>). <ce:bold>16c</ce:bold> was obtained according to general procedure B as colorless oil. (yield, 77%; TLC, PE: EA = 20:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.5) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 7.65 (d, <ce:italic>J</ce:italic> = 9.0 Hz, 1H), 7.08 (dd, <ce:italic>J</ce:italic> = 9.0, 2.3 Hz, 1H), 6.72 (d, <ce:italic>J</ce:italic> = 2.3 Hz, 1H), 5.79 (dd, <ce:italic>J</ce:italic> = 9.8, 2.3 Hz, 1H), 3.90–3.82 (m, 1H), 3.75–3.65 (m, 1H), 2.39–2.27 (m, 1H), 2.05–1.90 (m, 2H), 1.78–1.64 (m, 1H), 1.61–1.50 (m, 2H), 0.97 (s, 9H), 0.19 (s, 6H).</ce:para>
                        <ce:para id="p0955" view="all">MS (ESI), <ce:italic>m/z</ce:italic>: 481.1 [M + Na]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0960" view="all">
                           <ce:bold>3-iodo-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazol-5-ol</ce:bold> (<ce:bold>16d</ce:bold>). To a solution of <ce:bold>16c</ce:bold> (2 g, 4.4 mmol) in THF (20 mL) was added tetrabutylammonium fluoride (1.0 M solution in THF, 22 mL, 22 mmol). The mixture was stirred at room temperature for 6 h. Then extracted by EtOAc and washed with H<ce:inf loc="post">2</ce:inf>O followed by brine. The organic layers were dried over anhydrous Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>, filtered and evaporated. The crude material was purified by silica gel column chromatography (25–30% EtOAc in petroleum ether) to afford product <ce:bold>16d</ce:bold> as white solid. (1.2 g; yield, 82%; TLC, PE: EA = 3:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.2) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 9.52 (s, 1H), 7.57 (d, <ce:italic>J</ce:italic> = 9.0 Hz, 1H), 7.02 (dd, <ce:italic>J</ce:italic> = 8.9, 2.3 Hz, 1H), 6.65 (d, <ce:italic>J</ce:italic> = 2.2 Hz, 1H), 5.74 (dd, <ce:italic>J</ce:italic> = 9.9, 2.5 Hz, 1H), 3.90–3.80 (m, 1H), 3.75–3.63 (m, 1H), 2.39–2.25 (m, 1H), 2.04–1.88 (m, 2H), 1.79–1.62 (m, 1H), 1.61–1.49 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 343.0 [M - H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0965" view="all">
                           <ce:bold>5-((3,5-difluorobenzyl)oxy)-3-iodo-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>16e</ce:bold>). To a solution of <ce:bold>16d</ce:bold> (1.2 g, 3.5 mmol) and K<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> (960 mg, 7 mmol) in DMF (20 mL) was added 3,5-bifluorobenzyl bromide (1.5 g, 7 mmol). The mixture was added at 45 °C overnight and cooled to room temperature. Then extracted by EtOAc and washed with H<ce:inf loc="post">2</ce:inf>O followed by brine. The organic layers were dried over anhydrous Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>, filtered and evaporated. The crude material was purified by silica gel column chromatography (5–10% EtOAc in petroleum ether) to afford product <ce:bold>16e</ce:bold> as white solid. (1.4 g; yield, 88%; TLC, PE: EA = 20:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 7.70 (d, <ce:italic>J</ce:italic> = 9.1 Hz, 1H), 7.31–7.16 (m, 4H), 6.89 (d, <ce:italic>J</ce:italic> = 2.3 Hz, 1H), 5.80 (dd, <ce:italic>J</ce:italic> = 9.8, 2.3 Hz, 1H), 5.22 (s, 2H), 3.90–3.82 (m, 1H), 3.75–3.66 (m, 1H), 2.40–2.27 (m, 1H), 2.05–1.90 (m, 2H), 1.78–1.64 (m, 1H), 1.60–1.50 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 493.0 [M + Na]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0970" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-5-((3,5-difluorobenzyl)oxy)-3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>16f</ce:bold>). <ce:bold>16f</ce:bold> was obtained according to general procedure C as white solid. (yield, 51%; TLC, PE: EA = 5:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 8.61 (d, <ce:italic>J</ce:italic> = 5.9 Hz, 1H), 7.93 (d, <ce:italic>J</ce:italic> = 16.3 Hz, 1H), 7.82 (td, <ce:italic>J</ce:italic> = 7.6, 1.8 Hz, 1H), 7.75–7.64 (m, 3H), 7.52 (d, <ce:italic>J</ce:italic> = 16.3 Hz, 1H), 7.31–7.17 (m, 5H), 5.85 (dd, <ce:italic>J</ce:italic> = 9.7, 2.5 Hz, 1H), 5.29 (s, 2H), 3.94–3.86 (m, 1H), 3.80–3.69 (m, 1H), 2.47–2.34 (m, 1H), 2.09–1.95 (m, 2H), 1.81–1.69 (m, 1H), 1.66–1.54 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 448.1 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0975" view="all">
                           <ce:bold>17a</ce:bold>-<ce:bold>17c</ce:bold> were obtained following the synthetic procedures of <ce:bold>16a-16c</ce:bold>.</ce:para>
                        <ce:para id="p0980" view="all">
                           <ce:bold>5-(((tert-butyldimethylsilyl)oxy)methyl)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>17a</ce:bold>). (yield, 82%; TLC, PE: EA = 10:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 13.06 (s, 1H), 8.03 (s, 1H), 7.65 (s, 1H), 7.50 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 1H), 7.28 (dd, <ce:italic>J</ce:italic> = 8.6, 1.5 Hz, 1H), 4.77 (s, 2H), 0.89 (s, 9H), 0.07 (s, 6H). MS (ESI), <ce:italic>m/z</ce:italic>: 285.1 [M + Na]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0985" view="all">
                           <ce:bold>5-(((tert-butyldimethylsilyl)oxy)methyl)-3-iodo-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>17b</ce:bold>). (yield, 85%; TLC, PE: EA = 10:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.4) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, Chloroform-<ce:italic>d</ce:italic>) δ 11.62 (s, 1H), 7.56 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H), 7.44 (d, <ce:italic>J</ce:italic> = 9.0 Hz, 2H), 4.86 (s, 2H), 0.97 (s, 9H), 0.13 (s, 6H). MS (ESI), <ce:italic>m/z</ce:italic>: 387.0 [M - H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0990" view="all">
                           <ce:bold>5-(((tert-butyldimethylsilyl)oxy)methyl)-3-iodo-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>17c</ce:bold>). (yield, 63%; TLC, PE: EA = 20:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 7.71 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 7.42 (dd, <ce:italic>J</ce:italic> = 8.8, 1.5 Hz, 1H), 7.37 (s, 1H), 5.83 (dd, <ce:italic>J</ce:italic> = 9.8, 2.3 Hz, 1H), 4.82 (s, 2H), 3.91–3.82 (m, 1H), 3.75–3.65 (m, 1H), 2.43–2.29 (m, 1H), 2.06–1.93 (m, 2H), 1.78–1.66 (m, 1H), 1.60–1.52 (m, 2H), 0.91 (s, 9H), 0.08 (s, 6H). MS (ESI), <ce:italic>m/z</ce:italic>: 495.0 [M + Na]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p0995" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-5-(((tert-butyldimethylsilyl)oxy)methyl)-3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>17d</ce:bold>). <ce:bold>17d</ce:bold> was obtained according to general procedure C as white solid. (yield, 51%; TLC, PE: EA = 5:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 8.61 (d, <ce:italic>J</ce:italic> = 3.9 Hz, 1H), 8.08 (s, 1H), 7.93 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.82 (td, <ce:italic>J</ce:italic> = 7.6, 1.8 Hz, 1H), 7.74 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 7.65 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.55 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.43 (dd, <ce:italic>J</ce:italic> = 8.7, 1.4 Hz, 1H), 7.32–7.24 (m, 1H), 5.86 (dd, <ce:italic>J</ce:italic> = 9.7, 2.5 Hz, 1H), 4.87 (s, 2H), 3.95–3.85 (m, 1H), 3.80–3.68 (m, 1H), 2.49–2.36 (m, 1H), 2.10–1.94 (m, 2H), 1.82–1.68 (m, 1H), 1.63–1.54 (m, 2H), 0.92 (s, 9H), 0.10 (s, 6H). MS (ESI), <ce:italic>m/z</ce:italic>: 450.3 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p1000" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-(3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazol-5-yl)methanol</ce:bold> (<ce:bold>17e</ce:bold>). <ce:bold>17e</ce:bold> was obtained following the synthetic procedures of <ce:bold>16d</ce:bold>. (yield, 73%; TLC, PE: EA = 3:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.2) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 8.61 (d, <ce:italic>J</ce:italic> = 4.0 Hz, 1H), 8.09 (s, 1H), 7.93 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.82 (td, <ce:italic>J</ce:italic> = 7.6, 1.9 Hz, 1H), 7.74 (d, <ce:italic>J</ce:italic> = 3.5 Hz, 1H), 7.72 (d, <ce:italic>J</ce:italic> = 2.5 Hz, 1H), 7.57 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.45 (dd, <ce:italic>J</ce:italic> = 8.7, 1.5 Hz, 1H), 7.32–7.25 (m, 1H), 5.88 (dd, <ce:italic>J</ce:italic> = 9.7, 2.5 Hz, 1H), 5.27 (t, <ce:italic>J</ce:italic> = 5.7 Hz, 1H), 4.66 (d, <ce:italic>J</ce:italic> = 5.0 Hz, 2H), 3.96–3.85 (m, 1H), 3.81–3.70 (m, 1H), 2.48–2.37 (m, 1H), 2.12–1.94 (m, 2H), 1.85–1.69 (m, 1H), 1.65–1.54 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 336.1 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p1005" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-5-((3,5-difluorophenoxy)methyl)-3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>17f</ce:bold>). To a solution of <ce:bold>17e</ce:bold> (1 g, 3 mmol), 3,5-difluorophenol (585 mg, 4.5 mmol) and PPh<ce:inf loc="post">3</ce:inf> (866 mg, 3.3 mmol) in anhydrous THF (15 mL) was added DIAD (668 mg, 3.3 mmol). The mixture was added at 0 °C for 3 h under argon. Then extracted by EtOAc and washed with H<ce:inf loc="post">2</ce:inf>O followed by brine. The organic layers were dried over anhydrous Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>, filtered and evaporated. The crude material was purified by silica gel column chromatography (25–30% EtOAc in petroleum ether) to afford product <ce:bold>17f</ce:bold> as colorless oil. (1.2 g; yield, 82%; TLC, PE: EA = 3:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.2) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 8.62 (d, <ce:italic>J</ce:italic> = 3.1 Hz, 1H), 8.33 (s, 1H), 7.95 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.86–7.77 (m, 2H), 7.70 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 7.65–7.54 (m, 2H), 7.32–7.26 (m, 1H), 6.87 (dd, <ce:italic>J</ce:italic> = 9.4, 2.2 Hz, 2H), 6.84–6.74 (m, 1H), 5.90 (dd, <ce:italic>J</ce:italic> = 9.7, 2.4 Hz, 1H), 5.28 (s, 2H), 3.95–3.86 (m, 1H), 3.82–3.69 (m, 1H), 2.49–2.38 (m, 1H), 2.09–1.98 (m, 2H), 1.84–1.69 (m, 1H), 1.66–1.52 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 448.1 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p1010" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazole-5-carbaldehyde</ce:bold> (<ce:bold>17g</ce:bold>). To a solution of <ce:bold>17e</ce:bold> (1 g, 3 mmol) in DCM (20 mL) was added Dess-Martin periodinane(1.9 g, 4.5 mmol). The mixture was added at room temperature for 2 h. Then extracted by DCM and washed with H<ce:inf loc="post">2</ce:inf>O followed by brine. The organic layers were dried over anhydrous Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>, filtered and evaporated. The crude material was purified by silica gel column chromatography (20–25% EtOAc in petroleum ether) to afford product <ce:bold>17g</ce:bold> as white solid. (620 mg; yield, 62%; TLC, PE: EA = 3:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.4) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 10.13 (s, 1H), 8.89 (s, 1H), 8.64 (d, <ce:italic>J</ce:italic> = 3.9 Hz, 1H), 8.00 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.95 (s, 2H), 7.85 (td, <ce:italic>J</ce:italic> = 7.6, 1.8 Hz, 1H), 7.78–7.69 (m, 2H), 7.35–7.30 (m, 1H), 5.98 (dd, <ce:italic>J</ce:italic> = 9.7, 2.4 Hz, 1H), 3.97–3.86 (m, 1H), 3.83–3.73 (m, 1H), 2.48–2.36 (m, 1H), 2.11–1.99 (m, 2H), 1.84–1.71 (m, 1H), 1.68–1.57 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 334.1[M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p1015" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-3,5-difluoro-<ce:italic>N</ce:italic>-((3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazol-5-yl)methyl)aniline</ce:bold> (<ce:bold>17h</ce:bold>). To a solution of <ce:bold>17g</ce:bold> (300 mg, 0.9 mmol), catalytic CH<ce:inf loc="post">3</ce:inf>COOH, 3,5-difluoroaniline (130 mg, 1 mmol) in THF (10 mL) was added NaBH(OAc)<ce:inf loc="post">3</ce:inf> (573 mg, 2.7 mmol). The mixture was stirred at 60 °C for 2 h and cooled to room temperature. Then extracted by EtOAc and washed with H<ce:inf loc="post">2</ce:inf>O followed by brine. The organic layers were dried over anhydrous Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>, filtered and evaporated. The crude material was purified by silica gel column chromatography (25–30% EtOAc in petroleum ether) to afford product <ce:bold>17h</ce:bold> as white solid. (190 mg; yield, 47%; TLC, PE: EA = 3:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.2) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 8.62 (d, <ce:italic>J</ce:italic> = 3.1 Hz, 1H), 8.18 (s, 1H), 7.92 (d, <ce:italic>J</ce:italic> = 16.3 Hz, 1H), 7.83 (td, <ce:italic>J</ce:italic> = 7.6, 1.9 Hz, 1H), 7.75 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 7.68 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 7.57 (d, <ce:italic>J</ce:italic> = 16.3 Hz, 1H), 7.48 (d, <ce:italic>J</ce:italic> = 7.2 Hz, 1H), 7.34–7.25 (m, 1H), 6.95 (t, <ce:italic>J</ce:italic> = 5.9 Hz, 1H), 6.30 (dd, <ce:italic>J</ce:italic> = 10.8, 2.3 Hz, 2H), 6.25–6.15 (m, 1H), 5.87 (dd, <ce:italic>J</ce:italic> = 9.7, 2.5 Hz, 1H), 4.43 (d, <ce:italic>J</ce:italic> = 5.7 Hz, 2H), 3.95–3.84 (m, 1H), 3.82–3.69 (m, 1H), 2.47–2.37 (m, 1H), 2.08–1.94 (m, 2H), 1.83–1.69 (m, 1H), 1.64–1.53 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 447.2 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p1020" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-3,5-difluoro-<ce:italic>N</ce:italic>-methyl-<ce:italic>N</ce:italic>-((3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazol-5-yl)methyl)aniline</ce:bold> (<ce:bold>17i</ce:bold>). <ce:bold>17i</ce:bold> was obtained following the synthetic procedures of <ce:bold>15p</ce:bold>. (yield, 67%; TLC, PE: EA = 3:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 8.61 (d, <ce:italic>J</ce:italic> = 5.8 Hz, 1H), 8.02 (s, 1H), 7.90 (d, <ce:italic>J</ce:italic> = 16.3 Hz, 1H), 7.82 (td, <ce:italic>J</ce:italic> = 7.7, 1.8 Hz, 1H), 7.73 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 7.65 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.52 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.33–7.27 (m, 2H), 6.50–6.41 (m, 2H), 6.36–6.27 (m, 1H), 5.86 (dd, <ce:italic>J</ce:italic> = 9.7, 2.5 Hz, 1H), 4.75 (s, 2H), 3.93–3.85 (m, 1H), 3.80–3.69 (m, 1H), 3.07 (s, 3H), 2.48–2.35 (m, 1H), 2.09–1.94 (m, 2H), 1.82–1.67 (m, 1H), 1.63–1.53 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 461.2 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p1025" view="all">
                           <ce:bold>18b-18c</ce:bold> were obtained following the synthetic procedures of <ce:bold>16b-16c</ce:bold>.</ce:para>
                        <ce:para id="p1030" view="all">
                           <ce:bold>3-iodo-1<ce:italic>H</ce:italic>-indazole-5-carboxylic acid methyl ester</ce:bold> (<ce:bold>18b</ce:bold>). (yield, 86%; TLC, PE: EA = 5:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.4) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 13.85 (s, 1H), 8.06 (s, 1H), 7.98 (dd, <ce:italic>J</ce:italic> = 8.8, 1.6 Hz, 1H), 7.65 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 1H), 3.88 (s, 3H).</ce:para>
                        <ce:para id="p1035" view="all">
                           <ce:bold>3-iodo-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazole-5-carboxylic acid methyl ester</ce:bold> (<ce:bold>18c</ce:bold>). (yield, 70%; TLC, PE: EA = 20:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.4) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 8.07–8.00 (m, 2H), 7.86 (d, <ce:italic>J</ce:italic> = 9.3 Hz, 1H), 5.90 (dd, <ce:italic>J</ce:italic> = 9.7, 2.4 Hz, 1H), 3.95–3.84 (m, 4H), 3.79–3.67 (m, 1H), 2.42–2.27 (m, 1H), 2.08–1.93 (m, 2H), 1.82–1.64 (m, 1H), 1.64–1.49 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 387.0 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p1040" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazole-5-carboxylic acid methyl ester</ce:bold> (<ce:bold>18d</ce:bold>). <ce:bold>18d</ce:bold> was obtained according to general procedure C as white solid. (yield, 51%; TLC, PE: EA = 5:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 8.77 (s, 1H), 8.62 (d, <ce:italic>J</ce:italic> = 4.8 Hz, 1H), 8.08–7.95 (m, 2H), 7.93–7.78 (m, 3H), 7.61 (d, <ce:italic>J</ce:italic> = 16.3 Hz, 1H), 7.36–7.28 (m, 1H), 5.96 (d, <ce:italic>J</ce:italic> = 9.5 Hz, 1H), 3.98–3.86 (m, 4H), 3.84–3.72 (m, 1H), 2.47–2.36 (m, 1H), 2.08–1.96 (m, 2H), 1.84–1.69 (m, 1H), 1.67–1.54 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 364.1[M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p1045" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazole-5-carboxylic acid</ce:bold> (<ce:bold>18e</ce:bold>). To a solution of <ce:bold>18d</ce:bold> (1 g, 2.8 mmol) in ethanol (20 mL) and H<ce:inf loc="post">2</ce:inf>O (5 ml) was added NaOH (336 mg, 8.4 mmol). The mixture was added at 60 °C for 4 h and cooled to room temperature. Then concentrated, and the residue was diluted with water. The solution was acidified to pH 6–7 with 1 N aqueous HCl. The precipitate was filtrated and dried to afford <ce:bold>18e</ce:bold> as a yellow solid. (740 mg; yield, 77%; TLC, PE: EA = 1:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.4) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 13.01 (s, 1H), 8.74 (s, 1H), 8.62 (d, <ce:italic>J</ce:italic> = 4.8 Hz, 1H), 8.08–7.94 (m, 2H), 7.89–7.78 (m, 3H), 7.60 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.36–7.25 (m, 1H), 5.95 (d, <ce:italic>J</ce:italic> = 10.7 Hz, 1H), 3.97–3.87 (m, 1H), 3.83–3.72 (m, 1H), 2.48–2.34 (m, 1H), 2.11–1.97 (m, 2H), 1.84–1.70 (m, 1H), 1.67–1.52 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 350.1 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p1050" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-<ce:italic>N</ce:italic>-(3,5-difluorophenyl)-3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazole-5-carboxamide</ce:bold> (<ce:bold>18f</ce:bold>). To a solution of <ce:bold>18e</ce:bold> (500 mg, 1.4 mmol), HATU (800 mg, 2.1 mmol), DIPEA (362 mg, 2.8 mmol) in DCM (10 mL) was added 3,5-difluoroaniline (271 mg, 2.1 mmol). The mixture was stirred at room temperature overnight. Then extracted by DCM and washed with H<ce:inf loc="post">2</ce:inf>O followed by brine. The organic layers were dried over anhydrous Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>, filtered and evaporated. The crude material was purified by silica gel column chromatography (25–30% EtOAc in petroleum ether) to afford product <ce:bold>18f</ce:bold> as white solid. (430 mg; yield, 65%; TLC, PE: EA = 3:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.2) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 10.71 (s, 1H), 8.82 (s, 1H), 8.64 (d, <ce:italic>J</ce:italic> = 3.2 Hz, 1H), 8.08–7.98 (m, 2H), 7.91 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H), 7.85 (td, <ce:italic>J</ce:italic> = 7.6, 1.8 Hz, 1H), 7.76–7.67 (m, 2H), 7.66–7.56 (m, 2H), 7.35–7.28 (m, 1H), 7.02–6.93 (m, 1H), 5.97 (dd, <ce:italic>J</ce:italic> = 9.5, 2.3 Hz, 1H), 3.97–3.89 (m, 1H), 3.86–3.72 (m, 1H), 2.47–2.37 (m, 1H), 2.14–1.97 (m, 2H), 1.85–1.70 (m, 1H), 1.69–1.54 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 461.2 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p1055" view="all">
                           <ce:bold>5-bromo-3-iodo-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>19a</ce:bold>). <ce:bold>19a</ce:bold> was obtained according to general procedure A as white solid. (yield, 90%; TLC, PE: EA = 5:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 13.69 (s, 1H), 7.61–7.60 (m, 1H), 7.55–7.53 (m, 2H).</ce:para>
                        <ce:para id="p1060" view="all">
                           <ce:bold>5-bromo-3-iodo-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>19b</ce:bold>). <ce:bold>19b</ce:bold> was obtained according to general procedure B as white solid. (yield, 77%; TLC, PE: EA = 20:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.4) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 7.75 (d, <ce:italic>J</ce:italic> = 9.3 Hz, 1H), 7.65–7.60 (m, 2H), 5.86 (dd, <ce:italic>J</ce:italic> = 9.7, 2.4 Hz, 1H), 3.90–3.81 (m, 1H), 3.78–3.67 (m, 1H), 2.40–2.27 (m, 1H), 2.05–1.92 (m, 2H), 1.78–1.65 (m, 1H), 1.61–1.52 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 406.9 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p1065" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-5-bromo-3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>19c</ce:bold>). <ce:bold>19c</ce:bold> was obtained according to general procedure C. (yield, 56%; TLC, PE: EA = 5:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 8.61 (d, <ce:italic>J</ce:italic> = 4.1 Hz, 1H), 8.46 (d, <ce:italic>J</ce:italic> = 1.8 Hz, 1H), 7.93 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.83 (td, <ce:italic>J</ce:italic> = 7.6, 1.8 Hz, 1H), 7.78 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 1H), 7.74 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 1H), 7.64–7.57 (m, 2H), 7.32–7.26 (m, 1H), 5.91 (dd, <ce:italic>J</ce:italic> = 9.6, 2.4 Hz, 1H), 3.94–3.85 (m, 1H), 3.80–3.72 (m, 1H), 2.47–2.35 (m, 1H), 2.10–1.96 (m, 2H), 1.82–1.68 (m, 1H), 1.64–1.54 (m, 2H). MS (ESI), <ce:italic>m/z</ce:italic>: 384.1 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p1070" view="all">
                           <ce:bold>
                              <ce:italic>N</ce:italic>-((<ce:italic>S</ce:italic>)-1-(3,5-difluorophenyl)ethyl)-3-((<ce:italic>E</ce:italic>)-2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazol-5-amine</ce:bold> (<ce:bold>19d</ce:bold>). To a solution of <ce:bold>19c</ce:bold> (500 mg, 1.3 mmol), (<ce:italic>S</ce:italic>)-1-(3,5-difluorophenyl) ethan-1-amine hydrochloride (387 mg, 2.0 mmol), sodium tert-butoxide (375 mg, 3.9 mmol) in toluene (20 mL) was added Pd<ce:inf loc="post">2</ce:inf>(dba)<ce:inf loc="post">3</ce:inf> (60 mg, 0.065 mmol) and BINAP (81 mg, 0.13 mmol). The reaction mixture was stirring at 110 °C overnight under argon then cooled to room temperature and concentrated in vacuo. Then extracted by EtOAc and washed with H<ce:inf loc="post">2</ce:inf>O followed by brine. The organic layers were dried over anhydrous Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>, filtered and evaporated. The crude material was purified by silica gel column chromatography (30–40% EtOAc in petroleum ether) to afford <ce:bold>19d</ce:bold> as yellow solid. (264 mg; yield, 44%; TLC, PE: EA = 1:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.5) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 8.59 (d, <ce:italic>J</ce:italic> = 6.7 Hz, 1H), 7.83–7.75 (m, 2H), 7.55 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.49 (d, <ce:italic>J</ce:italic> = 9.0 Hz, 1H), 7.28–7.18 (m, 4H), 7.03–6.94 (m, 2H), 6.86 (d, <ce:italic>J</ce:italic> = 2.0 Hz, 1H), 6.30 (d, <ce:italic>J</ce:italic> = 7.3 Hz, 1H), 5.71 (dt, <ce:italic>J</ce:italic> = 9.8, 2.7 Hz, 1H), 4.78–4.65 (m, 1H), 3.93–3.81 (m, 1H), 3.75–3.62 (m, 1H), 2.41–2.28 (m, 1H), 2.05–1.98 (m, 1H), 1.95–1.87 (m, 1H), 1.77–1.65 (m, 1H), 1.60–1.52 (m, 2H), 1.47 (d, <ce:italic>J</ce:italic> = 6.7 Hz, 3H). MS (ESI), <ce:italic>m/z</ce:italic>: 461.3 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p1075" view="all">
                           <ce:bold>
                              <ce:italic>N</ce:italic>-((<ce:italic>R</ce:italic>)-1-(3,5-difluorophenyl)ethyl)-3-((<ce:italic>E</ce:italic>)-2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2<ce:italic>H</ce:italic>-pyran-2-yl)-1<ce:italic>H</ce:italic>-indazol-5-amine</ce:bold> (<ce:bold>19e</ce:bold>). <ce:bold>19e</ce:bold> were obtained following the synthetic procedures of <ce:bold>19d</ce:bold>. (yield, 47%; TLC, PE: EA = 1:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.5) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 8.59 (d, <ce:italic>J</ce:italic> = 5.8 Hz, 1H), 7.84–7.74 (m, 2H), 7.55 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 1H), 7.49 (d, <ce:italic>J</ce:italic> = 8.9 Hz, 1H), 7.28–7.17 (m, 4H), 7.03–6.93 (m, 2H), 6.85 (d, <ce:italic>J</ce:italic> = 2.0 Hz, 1H), 6.30 (d, <ce:italic>J</ce:italic> = 7.3 Hz, 1H), 5.71 (dt, <ce:italic>J</ce:italic> = 9.7, 2.6 Hz, 1H), 4.77–4.67 (m, 1H), 3.91–3.82 (m, 1H), 3.75–3.64 (m, 1H), 2.43–2.27 (m, 1H), 2.06–1.96 (m, 1H), 1.96–1.86 (m, 1H), 1.78–1.65 (m, 1H), 1.62–1.52 (m, 2H), 1.49–1.42 (m, 3H). MS (ESI), <ce:italic>m/z</ce:italic>: 461.3 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p1080" view="all">
                           <ce:bold>5-bromo-3-iodo-1-((2-(trimethylsilyl)ethoxy)methyl)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>20a</ce:bold>). To a solution of <ce:bold>19a</ce:bold> (5 g, 15.5 mmol), KOH (1.74 g, 31 mmol) and TBAB (516 mg, 1.6 mmol) in DCM (50 mL) and H<ce:inf loc="post">2</ce:inf>O (50 mL) was added SEM-Cl (3.08 g, 23.3 mmol) dropwise. The reaction mixture was stirring at 0 °C overnight. Then extracted by DCM and washed with H<ce:inf loc="post">2</ce:inf>O followed by brine. The organic layers were dried over anhydrous Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>, filtered and evaporated. The crude material was purified by silica gel column chromatography (5% EtOAc in petroleum ether) to afford <ce:bold>20a</ce:bold> as colorless oil. (4.56 g; yield, 65%; TLC, PE: EA = 20:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 7.82–7.75 (m, 1H), 7.69–7.62 (m, 2H), 5.75 (s, 2H), 3.53–3.46 (m, 2H), 0.80–0.74 (m, 2H), −0.13 (s, 9H). MS (ESI), <ce:italic>m/z</ce:italic>: 453.0 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p1085" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-5-bromo-3-(2-(pyridin-2-yl)vinyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<ce:italic>H</ce:italic>-indazole</ce:bold> (<ce:bold>20b</ce:bold>). <ce:bold>20b</ce:bold> was obtained according to general procedure C as white solid. (yield, 50%; TLC, PE: EA = 7:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 8.61 (d, <ce:italic>J</ce:italic> = 3.8 Hz, 1H), 8.49 (d, <ce:italic>J</ce:italic> = 1.3 Hz, 1H), 7.93 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.82 (td, <ce:italic>J</ce:italic> = 7.6, 1.8 Hz, 1H), 7.78 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 1H), 7.74 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.67–7.59 (m, 2H), 7.33–7.25 (m, 1H), 5.79 (s, 2H), 3.58–3.51 (m, 2H), 0.85–0.75 (m, 2H), −0.12 (s, 9H). MS (ESI), <ce:italic>m/z</ce:italic>: 452.0 [M + Na]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p1090" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-<ce:italic>N</ce:italic>-(3,5-difluorophenyl)-3-(2-(pyridin-2-yl)vinyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<ce:italic>H</ce:italic>-indazol-5-amine</ce:bold> (<ce:bold>20c</ce:bold>). To a solution of <ce:bold>20b</ce:bold> (500 mg, 1.2 mmol), 3,5-difluoroaniline (232 mg, 1.8 mmol) and Cs<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> (782 mg, 2.4 mmol) in 1,4-dioxane (20 mL) was added Pd<ce:inf loc="post">2</ce:inf>(dba)<ce:inf loc="post">3</ce:inf> (55 mg, 0.06 mmol) and Xantphos (69 mg, 0.12 mmol). The reaction mixture was stirring at 105 °C overnight under argon then cooled to room temperature and concentrated in vacuo. Then extracted by EtOAc and washed with H<ce:inf loc="post">2</ce:inf>O followed by brine. The organic layers were dried over anhydrous Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>, filtered and evaporated. The crude material was purified by silica gel column chromatography (25–30% EtOAc in petroleum ether) to afford <ce:bold>20c</ce:bold> as yellow solid. (300 mg; yield, 54%; TLC, PE: EA = 3:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.3) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 8.71 (s, 1H), 8.60 (d, <ce:italic>J</ce:italic> = 5.1 Hz, 1H), 7.98–7.86 (m, 2H), 7.85–7.73 (m, 2H), 7.69 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.52 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.35 (dd, <ce:italic>J</ce:italic> = 8.9, 2.0 Hz, 1H), 7.31–7.22 (m, 1H), 6.61–6.42 (m, 3H), 5.77 (s, 2H), 3.62–3.51 (m, 2H), 0.88–0.76 (m, 2H), −0.10 (s, 9H). MS (ESI), <ce:italic>m/z</ce:italic>: 479.2 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                        <ce:para id="p1095" view="all">
                           <ce:bold>(<ce:italic>E</ce:italic>)-<ce:italic>N</ce:italic>-(3,5-difluorophenyl)-<ce:italic>N</ce:italic>-methyl-3-(2-(pyridin-2-yl)vinyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1<ce:italic>H</ce:italic>-indazol-5-amine</ce:bold> (<ce:bold>20d</ce:bold>). <ce:bold>20d</ce:bold> was obtained following the synthetic procedures of <ce:bold>15p</ce:bold>. (yield, 73%; TLC, PE: EA = 3:1; <ce:italic>R</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>f</ce:italic>
                           </ce:inf> ∼ 0.4) <ce:sup loc="post">1</ce:sup>H NMR (400 MHz, DMSO‑<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) δ 8.60 (d, <ce:italic>J</ce:italic> = 5.8 Hz, 1H), 8.14 (d, <ce:italic>J</ce:italic> = 1.5 Hz, 1H), 7.94 (d, <ce:italic>J</ce:italic> = 16.4 Hz, 1H), 7.86 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 1H), 7.80 (td, <ce:italic>J</ce:italic> = 7.6, 1.8 Hz, 1H), 7.70 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H), 7.60 (d, <ce:italic>J</ce:italic> = 16.3 Hz, 1H), 7.37 (dd, <ce:italic>J</ce:italic> = 8.9, 1.9 Hz, 1H), 7.31–7.24 (m, 1H), 6.49–6.40 (m, 1H), 6.31–6.20 (m, 2H), 5.81 (s, 2H), 3.62–3.51 (m, 2H), 3.36 (s, 3H), 0.93–0.69 (m, 2H), −0.12 (s, 9H). MS (ESI), <ce:italic>m/z</ce:italic>: 493.2 [M + H]<ce:sup loc="post">+</ce:sup>.</ce:para>
                     </ce:section>
                  </ce:section>
                  <ce:section id="sec6.2" view="all">
                     <ce:label>6.2</ce:label>
                     <ce:section-title id="sectitle0090">
                        <ce:italic>In vitro</ce:italic> enzymatic activity assay</ce:section-title>
                     <ce:para id="p1100" view="all">TrkA/B/C and the Z′-Lyte Kinase Assay Kit were purchased from Invitrogen. The assays were performed according to the manufacturer’s instructions. The concentrations of kinases were determined by optimization experiments and the concentrations used were 1.22 ng/μL, 0.056 ng/μL and 1.73 ng/μL. First, the solutions of the compounds were diluted from 10 to 10 M to 1x10-4 M in DMSO and a 400 μM compound solution was prepared (4 μL compound dissolved in 96 μL water). Second, a 100 μM ATP solution in 1.33 × kinase buffer was prepared. Third, a kinase/peptide mixture containing 2 × kinase and 4 μM Tyr1 peptide (PV3190; Invitrogen) was prepared immediately before use. A kinase/peptide mixture was prepared by diluting Z′-LYTE Tyr1 peptide (PV3190; Invitrogen) and kinase in 1 × Kinase Buffer, and an 0.2 μM Tyr1 phosphopeptide solution was made by adding Z′-LYTE Tyr1 phospho-peptide to 1 × Kinase Buffer. The final 10 μL reaction solution consists of 12.2 ng TrkA/0.56 ng TrkB/17.3 ng TrkC, 2 μM Tyr1 peptide in 1 × kinase buffer. For each assay, 10 μL kinase reactions, including 2.5 μL compound solution, 5 μL Kinase/Peptide Mixture, and 2.5 μL ATP solution were made at first. The plate wells were mixed thoroughly and incubated for 1 h at room temperature. Then 5 μL development solution was added to each well and the plate was incubated for 1 h at room temperature; the phosphopeptides were cleaved at this time. Finally, 5 μL of stop reagent was added to stop the reaction. For the control setting, 5 μL phosphopeptide solution instead of the kinase/peptide mixture was used as a 100% phosphorylation control. 2.5 μL 1.33 × kinase buffer instead of ATP solution was used as a 100% inhibition control, and 2.5 μL 4% DMSO instead of compound solution was used as the 0% inhibitor control. The plate was measured on an EnVision Multilabel Reader (PerkinElmer). Curve fitting and data presentation was performed using GraphPad Prism, version 5.0. Every experiment was repeated at least 2 times.</ce:para>
                  </ce:section>
                  <ce:section id="sec6.3" view="all">
                     <ce:label>6.3</ce:label>
                     <ce:section-title id="sectitle0095">Construction of BaF3 model and cell culture</ce:section-title>
                     <ce:para id="p1105" view="all">The murine BaF3 cells were purchased from DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen). The BaF3 cell lines stably expressing natively fused TRKA/B/C or various on-target point mutants were self-established by following procedures as previously described [<ce:cross-ref id="crosref0370" refid="bib44">44</ce:cross-ref>]. Briefly, wild-type NTRK-fusion genes including CD74-NTRK1, ETV6-NTRK2 and ETV6-NTRK3 were totally synthesized and cloned into pCDNA3.1(+) vectors (Invitrogen, Carlsbad, CA). Point mutations were introduced to wild-type constructs using the QuickChange XL Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA). The pcDNA3.1 plasmids containing different NTRK-fusion gene were introduced into Ba/F3 cells by electroporation (Amaxa Nucleofector II device) using the “Amaxa Cell Line Nucleofector Kit V” (VCA-1003) according to the manufacturer’s protocols. Stable strains were established by post-transfection selection of cells for 2 weeks with 800 μg/mL G418 (Merck, Whitehouse Station, NJ) and further selection with the withdrawal of interleukin-3 (IL-3, R&D) for 2 weeks. All of BaF3 stable cell lines were verified by DNA sequencing, protein expression and anti-proliferation against positive drugs.</ce:para>
                     <ce:para id="p1110" view="all">Parental Ba/F3 cells were cultured in RPMI 1640 media supplemented with 10% fetal bovine serum (FBS) and 10 ng/mL IL-3, while all NTRK fusion-transformed BaF3 stable cell lines were cultured in the same medium without IL-3.</ce:para>
                  </ce:section>
                  <ce:section id="sec6.4" view="all">
                     <ce:label>6.4</ce:label>
                     <ce:section-title id="sectitle0100">Anti-proliferation activity <ce:italic>in vitro</ce:italic>
                     </ce:section-title>
                     <ce:para id="p1115" view="all">Cells in the logarithmic phase were seeded in 96-well plates (5000∼10,000 cells/well). Twenty-four hours after seeding, cells were treated with serial dilutions of test compounds in medium at a final concentration of 0.1% DMSO and incubated for additional 72 h. At the end of treatment, cell counting kit-8 (CCK8, CK04, Dojindo Laboratories, Kumamoto, Japan) was added into the 96-well plates (10 μL/well) and incubated with the cells for 1–3 h. OD450 and OD650 were determined by a microplate reader. Absorbance value (A) for each well was calculated as OD450 – OD650. The cell viability rate for each well was calculated as V% = (As–Ac)/(Ab – Ac) × 100%. The data were the mean values from at least three independent experiments. IC<ce:inf loc="post">50</ce:inf> values were calculated by log(inhibitor) vs. response—Variable slope (four parameters) using GraphPad Prism 8.0 software (Graphpad Software, Inc.). As is the absorbance value of the test compound well, Ac is the absorbance value of the well with neither cells nor test compounds, and Ab is the absorbance value of the well with cells and vehicle control.</ce:para>
                  </ce:section>
                  <ce:section id="sec6.5" view="all">
                     <ce:label>6.5</ce:label>
                     <ce:section-title id="sectitle0105">Western blot analysis</ce:section-title>
                     <ce:para id="p1120" view="all">Cells were treated with various concentrations of each tested compound for a designated time. Cells were lysed in using 1 × SDS sample lysis buffer (CST recommended) with protease and phosphatase inhibitors. Cell lysates were loaded and electrophoresed onto 8–12% SDS-PAGE gel, and the separated proteins were transferred to a PVDF film. The film was blocked with 5% fat-free milk in TBS solution containing 0.5% Tween-20 for 4 h at room temperature, then incubated with the corresponding primary antibody (1:1000–1:200) overnight at 4 °C. After washing with TBST, HRP-conjugated secondary antibody was incubated for 2 h. Primary antibodies against Trk(pan) (92991), PLCγ1(5690), Erk1/2(4695), Akt (4685), phospho-TrkA/TrkB (4621), phospho-Erk1/2 (4370), phospho-Akt(9271), phospho-PLCγ1 (14008), GAPDH (2118) and anti-rabbit or anti-mouse IgG horseradish peroxidase (HRP)-linked secondary antibodies were purchased from Cell Signaling Technology (Boston, MA, USA). Primary antibody against phospho-TrkA/TrkB/TrkC (ab197071) was purchased from Abcam. The protein signals were visualized by ECL Western Blotting Detection Kit (Thermo Scientific, Waltham. MA, USA), and detected with Amersham Imager 600 system (GE, Boston, MA, USA).</ce:para>
                  </ce:section>
                  <ce:section id="sec6.6" view="all">
                     <ce:label>6.6</ce:label>
                     <ce:section-title id="sectitle0110">Determination of pharmacokinetic parameters in rats</ce:section-title>
                     <ce:para id="p1125" view="all">Sprague-Dawley rats (male, three rats per group) weighing 180–220 g were dosed with the test compounds intravenously and orally at a dose of 2 and 10 mg/kg, respectively. Compound <ce:bold>7 mb</ce:bold> was dissolved in mixed solvents (5% DMSO, 10% solutol, and 85% saline) for intravenous injection. Using 0.5% CMC-Na solution (800–1200 cps) as suspending agent for oral dosing. 0.2 mL blood samples were taken via jugular vein at appropriate time points, then placed in tubes containing K2-EDTA and stored on ice until centrifuged. The collection intervals of injection group were 0.083, 0.25, 0.5, 1, 2, 4, 6, 8, and 24 h, while 0.25, 0.5, 1, 2, 4, 6, 8, 10, and 24 h for oral group. The blood samples were centrifuged at 6800 g for 6 min at 2–8 °C within 1 h after collected and stored frozen at approximately −80 °C. An aliquot of 20 μL plasma sample was protein precipitated with 400 μL MeOH in which contains 100 ng/mL IS. The mixture was vortexed for 1 min and centrifuged at 18000 g for 7 min. Transfer 200 μL supernatant to 96 well plates. An aliquot of 1 μL supernatant was injected for LC-MS/MS analysis, and PK parameters were calculated by using DAS (Drug and Statistics) 2.0 software.</ce:para>
                  </ce:section>
                  <ce:section id="sec6.7" view="all">
                     <ce:label>6.7</ce:label>
                     <ce:section-title id="sectitle0115">Molecular modeling</ce:section-title>
                     <ce:para id="p1130" view="all">All computational docking studies were performed in Maestro 11.5 (Version 11.5.011, Schrödinger, New York, USA). The TrkA (PDB <ce:inter-ref id="intref0020" xlink:href="pdb:5KVT" xlink:type="simple">5KVT</ce:inter-ref>) protein structure was prepared with the “Protein Preparation Wizard” option by adding hydrogens and removing water molecules. The ligand structures were built in LigPrep module using OPLS3 force field. The grid-enclosing box was placed on the centroid of the 0LI. The docking program was further performed in Glide module in Maestro 11.5 by applying Standard precision approach.</ce:para>
                  </ce:section>
               </ce:section>
            </ce:sections>
            <ce:conflict-of-interest id="coi0010" view="all">
               <ce:section-title id="sectitle0120">Declaration of competing interest</ce:section-title>
               <ce:para id="p1135" view="all">The authors declare no interest of conflict.</ce:para>
            </ce:conflict-of-interest>
            <ce:acknowledgment id="ack0010" view="all">
               <ce:section-title id="sectitle0125">Acknowledgements</ce:section-title>
               <ce:para id="p1140" view="all">The authors appreciate the financial support from <ce:grant-sponsor id="gs1" sponsor-id="https://doi.org/10.13039/501100001809" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">National Natural Science Foundation of China</ce:grant-sponsor> (<ce:grant-number refid="gs1">21702075</ce:grant-number>, <ce:grant-number refid="gs1">81973158</ce:grant-number>), <ce:grant-sponsor id="gs4" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Key Laboratory of Precision Chemical Drug Development</ce:grant-sponsor> (<ce:grant-number refid="gs4">201805010007</ce:grant-number>), <ce:grant-sponsor id="gs2" sponsor-id="https://doi.org/10.13039/501100003453" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Natural Science Foundation of Guangdong Province</ce:grant-sponsor> (<ce:grant-number refid="gs2">2017A030310253</ce:grant-number>, <ce:grant-number refid="gs2">2019A1515011235</ce:grant-number>, <ce:grant-number refid="gs2">2019B020204002</ce:grant-number>) and <ce:grant-sponsor id="gs3" sponsor-id="https://doi.org/10.13039/501100004024" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">Jinan University</ce:grant-sponsor> for their financial support.</ce:para>
            </ce:acknowledgment>
            <ce:appendices view="all">
               <ce:section id="appsec1" view="extended">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0130">Supplementary data</ce:section-title>
                  <ce:para id="p1145" view="all">The following is the Supplementary data to this article:<ce:display>
                        <ce:e-component id="mmc1">
                           <ce:label>Multimedia component 1</ce:label>
                           <ce:alt-text id="alttext0015" role="short">Multimedia component 1</ce:alt-text>
                           <ce:link locator="mmc1" xlink:href="pii:S0223523420305249/mmc1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/46.1" xlink:type="simple"/></ce:link>
                        </ce:e-component>
                     </ce:display>
                  </ce:para>
               </ce:section>
               <ce:section id="appsec2" view="compact-standard">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0135">Supplementary data</ce:section-title>
                  <ce:para id="p1150" view="all">Supplementary data to this article can be found online at <ce:inter-ref id="intref0025" xlink:href="https://doi.org/10.1016/j.ejmech.2020.112552" xlink:type="simple">https://doi.org/10.1016/j.ejmech.2020.112552</ce:inter-ref>.</ce:para>
               </ce:section>
            </ce:appendices>
         </body>
         <tail view="all">
            <ce:bibliography id="cebib0010" view="all">
               <ce:section-title id="sectitle0140">References</ce:section-title>
               <ce:bibliography-sec id="cebibsec0010" view="all">
                  <ce:bib-reference id="bib1">
                     <ce:label>[1]</ce:label>
                     <sb:reference id="sref1">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.J.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.F.</ce:given-name>
                                 <ce:surname>Reichardt</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Trk receptors: roles in neuronal signal transduction</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Annu. Rev. Biochem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>72</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>609</sb:first-page>
                              <sb:last-page>642</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1146/annurev.biochem.72.121801.161629</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0020">E.J. Huang, L.F. Reichardt, Trk receptors: roles in neuronal signal transduction, Annu. Rev. Biochem. 72 (2003) 609-642. https://doi.org/10.1146/annurev.biochem.72.121801.161629.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib2">
                     <ce:label>[2]</ce:label>
                     <sb:reference id="sref2">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.D.</ce:given-name>
                                 <ce:surname>Skaper</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The neurotrophin family of neurotrophic factors: an overview</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Methods Mol. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>846</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>12</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1007/978-1-61779-536-7_1</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0025">S.D. Skaper, The neurotrophin family of neurotrophic factors: an overview, Methods Mol. Biol. 846 (2012) 1-12. https://doi.org/10.1007/978-1-61779-536-7_1.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib3">
                     <ce:label>[3]</ce:label>
                     <sb:reference id="sref3">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Deinhardt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.V.</ce:given-name>
                                 <ce:surname>Chao</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Trk receptors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Handb. Exp. Pharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>220</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>103</sb:first-page>
                              <sb:last-page>119</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1007/978-3-642-45106-5_5</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0030">K. Deinhardt, M.V. Chao, Trk receptors, Handb. Exp. Pharmacol. 220 (2014) 103-119. https://doi.org/10.1007/978-3-642-45106-5_5.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib4">
                     <ce:label>[4]</ce:label>
                     <sb:reference id="sref4">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Martin-Zanca</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Oskam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Mitra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Copeland</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Barbacid</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Molecular and biochemical characterization of the human trk proto-oncogene</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cell Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>1989</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>24</sb:first-page>
                              <sb:last-page>33</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1128/MCB.9.1.24</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0035">D. Martin-Zanca, R. Oskam, G. Mitra, T. Copeland, M. Barbacid, Molecular and biochemical characterization of the human trk proto-oncogene, Mol. Cell. Biol. 9 (1989) 24-33. https://doi.org/10.1128/MCB.9.1.24.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib5">
                     <ce:label>[5]</ce:label>
                     <sb:reference id="sref5">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Klein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.F.</ce:given-name>
                                 <ce:surname>Parada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Coulier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Barbacid</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>trkB, a novel tyrosine protein kinase receptor expressed during mouse neural development</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>EMBO J.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>1989</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3701</sb:first-page>
                              <sb:last-page>3709</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1002/j.1460-2075.1989.tb08545.x</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0040">R. Klein, L.F. Parada, F. Coulier, M. Barbacid, trkB, a novel tyrosine protein kinase receptor expressed during mouse neural development, EMBO J. 8 (1989) 3701-3709. https://doi.org/10.1002/j.1460-2075.1989.tb08545.x.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib6">
                     <ce:label>[6]</ce:label>
                     <sb:reference id="sref6">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Lamballe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Klein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Barbacid</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>trkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>66</sb:volume-nr>
                              </sb:series>
                              <sb:date>1991</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>967</sb:first-page>
                              <sb:last-page>979</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/0092-8674(91)90442-2</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0045">F. Lamballe, R. Klein, M. Barbacid, trkC, a new member of the trk family of tyrosine protein kinases, is a receptor for neurotrophin-3, Cell. 66 (1991) 967-979. https://doi.org/10.1016/0092-8674(91)90442-2.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib7">
                     <ce:label>[7]</ce:label>
                     <sb:reference id="sref7">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Cocco</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Scaltriti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Drilon</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>NTRK fusion-positive cancers and TRK inhibitor therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Clin. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>731</sb:first-page>
                              <sb:last-page>747</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/s41571-018-0113-0</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0050">E. Cocco, M. Scaltriti, A. Drilon, NTRK fusion-positive cancers and TRK inhibitor therapy, Nat. Rev. Clin. Oncol. 15 (2018) 731-747. https://doi.org/10.1038/s41571-018-0113-0.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib8">
                     <ce:label>[8]</ce:label>
                     <sb:reference id="sref8">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Vaishnavi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.T.</ce:given-name>
                                 <ce:surname>Le</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.C.</ce:given-name>
                                 <ce:surname>Doebele</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>TRKing down an old oncogene in a new era of targeted therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>25</sb:first-page>
                              <sb:last-page>34</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1158/2159-8290.CD-14-0765</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0055">A. Vaishnavi, A.T. Le, R.C. Doebele, TRKing down an old oncogene in a new era of targeted therapy, Cancer Discov. 5 (2015) 25-34. https://doi.org/10.1158/2159-8290.CD-14-0765.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib9">
                     <ce:label>[9]</ce:label>
                     <sb:reference id="sref9">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Pulciani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Santos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.V.</ce:given-name>
                                 <ce:surname>Lauver</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.K.</ce:given-name>
                                 <ce:surname>Long</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Aaronson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Barbacid</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Oncogenes in solid human tumours</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>300</sb:volume-nr>
                              </sb:series>
                              <sb:date>1982</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>539</sb:first-page>
                              <sb:last-page>542</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/300539a0</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0060">S. Pulciani, E. Santos, A.V. Lauver, L.K. Long, S.A. Aaronson, M. Barbacid, Oncogenes in solid human tumours. Nature 300 (1982) 539-542. https://doi.org/10.1038/300539a0.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib10">
                     <ce:label>[10]</ce:label>
                     <sb:reference id="sref10">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Amatu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Sartore-Bianchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Siena</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>NTRK gene fusions as novel targets of cancer therapy across multiple tumour types</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ESMO Open</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:article-number>e000023</sb:article-number>
                           <ce:doi>10.1136/esmoopen-2015-000023</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0065">A. Amatu, A. Sartore-Bianchi, S. Siena, NTRK gene fusions as novel targets of cancer therapy across multiple tumour types, ESMO Open. 1(2016) e000023. https://doi.org/10.1136/esmoopen-2015-000023.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib11">
                     <ce:label>[11]</ce:label>
                     <sb:reference id="sref11">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Drilon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Dogan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Gounder</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Arcila</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Hyman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Hechtman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Wei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.R.</ce:given-name>
                                 <ce:surname>Cam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Christiansen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Luo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.C.</ce:given-name>
                                 <ce:surname>Maneval</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Bauer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Patel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.V.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.H.I.</ce:given-name>
                                 <ce:surname>Ou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Farago</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Shaw</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.F.</ce:given-name>
                                 <ce:surname>Shoemaker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Hornby</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Multani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ladanyi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Berger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Katabi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Ghossein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.L.</ce:given-name>
                                 <ce:surname>Ho</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Ann. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>27</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>920</sb:first-page>
                              <sb:last-page>926</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1093/annonc/mdw042</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0070">A. Drilon, G. Li, S. Dogan, M. Gounder, R. Shen, M. Arcila, L. Wang, D.M. Hyman, J. Hechtman, G. Wei, N.R. Cam, J. Christiansen, D. Luo, E.C. Maneval, T. Bauer, M. Patel, S.V. Liu, S.H.I. Ou, A. Farago, A. Shaw, R.F. Shoemaker, J. Lim, Z. Hornby, P. Multani, M. Ladanyi, M. Berger, N. Katabi, R. Ghossein, A.L. Ho, What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC), Ann. Oncol. 27 (2016) 920-926. https://doi.org/10.1093/annonc/mdw042.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib12">
                     <ce:label>[12]</ce:label>
                     <sb:reference id="sref12">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Tognon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.R.</ce:given-name>
                                 <ce:surname>Knezevich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Huntsman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.D.</ce:given-name>
                                 <ce:surname>Roskelley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Melnyk</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Mathers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Becker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Carneiro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>MacPherson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Horsman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Poremba</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.H.B.</ce:given-name>
                                 <ce:surname>Sorensen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Expression of the etv6-ntrk3 gene fusion as a primary event in human secretory breast carcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>367</sb:first-page>
                              <sb:last-page>376</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/S1535-6108(02)00180-0</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0075">C. Tognon, S.R. Knezevich, D. Huntsman, C.D. Roskelley, N. Melnyk, J.A. Mathers, L. Becker, F. Carneiro, N. MacPherson, D. Horsman, C. Poremba, P. H.B Sorensen, Expression of the etv6-ntrk3 gene fusion as a primary event in human secretory breast carcinoma, Cancer Cell. 2 (2002) 367-376. https://doi.org/10.1016/S1535-6108(02)00180-0.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib13">
                     <ce:label>[13]</ce:label>
                     <sb:reference id="sref13">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Knezevich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>McFadden</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Tao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Sorensen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Genet.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>1998</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>184</sb:first-page>
                              <sb:last-page>187</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/ng0298-184</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0080">S. Knezevich, D. McFadden, W. Tao, J. Lim, P. Sorensen, A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma, Nat. Genet. 18 (1998) 184−187. https://doi.org/10.1038/ng0298-184.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib14">
                     <ce:label>[14]</ce:label>
                     <sb:reference id="sref14">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Greco</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Miranda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Pierotti</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Rearrangements of NTRK1 gene in papillary thyroid carcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cell. Endocrinol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>321</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>44</sb:first-page>
                              <sb:last-page>49</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.mce.2009.10.009</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0085">A. Greco, C. Miranda, M.A. Pierotti, Rearrangements of NTRK1 gene in papillary thyroid carcinoma, Mol. Cell. Endocrinol. 321 (2010) 44-49. https://doi.org/10.1016/j.mce.2009.10.009.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib15">
                     <ce:label>[15]</ce:label>
                     <sb:reference id="sref15">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Frattini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Trifonov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Chan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Castano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Lia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Abate</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.T.</ce:given-name>
                                 <ce:surname>Keir</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.X.</ce:given-name>
                                 <ce:surname>Ji</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Zoppoli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Niola</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Danussi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Dolgalev</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Porrati</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Pellegatta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Heguy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Gupta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Pisapia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Canoll</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.N.</ce:given-name>
                                 <ce:surname>Bruce</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.E.</ce:given-name>
                                 <ce:surname>McLendon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Aldape</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Finocchiaro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Mikkelsen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.G.</ce:given-name>
                                 <ce:surname>Prive</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.D.</ce:given-name>
                                 <ce:surname>Bigner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Lasorella</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Rabadan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Iavarone</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The integrated landscape of driver genomic alterations in glioblastoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Genet.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>45</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1141</sb:first-page>
                              <sb:last-page>1149</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/ng.2734</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0090">V. Frattini, V. Trifonov, J.M. Chan, A. Castano, M. Lia, F. Abate, S.T. Keir, A.X. Ji, P. Zoppoli, F. Niola, C. Danussi, I. Dolgalev, P. Porrati, S. Pellegatta, A. Heguy, G. Gupta, D.J. Pisapia, P. Canoll, J.N. Bruce, R.E. McLendon, H. Yan, K. Aldape, G. Finocchiaro, T. Mikkelsen, G.G. Prive, D.D. Bigner, A. Lasorella, R. Rabadan, A. Iavarone, The integrated landscape of driver genomic alterations in glioblastoma, Nat. Genet. 45 (2013) 1141-1149. https://doi.org/10.1038/ng.2734</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib16">
                     <ce:label>[16]</ce:label>
                     <sb:reference id="sref16">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.J.</ce:given-name>
                                 <ce:surname>Cho</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.E.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>An</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.H.</ce:given-name>
                                 <ce:surname>Cho</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.H.</ce:given-name>
                                 <ce:surname>Ko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Joo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.H.</ce:given-name>
                                 <ce:surname>Nam</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>NTRK1 fusion in glioblastoma multiforme</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>PloS One</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:article-number>e91940</sb:article-number>
                           <ce:doi>10.1371/journal.pone.0091940</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0095">J. Kim, Y. Lee, H.J. Cho, Y.E. Lee, J. An, G.H. Cho, Y.H. Ko, K.M. Joo, D.H. Nam, NTRK1 fusion in glioblastoma multiforme, PLoS One. 9 (2014) e91940. https://doi.org/10.1371/journal.pone.0091940.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib17">
                     <ce:label>[17]</ce:label>
                     <sb:reference id="sref17">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Vaishnavi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Capelletti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.T.</ce:given-name>
                                 <ce:surname>Le</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kako</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Butaney</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Ercan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Mahale</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.D.</ce:given-name>
                                 <ce:surname>Davies</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.L.</ce:given-name>
                                 <ce:surname>Aisner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.B.</ce:given-name>
                                 <ce:surname>Pilling</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.M.</ce:given-name>
                                 <ce:surname>Berge</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Sasaki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Kryukov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.A.</ce:given-name>
                                 <ce:surname>Garraway</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.S.</ce:given-name>
                                 <ce:surname>Hammerman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Haas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.W.</ce:given-name>
                                 <ce:surname>Andrews</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Lipson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Stephens</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.A.</ce:given-name>
                                 <ce:surname>Miller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Varella-Garcia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Janne</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.C.</ce:given-name>
                                 <ce:surname>Doebele</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1469</sb:first-page>
                              <sb:last-page>1472</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/nm.3352</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0100">A. Vaishnavi, M. Capelletti, A.T. Le, S. Kako, M. Butaney, D. Ercan, S. Mahale, K.D. Davies, D.L. Aisner, A.B. Pilling, E.M. Berge, J. Kim, H. Sasaki, S. Park, G. Kryukov, L.A. Garraway, P.S. Hammerman, J. Haas, S.W. Andrews, D. Lipson, P.J. Stephens, V.A. Miller, M. Varella-Garcia, P.A. Janne, R.C. Doebele, Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer, Nat. Med. 19 (2013) 1469-1472. https://doi.org/10.1038/nm.3352.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib18">
                     <ce:label>[18]</ce:label>
                     <sb:reference id="sref18">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Bailey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Schirrmacher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Farrell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Bernard-Gauthier</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 – Part I</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Expert Opin. Ther. Pat.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>27</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>733</sb:first-page>
                              <sb:last-page>751</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1080/13543776.2017.1297796</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0105">J.J. Bailey, R. Schirrmacher, K. Farrell, V. Bernard-Gauthier, Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I, Expert Opin Ther Pat, 27 (2017) 733-751. https://doi.org/10.1080/13543776.2017.1297796.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib19">
                     <ce:label>[19]</ce:label>
                     <sb:reference id="sref19">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Bailey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Schirrmacher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Farrell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Bernard-Gauthier</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 – Part II</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Expert Opin. Ther. Pat.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>27</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>831</sb:first-page>
                              <sb:last-page>849</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1080/13543776.2017.1297797</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0110">J.J. Bailey, R. Schirrmacher, K. Farrell, V. Bernard-Gauthier, Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II, Expert Opin Ther Pat, 27 (2017) 831-849. https://doi.org/10.1080/13543776.2017.1297797.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib20">
                     <ce:label>[20]</ce:label>
                     <sb:reference id="sref20">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Bailey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Jaworski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Tung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Wängler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Wängler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Schirrmacher</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Tropomyosin receptor kinase inhibitors: an updated patent review for 2016-2019</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Expert Opin. Ther. Pat.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>30</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>325</sb:first-page>
                              <sb:last-page>339</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1080/13543776.2020.1737011</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0115">J.J. Bailey, C. Jaworski, D. Tung, C. Wangler, B. Wangler, R. Schirrmacher, Tropomyosin receptor kinase inhibitors: an updated patent review for 2016-2019, Expert Opin Ther Pat. 30 (2020) 325-339. https://doi.org/10.1080/13543776.2020.1737011.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib21">
                     <ce:label>[21]</ce:label>
                     <sb:reference id="sref21">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Bernard-Gauthier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Bailey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.V.</ce:given-name>
                                 <ce:surname>Mossine</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Lindner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Vomacka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Aliaga</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Shao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Quesada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Sherman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Mahringer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kostikov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Grand’Maison</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Rosa-Neto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.-P.</ce:given-name>
                                 <ce:surname>Soucy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Thiel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.R.</ce:given-name>
                                 <ce:surname>Kaplan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Fricker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Wangler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Bartenstein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Schirrmacher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.H.</ce:given-name>
                                 <ce:surname>Scott</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A kinome-wide selective radiolabeled TrkB/C inhibitor for in vitro and in vivo neuroimaging: synthesis, preclinical evaluation, and first-in-human</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>60</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6897</sb:first-page>
                              <sb:last-page>6910</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acs.jmedchem.7b00396</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0120">V. Bernard-Gauthier, J.J. Bailey, A.V. Mossine, S. Lindner, L. Vomacka, A. Aliaga, X. Shao, C.A. Quesada, P. Sherman, A. Mahringer, A. Kostikov, M. Grand’Maison, P. Rosa-Neto, J.-P. Soucy, A. Thiel, D.R. Kaplan, G. Fricker, B. Wangler, P. Bartenstein, R. Schirrmacher, P.J.H. Scott, A kinome-wide selective radiolabeled TrkB/C inhibitor for in vitro and in vivo neuroimaging: synthesis, preclinical evaluation, and first-in-human, J. Med. Chem. 60 (2017) 6897-6910. https://doi.org/10.1021/acs.jmedchem.7b00396.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib22">
                     <ce:label>[22]</ce:label>
                     <sb:reference id="sref22">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Bernard-Gauthier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.V.</ce:given-name>
                                 <ce:surname>Mossine</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Mahringer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Aliaga</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Bailey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Shao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Stauff</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Arteaga</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Sherman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Grand’Maison</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.-L.</ce:given-name>
                                 <ce:surname>Rochon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Wängler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Wängler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Bartenstein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kostikov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.R.</ce:given-name>
                                 <ce:surname>Kaplan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Fricker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Rosa-Neto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.H.</ce:given-name>
                                 <ce:surname>Scott</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Schirrmacher</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of [18F]TRACK, a fluorine-18-labeled tropomyosin receptor kinase (Trk) inhibitor for PET imaging</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>61</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1737</sb:first-page>
                              <sb:last-page>1743</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acs.jmedchem.7b01607</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0125">V. Bernard-Gauthier, A.V. Mossine, A. Mahringer, A. Aliaga, J.J. Bailey, X. Shao, J. Stauff, J. Arteaga, P. Sherman, M. Grand’Maison, P.-L. Rochon, B. Wangler, C. Wangler, P. Bartenstein, A. Kostikov, D.R. Kaplan, G. Fricker, P. Rosa-Neto, P.J.H. Scott, R. Schirrmacher, Identification of [18F]TRACK, a fluorine-18-labeled tropomyosin receptor kinase (Trk) inhibitor for PET imaging, J. Med. Chem. 61 (2018) 1737-1743. https://doi.org/10.1021/acs.jmedchem.7b01607.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib23">
                     <ce:label>[23]</ce:label>
                     <sb:reference id="sref23">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Bailey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Kaiser</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Lindner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wüst</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Thiel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.-P.</ce:given-name>
                                 <ce:surname>Soucy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Rosa-Neto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.H.</ce:given-name>
                                 <ce:surname>Scott</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Unterrainer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.R.</ce:given-name>
                                 <ce:surname>Kaplan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Wängler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Wängler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Bartenstein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Bernard-Gauthier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Schirrmacher</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>First-in-Human brain imaging of [18F]TRACK, a PET tracer for tropomyosin receptor kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Chem. Neurosci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2697</sb:first-page>
                              <sb:last-page>2702</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acschemneuro.9b00144</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0130">J.J. Bailey, L. Kaiser, S. Lindner, M. Wust, A. Thiel, J.-P. Soucy, P. Rosa-Neto, P.J.H. Scott, M. Unterrainer, D.R. Kaplan, C. Wangler, B. Wangler, P. Bartenstein, V. Bernard-Gauthier, R. Schirrmacher, First-in-Human Brain Imaging of [18F]TRACK, a PET tracer for Tropomyosin Receptor Kinases. ACS Chem Neurosci. 10 (2019) 2697-2702. https://doi.org/10.1021/acschemneuro.9b00144.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib24">
                     <ce:label>[24]</ce:label>
                     <sb:reference id="sref24">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.C.</ce:given-name>
                                 <ce:surname>Doebele</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.E.</ce:given-name>
                                 <ce:surname>Davis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Vaishnavi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.T.</ce:given-name>
                                 <ce:surname>Le</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Estrada-Bernal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Keysar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Jimeno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Varella-Garcia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.L.</ce:given-name>
                                 <ce:surname>Aisner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Stephens</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Morosini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.B.</ce:given-name>
                                 <ce:surname>Tuch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Fernandes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Nanda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Low</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1049</sb:first-page>
                              <sb:last-page>1057</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1158/2159-8290.CD-15-0443</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0135">R.C. Doebele, L.E. Davis, A. Vaishnavi, A.T. Le, A. Estrada-Bernal, S. Keysar, A. Jimeno, M. Varella-Garcia, D.L. Aisner, Y. Li, J. Stephens, D. Morosini, B.B. Tuch, M. Fernandes, N. Nanda, J.A. Low, An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101, Cancer Discov. 5 (2015) 1049-1057. https://doi.org/10.1158/2159-8290.CD-15-0443.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib25">
                     <ce:label>[25]</ce:label>
                     <sb:reference id="sref25">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Menichincheri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Ardini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Magnaghi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Avanzi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Banfi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Bossi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Buffa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Canevari</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Ceriani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Colombo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Corti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Donati</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Fasolini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Felder</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Fiorelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Fiorentini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Galvani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Isacchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.L.</ce:given-name>
                                 <ce:surname>Borgia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Marchionni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Nesi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Orrenius</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Panzeri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Pesenti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Rusconi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.B.</ce:given-name>
                                 <ce:surname>Saccardo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Vanotti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Perrone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Orsini</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of entrectinib: a new 3-aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ros oncogene 1 kinase (ROS1), and pan-tropomyosin receptor kinases (Pan-TRKs) inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>59</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3392</sb:first-page>
                              <sb:last-page>3408</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/acs.jmedchem.6b00064</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0140">M. Menichincheri, E. Ardini, P. Magnaghi, N. Avanzi, P. Banfi, R. Bossi, L. Buffa, G. Canevari, L. Ceriani, M. Colombo, L. Corti, D. Donati, M. Fasolini, E. Felder, C. Fiorelli, F. Fiorentini, A. Galvani, A. Isacchi, A.L. Borgia, C. Marchionni, M. Nesi, C. Orrenius, A. Panzeri, E. Pesenti, L. Rusconi, M.B. Saccardo, E. Vanotti, E. Perrone, P. Orsini, Discovery of entrectinib: a new 3-aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ros oncogene 1 kinase (ROS1), and pan-tropomyosin receptor kinases (Pan-TRKs) inhibitor, J. Med. Chem. 59 (2016) 3392-3408. https://doi.org/10.1021/acs.jmedchem.6b00064.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib26">
                     <ce:label>[26]</ce:label>
                     <sb:reference id="sref26">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.L.</ce:given-name>
                                 <ce:surname>Richard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.B.</ce:given-name>
                                 <ce:surname>Christiane</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Deborah</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Michele</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Karina</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.S.</ce:given-name>
                                 <ce:surname>John</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Yohannes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Earl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.W.</ce:given-name>
                                 <ce:surname>Douglas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Hao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.E.</ce:given-name>
                                 <ce:surname>Linda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Renee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Paul</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.Y.</ce:given-name>
                                 <ce:surname>Violeta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.S.</ce:given-name>
                                 <ce:surname>Douglas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Man</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Allison</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Patricia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Steven</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.B.</ce:given-name>
                                 <ce:surname>Rachael</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6523</sb:first-page>
                              <sb:last-page>6540</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/jm3005866</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0145">T.L. Richard, M.B. Christiane, M.C. Deborah, P. Michele, R. Karina, C.S. John, T. Yohannes, M. Earl, A.W. Douglas, C. Hao, F.E. Linda, E. Renee, S.A. Paul, L.Y. Violeta, C.S. Douglas, X. Man, D. Allison, M. Patricia, S. Steven, L.B. Rachael, The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer, J. Med. Chem. 55 (2016) 6523−6540. https://doi.org/10.1021/jm3005866.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib27">
                     <ce:label>[27]</ce:label>
                     <sb:reference id="sref27">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Fuse</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Okada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Oh-Hara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Ogura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Fujita</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Katayama</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mechanisms of resistance to NTRK inhibitors and therapeutic strategies in NTRK1-rearranged cancers</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Canc. Therapeut.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2130</sb:first-page>
                              <sb:last-page>2143</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1158/1535-7163.MCT-16-0909</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0150">M.J. Fuse, K. Okada, T. Oh-Hara, H. Ogura, N. Fujita, R. Katayama, Mechanisms of resistance to NTRK inhibitors and therapeutic strategies in NTRK1-rearranged cancers, Mol. Cancer Ther. 16 (2017) 2130−2143. https://doi.org/10.1158/1535-7163.MCT-16-0909.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib28">
                     <ce:label>[28]</ce:label>
                     <sb:reference id="sref28">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.M.</ce:given-name>
                                 <ce:surname>Yakes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Tan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Yamaguchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Qian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Chu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Bentzien</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Cancilla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Orf</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>You</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>Laird</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Engst</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lesch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.C.</ce:given-name>
                                 <ce:surname>Chou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.H.</ce:given-name>
                                 <ce:surname>Joly</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Canc. Therapeut.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2298</sb:first-page>
                              <sb:last-page>2308</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1158/1535-7163.Mct-11-0264</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0155">F.M. Yakes, J. Chen, J. Tan, K. Yamaguchi, Y. Shi, P. Yu, F. Qian, F. Chu, F. Bentzien, B. Cancilla, J. Orf, A. You, A.D. Laird, S. Engst, L. Lee, J. Lesch, Y.C. Chou, A.H. Joly, Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth, Mol. Cancer Ther. 10 (2011) 2298-2308. https://doi.org/10.1158/1535-7163.Mct-11-0264.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib29">
                     <ce:label>[29]</ce:label>
                     <sb:reference id="sref29">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.L.</ce:given-name>
                                 <ce:surname>Shamroe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Comeau</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Ponatinib: a new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Ann. Pharmacother.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>47</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1540</sb:first-page>
                              <sb:last-page>1546</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/10.1177/1060028013501144</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0160">C.L. Shamroe, J.M. Comeau, Ponatinib: a new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia, Ann. Pharmacother. 47 (2013), 1540-1546. https://doi.org/10.1021/10.1177/1060028013501144.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib30">
                     <ce:label>[30]</ce:label>
                     <sb:reference id="sref30">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Drilon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kummar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Moreno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Patel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>Lassen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Rosen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.H.</ce:given-name>
                                 <ce:surname>Childs</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Nanda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Cox</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.C.</ce:given-name>
                                 <ce:surname>Ku</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.F.</ce:given-name>
                                 <ce:surname>Farago</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Activity of larotrectinib in TRK fusion lung cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Ann. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>30</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>43</sb:first-page>
                              <sb:last-page>44</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1093/annonc/mdz063.009</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0165">A. Drilon, S. Kummar, V. Moreno, J. Patel, U. Lassen, L. Rosen, B.H. Childs, S. Nanda, M.C. Cox, N.C. Ku, A.F. Farago, Activity of larotrectinib in TRK fusion lung cancer, Annals of Oncology. 30 (2019) 43-44. https://doi.org/10.1093/annonc/mdz063.009.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib31">
                     <ce:label>[31]</ce:label>
                     <sb:reference id="sref31">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Drilon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.W.</ce:given-name>
                                 <ce:surname>Laetsch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kummar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.G.</ce:given-name>
                                 <ce:surname>DuBois</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.N.</ce:given-name>
                                 <ce:surname>Lassen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.D.</ce:given-name>
                                 <ce:surname>Demetri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Nathenson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.C.</ce:given-name>
                                 <ce:surname>Doebele</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.F.</ce:given-name>
                                 <ce:surname>Farago</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.S.</ce:given-name>
                                 <ce:surname>Pappo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Turpin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Dowlati</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Brose</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Mascarenhas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Federman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Berlin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.S.</ce:given-name>
                                 <ce:surname>El-Deiry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Baik</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Deeken</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Boni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Nagasubramanian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Taylor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.R.</ce:given-name>
                                 <ce:surname>Rudzinski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>MericBernstam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.P.S.</ce:given-name>
                                 <ce:surname>Sohal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.C.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.E.</ce:given-name>
                                 <ce:surname>Raez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.F.</ce:given-name>
                                 <ce:surname>Hechtman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Benayed</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ladanyi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.B.</ce:given-name>
                                 <ce:surname>Tuch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ebata</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Cruickshank</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.C.</ce:given-name>
                                 <ce:surname>Ku</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Cox</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Hawkins</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Hong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Hyman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Efficacy of Larotrectinib in TRK fusion-positive cancers in adults and children</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>N. Engl. J. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>378</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>731</sb:first-page>
                              <sb:last-page>739</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1056/NEJMoa1714448</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0170">A. Drilon, T.W. Laetsch, S. Kummar, S.G. DuBois, U.N. Lassen, G.D. Demetri, M. Nathenson, R.C. Doebele, A.F. Farago, A.S. Pappo, B. Turpin, A. Dowlati, M.S. Brose, L. Mascarenhas, N. Federman, J. Berlin, W.S. El-Deiry, C. Baik, J. Deeken, V. Boni, R. Nagasubramanian, M. Taylor, E.R. Rudzinski, F. MericBernstam, D.P.S. Sohal, P.C. Ma, L.E. Raez, J.F. Hechtman, R. Benayed, M. Ladanyi, B.B. Tuch, K. Ebata, S. Cruickshank, N.C. Ku, M.C. Cox, D.S. Hawkins, D.S. Hong, D.M. Hyman, Efficacy of Larotrectinib in TRK fusion-positive cancers in adults and children, N. Engl. J. Med. 378 (2018) 731-739. https://doi.org/10.1056/NEJMoa1714448.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib32">
                     <ce:label>[32]</ce:label>
                     <sb:reference id="sref32">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Hyman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.M.</ce:given-name>
                                 <ce:surname>van Tilburg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.M.</ce:given-name>
                                 <ce:surname>Albert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.W.</ce:given-name>
                                 <ce:surname>Tan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Geoerger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.F.</ce:given-name>
                                 <ce:surname>Farago</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.W.</ce:given-name>
                                 <ce:surname>Laetsch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kummar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Doz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.N.</ce:given-name>
                                 <ce:surname>Lassen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.G.</ce:given-name>
                                 <ce:surname>DuBois</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>McDermott</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Mascarenhas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Berlin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.R.</ce:given-name>
                                 <ce:surname>Rudzinski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Cox</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Nanda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.H.</ce:given-name>
                                 <ce:surname>Childs</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Drilon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Hong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Ann. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>30</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>162</sb:first-page>
                              <sb:last-page>163</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0175">D.M. Hyman, C.M. van Tilburg, C.M. Albert, D.S.W. Tan, B. Geoerger, A.F. Farago, T.W. Laetsch, S. Kummar, F. Doz, U.N. Lassen, S.G. DuBois, R. McDermott, L. Mascarenhas, J.D. Berlin, E.R. Rudzinski, M.C. Cox, S. Nanda, B.H. Childs, A. Drilon, D.S. Hong, Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer, Annals of Oncology. 30 (2019) 162-163.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib33">
                     <ce:label>[33]</ce:label>
                     <sb:reference id="sref33">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Russo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Misale</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Crisafulli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Corti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Rospo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Novara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Mussolin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Bartolini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Wei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Cam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Patel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Yan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Shoemaker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Wild</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Siravegna</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Lazzari</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.F.</ce:given-name>
                                 <ce:surname>Di</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Bardelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.S.</ce:given-name>
                                 <ce:surname>Bianchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Siena</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>36</sb:first-page>
                              <sb:last-page>44</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1158/2159-8290.CD-15-0940</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0180">M. Russo, S. Misale, G. Crisafulli, G. Corti, G. Rospo, L. Novara, B. Mussolin, A. Bartolini, G. Wei, N. Cam, R. Patel, S. Yan, R. Shoemaker, R. Wild, G. Li, G. Siravegna, L. Lazzari, N.F. Di, A. Bardelli, A.S. Bianchi, S. Siena, Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer, Cancer Discov. 6 (2016) 36-44. https://doi.org/10.1158/2159-8290.CD-15-0940.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib34">
                     <ce:label>[34]</ce:label>
                     <sb:reference id="sref34">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Drilon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Nagasubramanian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.F.</ce:given-name>
                                 <ce:surname>Blake</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Ku</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.B.</ce:given-name>
                                 <ce:surname>Tuch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ebata</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Smith</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Lauriault</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.R.</ce:given-name>
                                 <ce:surname>Kolakowski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.J.</ce:given-name>
                                 <ce:surname>Brandhuber</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.D.</ce:given-name>
                                 <ce:surname>Larsen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.S.</ce:given-name>
                                 <ce:surname>Bouhana</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.L.</ce:given-name>
                                 <ce:surname>Winski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Hamor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.I.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Parker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.H.</ce:given-name>
                                 <ce:surname>Morales</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.X.</ce:given-name>
                                 <ce:surname>Sullivan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.E.</ce:given-name>
                                 <ce:surname>DeWolf</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.A.</ce:given-name>
                                 <ce:surname>Wollenberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.R.</ce:given-name>
                                 <ce:surname>Gordon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.N.</ce:given-name>
                                 <ce:surname>Douglas-Lindsay</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Scaltriti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Benayed</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Raj</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Hanusch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Schram</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Jonsson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.F.</ce:given-name>
                                 <ce:surname>Berger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.F.</ce:given-name>
                                 <ce:surname>Hechtman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.S.</ce:given-name>
                                 <ce:surname>Taylor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Andrews</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Rothenberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Hyman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Canc. Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>963</sb:first-page>
                              <sb:last-page>972</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1158/2159-8290.CD-17-0507</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0185">A. Drilon, R. Nagasubramanian, J.F. Blake, N. Ku, B.B. Tuch, K. Ebata, S. Smith, V. Lauriault, G.R. Kolakowski, B.J. Brandhuber, P.D. Larsen, K.S. Bouhana, S.L. Winski, R. Hamor, W.I. Wu, A. Parker, T.H. Morales, F.X. Sullivan, W.E. DeWolf, L.A. Wollenberg, P.R. Gordon, D.N. Douglas-Lindsay, M. Scaltriti, R. Benayed, S. Raj, B. Hanusch, A.M. Schram, P. Jonsson, M.F. Berger, J.F. Hechtman, B.S. Taylor, S. Andrews, S.M. Rothenberg, D.M. Hyman, A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors, Cancer Discov. 7 (2017) 963−972. https://doi.org/10.1158/2159-8290.CD-17-0507.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib35">
                     <ce:label>[35]</ce:label>
                     <sb:reference id="sref35">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Richard</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Selectively nonselective kinase inhibition: striking the right balance</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>53</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1413</sb:first-page>
                              <sb:last-page>1437</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/jm901132v</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0190">M. Richard, Selectively Nonselective Kinase Inhibition: Striking the Right Balance, J. Med. Chem. 53 (2010), 1413-1437. https://doi.org/10.1021/jm901132v.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib36">
                     <ce:label>[36]</ce:label>
                     <sb:reference id="bib36a">
                        <ce:label>(a)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.F.</ce:given-name>
                                 <ce:surname>Littke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.Y.</ce:given-name>
                                 <ce:surname>Dai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.C.</ce:given-name>
                                 <ce:surname>Fu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Versatile catalysts for the Suzuki cross-coupling of arylboronic acids with aryl and vinyl halides and triflates under mild conditions</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Am. Chem. Soc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>122</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4020</sb:first-page>
                              <sb:last-page>4028</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1002/chin.200031067</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0195">A.F. Littke, C.Y. Dai, G.C. Fu, Versatile catalysts for the Suzuki cross-coupling of arylboronic acids with aryl and vinyl halides and triflates under mild conditions. J. Am. Chem. Soc. 122 (2000) 4020-4028. https://doi.org/10.1002/chin.200031067.</ce:source-text>
                     <sb:reference id="bib36b">
                        <ce:label>(b)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kotha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Lahiri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Kashinath</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Recent applications of the Suzuki-Miyaura cross-coupling reaction in organic synthesis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Tetrahedron</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>58</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>9633</sb:first-page>
                              <sb:last-page>9695</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/S0040-4020(02)01188-2</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0200">S. Kotha, K. Lahiri, D. Kashinath, Recent applications of the Suzuki-Miyaura cross-coupling reaction in organic synthesis, Tetrahedron 58 (2002) 9633-9695. https://doi.org/10.1016/S0040-4020(02)01188-2.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib37">
                     <ce:label>[37]</ce:label>
                     <sb:reference id="sref36">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Chinchilla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Najera</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The sonogashira reaction: a booming methodology in synthetic organic chemistry</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>107</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>874</sb:first-page>
                              <sb:last-page>922</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/cr050992x</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0205">R. Chinchilla, C. Najera, The sonogashira reaction: a booming methodology in synthetic organic chemistry, Chem. Rev. 107 (2007) 874-922. https://doi.org/10.1021/cr050992x.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib38">
                     <ce:label>[38]</ce:label>
                     <sb:reference id="sref37">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.F.</ce:given-name>
                                 <ce:surname>Heck</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>Nolley</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Palladium-catalyzed vinylic hydrogen substitution reactions with aryl, benzyl, and styryl halides</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Org. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>37</sb:volume-nr>
                              </sb:series>
                              <sb:date>1972</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2320</sb:first-page>
                              <sb:last-page>2322</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/jo00979a024</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0210">R.F. Heck and J. P. Nolley, Palladium-catalyzed vinylic hydrogen substitution reactions with aryl, benzyl, and styryl halides, J. Org. Chem. 37 (1972) 2320-2322. https://doi.org/10.1021/jo00979a024.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib39">
                     <ce:label>[39]</ce:label>
                     <sb:reference id="sref38">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Mitsunobu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Yamada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Mukaiyama</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Preparation of esters of phosphoric acid by the reaction of trivalent phosphorus compounds with diethyl azodicarboxylate in the presence of alcohols</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bull. Chem. Soc. Jpn.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>40</sb:volume-nr>
                              </sb:series>
                              <sb:date>1967</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>935</sb:first-page>
                              <sb:last-page>939</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1246/bcsj.40.935</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0215">O. Mitsunobu, M. Yamada, T. Mukaiyama, Preparation of Esters of Phosphoric Acid by the Reaction of Trivalent Phosphorus Compounds with Diethyl Azodicarboxylate in the Presence of Alcohols, Bull. Chem. Soc. Jpn. 40 (1967) 935-939. http://doi.org/10.1246/bcsj.40.935.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib40">
                     <ce:label>[40]</ce:label>
                     <sb:reference id="bib40a">
                        <ce:label>(a)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.G.</ce:given-name>
                                 <ce:surname>Anil</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.B.</ce:given-name>
                                 <ce:surname>Stephen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Palladium-catalyzed aromatic aminations with in situ generated aminostannanes</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Am. Chem. Soc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>116</sb:volume-nr>
                              </sb:series>
                              <sb:date>1994</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7901</sb:first-page>
                              <sb:last-page>7902</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/ja00096a059</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0220">S.G. Anil, L.B. Stephen, Palladium-catalyzed aromatic aminations with in situ generated aminostannanes, J. Am. Chem. Soc. 116 (1994) 7901-7902. https://doi.org/10.1021/ja00096a059.</ce:source-text>
                     <sb:reference id="bib40b">
                        <ce:label>(b)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Paul</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Patt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.F.</ce:given-name>
                                 <ce:surname>Hartwig</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Palladium-catalyzed formation of carbon-nitrogen bonds. Reaction intermediates and catalyst improvements in the hetero cross-coupling of aryl halides and tin amides</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Am. Chem. Soc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>116</sb:volume-nr>
                              </sb:series>
                              <sb:date>1994</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5969</sb:first-page>
                              <sb:last-page>5970</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/ja00092a058</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0225">F. Paul, J. Patt, J.F. Hartwig, Palladium-catalyzed formation of carbon-nitrogen bonds. Reaction intermediates and catalyst improvements in the hetero cross-coupling of aryl halides and tin amides, J. Am. Chem. Soc. 116 (1994) 5969-5970. http://doi.org/10.1021/ja00092a058.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib41">
                     <ce:label>[41]</ce:label>
                     <sb:reference id="sref39">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Rodems</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.D.</ce:given-name>
                                 <ce:surname>Hamman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Shah</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Heidary</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Makings</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>Stack</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.A.</ce:given-name>
                                 <ce:surname>Pollok</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A FRET-based assay platform for ultra-high density drug screening of protein kinases and phosphatases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Assay Drug Dev. Technol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>9</sb:first-page>
                              <sb:last-page>19</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1089/154065802761001266</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0230">S.M. Rodems, B.D. Hamman, C. Lin, J. Zhao, S. Shah, D. Heidary, L. Makings, J.H. Stack, B.A. Pollok, A FRET-based assay platform for ultra-high density drug screening of protein kinases and phosphatases, Assay Drug Dev. Technol. 1 (2002) 9-19. https://doi.org/10.1089/154065802761001266.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib42">
                     <ce:label>[42]</ce:label>
                     <sb:reference id="sref40">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Shirahashi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Toriihara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Suenaga</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yoshida</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Akaogi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Endou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wakabayashi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Takashima</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The discovery of novel 3-aryl-indazole derivatives as peripherally restricted pan-Trk inhibitors for the treatment of pain</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>29</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2023</sb:first-page>
                              <sb:last-page>2326</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1016/j.bmcl.2019.06.018</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0235">H. Shirahashi, E. Toriihara, Y. Suenaga, H. Yoshida, K. Akaogi, Y. Endou, M. Wakabayashi, M. Takashima. The discovery of novel 3-aryl-indazole derivatives as peripherally restricted pan-Trk inhibitors for the treatment of pain. Bioorg. Med. Chem. Lett. 29 (2019) 2023-2326. https://doi.org/10.1016/j.bmcl.2019.06.018.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib43">
                     <ce:label>[43]</ce:label>
                     <sb:reference id="sref41">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Abian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.H.</ce:given-name>
                                 <ce:surname>Biggs</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.K.</ce:given-name>
                                 <ce:surname>Treiber</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.E.</ce:given-name>
                                 <ce:surname>Atteridge</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.D.</ce:given-name>
                                 <ce:surname>Azimioara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.G.</ce:given-name>
                                 <ce:surname>Benedetti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.A.</ce:given-name>
                                 <ce:surname>Carter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Ciceri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Edeen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Floyd</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Ford</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Galvin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Gerlach</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Grotzfeld</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Herrgard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.E.</ce:given-name>
                                 <ce:surname>Insko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Insko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.G.</ce:given-name>
                                 <ce:surname>Lai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Lelias</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Mehta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.V.</ce:given-name>
                                 <ce:surname>Milanov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Velasco</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.M.</ce:given-name>
                                 <ce:surname>Wodicka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.K.</ce:given-name>
                                 <ce:surname>Patel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.P.</ce:given-name>
                                 <ce:surname>Zarrinkar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Lockhart</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A small molecule-kinase interaction map for clinical kinase inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Biotechnol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>329</sb:first-page>
                              <sb:last-page>336</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1038/nbt1068</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0240">M.A. Abian, W.H. Biggs, D.K. Treiber, C.E. Atteridge, M.D. Azimioara, M.G. Benedetti, T.A. Carter, P. Ciceri, P.T. Edeen, M. Floyd, J.M. Ford, M. Galvin, J.L. Gerlach, R.M. Grotzfeld, S. Herrgard, D.E. Insko, M.A. Insko, A.G. Lai, J.M. Lelias, S.A. Mehta, Z.V. Milanov, A.M. Velasco, L.M. Wodicka, H.K. Patel, P.P. Zarrinkar, D.J. Lockhart, A small molecule-kinase interaction map for clinical kinase inhibitors, Nat. Biotechnol. 23 (2005) 329- 336. https://doi.org/10.1038/nbt1068.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib44">
                     <ce:label>[44]</ce:label>
                     <sb:reference id="sref42">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Ren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Pan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Wen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Long</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Luo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Feng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhuang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Leng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Lang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Bai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>She</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Tu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Pan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster regioneabelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>56</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>879</sb:first-page>
                              <sb:last-page>894</sb:last-page>
                           </sb:pages>
                           <ce:doi>10.1021/jm301581y</ce:doi>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0245">X. Ren, X. Pan, Z. Zhang, D. Wang, X. Lu, Y. Li, D. Wen, H. Long, J. Luo, Y. Feng, X. Zhuang, F. Zhang, J. Liu, F. Leng, X. Lang, Y. Bai, M. She, Z. Tu, J. Pan, K. Ding, Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster regioneabelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib, J. Med. Chem. 56 (2013) 879-894. https://doi.org/10.1021/jm301581y.</ce:source-text>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>